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Poly-Q expanded exon 1 of huntingtin (Q103) fused to GFP is toxic to yeast cells 
containing endogenous yeast prions, [PIN+] ([RNQ+]) and/or [PSI+], which presumably 
serve as aggregation nuclei. Propagation of yeast prions is modulated by the 
chaperones of Hsp100/70/40 complex. While some chaperones were reported to 
influence poly-Q aggregation in yeast, it was not clear whether they do it directly or via 
affecting yeast prions. Our data show that while dominant negative Hsp104 mutants 
antagonize poly-Q aggregation and toxicity by eliminating endogenous yeast prions, 
some mutant alleles of Hsp104 decreases size and ameliorate toxicity of poly-Q 
aggregates without affecting prion propagation. Elevated levels of the yeast Hsp40 
proteins, Ydj1 and Sis1, exhibit opposite effects on poly-Q aggregation and toxicity 
without influencing prion propagation. Among the yeast Hsp70s, only overproduction of 
Ssa4 antagonized poly-Q toxicity.  We have also isolated dominant Anti-poly-Q-toxicity 
(AQT) mutants counteracting poly-Q toxicity only in the absence of the major ubiquitin-
conjugating enzyme Ubc4. Prion forming potential of other Q-rich proteins and influence 
of Q and P-rich regions on prion propagation were also studied. Our data connects poly-
Q aggregation and toxicity to the stress defense pathway in yeast. As many stress-
defense proteins are conserved between yeast and mammals, our data shed light on 








Mammalian neurodegenerative disorders 
            
Role of protein aggregation in mammalian neurodegenerative disorders 
             Neurodegenerative diseases are a varied assortment of central nervous system 
disorders characterized by the gradual and progressive loss of neural tissue or nerve 
cells. A large number of such sporadic and hereditary neurodegenerative disorders are 
characterized neuropathologically by intracellular and/or extracellular aggregates of 
proteinaceous fibrils or amyloids (see Table 1.1). These lesions are not mere markers of 
the disease state but are directly implicated in progressive brain degeneration. Most 
often, aggregation is a result of abnormal protein-protein interactions (for review see 
Trojanowski et al., 1998). This is exemplified by the intranuclear neuronal inclusions that 
are formed by the aggregation of mutant proteins harboring abnormally expanded 
polyglutamine tracts in hereditary tri-nucleotide repeat disorders like Huntington’s 
disease (HD), the intracytoplasmic neurofibrillary tangles (NFTs), as well as the 
extracellular amyloid or senile plaques (SPs) in sporadic and familial Alzheimer’s 
disease (AD), and by the prion protein deposits in the brains of patients with a sporadic 
or genetic form of spongiform encephalopathy. 
             The sporadic AD and familial AD represent the heterogeneous ends of a 
disease spectrum that overlaps with a large group of disorders with prominent tau 
protein-rich tangle pathology in the brain known as "taupathies" on the one hand, and 
those with prominent α-synuclein-rich inclusion pathology in the brain known as 
"synucleinopathies" (see Table 1.1). In Taupathies, the protein aberrantly present in an  
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Table 1.1 Neurodegenerative diseases characterized by filamentous lesions formed from 
aggregated peptides/proteins 
 
Disease                                 Lesion/Components                        Location 
Alzheimer's Disease (AD)          Senile Plaques/                               Extracellular 
                                                         β-Amyloid 
                                                        Neurofibrillary tangles/                  Intracytoplasmic 
                                                        PHFtau   
 
Amyotrophic Lateral                        Spheroids/                                    Intracytoplasmic 
Sclerosis (ALS)  
 
Dementia with Lewy                        Lewy Bodies/                                Intracytoplasmic  
Bodies (DLB)                                                      α-synuclein    
 
Multiple System Atrophy (MSA)        Glial Cell Inclusions                       Intracytoplasmic 
                                                         /α-synuclein 
 
Neuronal intranuclear                      Inclusions/Expanded                      Intranuclear 
inclusion disease                             polyglutamine tracts 
 
Parkinson's Disease (PD)               Lewy Bodies/                                Intracytoplasmic 
                                                        α-synuclein 
 
Prion diseases                                Amyloid plaques/Prion                    Extracellular 
 
Taupathies*                                                         Neurofibrillary tangles/                  Intracytoplasmic 
                                                       AD-like PHFtau 
 
Tri-nucleotide repeat                      Inclusions/Expanded                        Intranuclear 
diseases                                         polyglutamine tracts 
 
Lewy Body Variant                         Senile Plaques/                                Extracellular                                  
Alzheimers disease                        β-Amyloid                                                                
(AD + DLB) 
                                                       Neurofibrillary tangles/                Intracytoplasmic 
                                                       PHFtau   
 
        Lewy Bodies/NF                         Intracytoplasmic 
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aggregated form is the microtubule-associated protein tau. Abnormal phosphorylation of 
tau results in a pre-tangle stage leading to the formation of filamentous polymers called  
paired-helical filaments (PHF). Aggregation of this PHF results in the formation of 
cytoplasmic (intracellular) NFT (for review see Avilla, 2000). 
In Synucleinopathies, the protein α-synuclein is modified to form aggregates and 
is the major component of Lewy bodies. Although Lewy bodies (LBs) are regarded as 
hallmark intracytoplasmic neuronal inclusions of Parkinson’s disease (PD), they also 
occur commonly in the brains of patients with the typical clinical and pathological 
features of AD (Hardy et al., 1998). Alzheimer’s disease is also marked by the 
aggregation of dysfunctional β-amyloid –major component of senile plaques. This 
overlap is striking and underlines the notion of "fatal attractions" among brain proteins as 
a common mechanistic theme to account for brain degeneration in neurodegenerative 
disorders of the elderly (for review seeTrojanowski, et al., 1998). Strange enigma of 
these protein aggregation related disorders is that the familial form is caused by 
missense mutations in the gene encoding the disease protein forming the hallmark brain 
lesions while the sporadic form is caused by the corresponding wild type protein causing 
the same brain lesions.  
 
Neurodegenerative disorders involving expanded polyglutamine tracts  
           Proteins containing expanded polyglutamine tracts in addition to already 
mentioned tau, α-synuclein and β-amyloid are responsible for two major groups of 
neurodegenerative disorders: neuronal intranuclear inclusion disease and the tri-
nucleotide repeat disorders (see Table 1.1). A significant overlap exists between the two 
groups of disorders. In both cases, causative protein causes intraneuronal intranuclear 
inclusions. The latter group is more defined and discussed. The tri-nucleotide repeat 
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disorders can be dividied into polyglutamine (poly-Q) expansion disorders and non-
polyglutamine expansion disorders. Huntington’s disease is one of the diseases 
belonging to the polyglutamine expansion disorders involving CAG (Q) repeats while 
Friedreich Ataxia involving expansion of GAA (E) repeats and Fragile X syndrome 
involving expansion of CGG ® repeats are some examples of non-polyglutamine 
expansion disorders. 
 Poly-Q expansions in several unrelated proteins are responsible for atleast nine 
inherited neurodegenerative diseases (see Table 1.2). In all the cases, proteins are  
are expressed widely in brain and in other tissues, yet each is toxic in a different, highly 
specific group of neurons and produces a distinct pathology. All nine disorders show late 
onset of neurological symptoms with progressive neuronal dysfunction. As mentioned 
earlier, the characteristic feature of poly-Q diseases is the formation of insoluble, 
granular and fibrous deposits in affected neurons termed as neuronal inclusions (Perutz, 
et al., 1999). In 1994, Perutz proposed that long sequences of poly-Q might be able to  
 
 
Table 1.2 Neurodegenerative disorders caused by poly-Q expansions 
Disease                                               Protein containing                    Mode              
Pathology                                           poly-Q expansion               of inheritance 
             
Huntington’s disease (HD)                 Huntingtin                                   Autosomal 
Spinobulbar                                        Androgen receptor                     X-linked             
muscular atrophy                                                                                    
(Kennedy’s disease) 
 
Dentatorubral                                      Atrophin-1                                  Autosomal 
pallidoluysian atrophy 
 
Spinocerebellar                                  SCA 1,2,3,6,7                             Autosomal 
ataxia (SCA) types                             and 13 proteins       
1,2,3,6,7 and 13 
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form stable β-hairpins (Perutz, et al., 1994). These structures also called “polar zippers” 
consist of poly-Q-containing β-strands held together by hydrogen bonds between both 
main-chain and side-chain amides. Poly-Q-containing hairpins may self-associate to 
form stable β-sheet aggregates with fibrillar morphology. Interestingly certain 
transcription factors containing poly-Q segments in the nonpathological range, such as 
TATA-binding protein (TBP) and CREB-binding protein (CBP) were detected in neuronal 
inclusions. Sequestration of these essential proteins via poly-Q-poly-Q interaction is 
suggested to cause neuronal toxicity (Perez et al., 1998; Kazantsev et al., 1999; 
Nucifora et al., 2001). Additional proteins detected in neuronal inclusions were ubiquitin 
(Ub), 19S and 20S proteasome complexes and several molecular chaperones (Paulson 
et al., 1997; Davies et al., 1997; Cummings et al., 1998; Chai et al., 1999; Waelter et al., 
2001). 
Huntington’s disease is one of the best known poly-Q disorders. Molecular 
genetics has revealed the disease trigger, an inherited unstable CAG expansion in the 
N-terminl exon1 of a novel 4p16.3 gene that lengthens a polyglutamine segment in the 
350kDa protein huntingtin (Htt). The protein has unknown but essential function. The 
major characteristic of HD is a selective loss of neurons in the striatum and cortex 
leading to movement disorders, dementia, and eventually death. The toxicity of Htt in 
specific neurons correlates with the length of the glutamine expansion, but the 
mechanism of toxicity is unknown. When poly-Q tracts exceed the length of ~37 
residues, disease ensues. The length of the poly-Q stretch inversely correlates with the 
time of onset of the disease and the time of formation of Htt aggregates (Martindale et 
al., 1998). Poly-Q expansion in Htt can cause cellular dysfunction either by sequestering 
important cellular proteins or could partially inhibit the Ubiquitin (Ub)-proteasome 
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pathway for protein degradation similar to what was proposed in general for poly-Q 
expansion disorders. These two mechanisms are not exclusive but may act in 
conjunction (Sakahira et al., 2002). N-terminal fragments of Htt with poly-Q extensions 
was indeed shown to be involved in numerous protein-protein interactions (for review 
see Li and Li., 2004). This fragment aggregated and was even more toxic than full length 
Htt when expressed in transgenic animals or cultured cells (Mangiarini et al., 1996; 
Davies et al., 1997). This suggests that at least some parameters of poly-Q associated 
aggregation and toxicity could be reproduced in the experimental assays using only N-
terminal (exon 1) poly-Q expanded fragments of Htt.   
  
Neurodegenerative disorders involving prion proteins 
In 1982, Stanley Prusiner first coined the term ‘Prion’ to describe protein as a 
novel infectious agent. Prions are protein isoforms that reproduce themselves by 
converting normal protein of the same sequence into a prion state (Prusiner, 1982). 
Therefore, prion infection does not require transmission of any nucleic acid and is 
instead transmitted by the protein itself. The mammalian prion diseases like Bovine 
spongiform encephalopathy (BSE) also known as “Mad Cow Disease” affecting cattle, 
Scrapie affecting sheep, Gerstmann-Straussler-Scheinker Disease (GSS) and 
Creutzfeldt-Jacob Disease (CJD) affecting human are characterized by the accumulation 
of the PrP protein. The normal protein designated as PrPC and the pathological or 
infectious form designated as PrPSC have the same genetic structure but differ in their 
structure as mentioned previously. Circular dichroism and NMR analysis indicated that 
PrPC consists of mostly α-helical structures, while PrPSC has high β-sheet content 
(Heller, 1996; Nguyen et al., 1995). PrPSC molecules form large fibrillar amyloid 
structures called amyloid plaques and this ability is attributed to the high β-sheet content. 
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Thus etiology of other human degenerative diseases like Alzheimer’s, Huntington’s etc 
shares a remarkable similarity with the prion diseases ie ability of the causative protein 





The three extensively studied non-mendelian prion elements in S cerevisiae are 
[PSI+], [URE3] and [RNQ+]. Yeast prions are passed from one yeast cell to another 
through the cytoplasm, either from mother to daughter cell during budding, from parent 
diploid to spore clones during meiosis or through cytoplasmic mixing during mating. In 
addition to these three prions, several other ‘candidate prions’ are identified using 
genetic and biochemical methods, eg [NU+] (Sondheimer and Lindquist, 2000; Santoso 
et al., 2000; Derkatch et al., 2001). Table 1.3 gives details of the features of these yeast 
prions. 
A non-Mendelian element can be considered prion only if it satisfies several  
 
 














%Gln + Asn 
in PFD 
SUP35 Sup35 Translation 
termination 
 
[PSI+] aa 1-123 43 
RNQ1 Rnq1 Unknown 
 
[RNQ+] aa 153-405 43 
URE2 Ure2 Nitrogen 
catabolism 
 
[URE3] aa 1-89 47 
NEW1 New1 Unknown [NU+] aa 1-153 26 
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criteria  (Wickner, 1994). The spontaneous appearance of prions in yeast occurs at a 
very low rate, on the order of 10-6 in a given population. The first criteria that must be 
met is that overexpression of the normal cellular counterpart of a prion protein must 
increase the rate of prion induction. Second, once the prion forms, it should be self-
propagating and transmissible. In yeast, this means it should be transmitted through 
mitosis, meiosis, and during mating. In addition, there is a relationship between the 
chromosomal copy of the gene coding for the prion protein and the prion phenotype, that 
is, prion proteins are not completely independent of the gene that codes for them. 
Mutations in the prion gene leads to alterations of the prion phenotype, and elimination 
of that gene or its prion forming domain will eliminate the prion as well. Finally, all yeast 
prions described to date are reversibly cured by millimolar quantities of non-mutagenic 
agents such as guanidine hydrochloride (GuHCl). 
 
Yeast prion [PSI+]  
              The yeast prion [PSI+] is an aggregated form of Sup35 that was first identified 
as a factor which increased efficiency of readthrough of stop codons in a process called 
nonsense suppression (Cox, 1965). Sup35 functions with Sup45 to identify stop codons 
and terminate translation. Sup35 protein is essential such that cells lacking a functional 
copy of SUP35 are not viable. The reporter system used to assay the presence of [PSI+] 
in the cell relies on its basic function of translation termination. [PSI+] causes nonsense 
suppression of a premature stop codon present in the allele of ADE1 gene (ade1-14UGA). 
[psi-] cells referring to PrPC state contain soluble functional form of Sup35 that can 
terminate translation. In contrast to a [psi-] cell, Sup35 produced in a [PSI+] cell is 
sequestered into an aggregated form, increasing the level of nonsense suppression of 
the ade1-14 UGA mutation enabling them to generate Ade1 product (Figure 1.1 A). Thus 
[PSI+] cells are able to grow on medium lacking adenine (-Ade medium). The [PSI+] cells 
 9
appear white in color when grown on rich medium like YPD due to the accumulation of 
the white pigment, on the other hand, the [psi-] cells appear red on YPD and cannot 
grow on –Ade medium (Figure 1.1 B). In [PSI+] cells, majority of Sup35 is found in the 
aggregated (insoluble) fraction, while majority of Sup35 in [psi-] cells is detected in the 
soluble fraction (Patino et al., 1996; Paushkin et al., 1996) as depicted in Figure 1.1 C. 
The Sup35 protein of 685 aa could be subdivided into three regions: N-proximal 
or Sup35N, middle or Sup35M, and C-proximal or Sup35C. The Sup35N region of 123 
aa, rich in glutamines (Q) and asparagines (N), which is common to another yeast prion 
[URE3] and to the Huntington disease protein huntingtin is dispensable for termination 
function but solely responsible for the formation and propagation of [PSI+]. It also 
contains tandem imperfect oligopeptide repeats (PQGGYQQYN) similar to those 
(PHGGGWGQ) of the mammalian prion determinant PrP (Kushnirov et al., 1988). In 
both cases, the repeat expansion is known to increase the frequency of prion conversion 
(Prusiner and Scott, 1997; Liu and Lindquist, 1999). All prions known to date are protein 
aggregates, believed to transmit the aggregated state via the "seeded" or "nucleated" 
polymerization process (Lansbury and Caughey, 1995). In vitro (and at least in certain 
cases in vivo), prion aggregates were shown to possess properties of amyloids, highly 
ordered fiber-like structures (Prusiner, 1997; Chernoff, 2001; Wickner et al., 2001). 
 
Yeast prion [PIN+]/[RNQ+] 
The presence of [PIN+] is required for [PSI+] inducibility ie it is necessary for 
[PSI+] to appear spontaneously or following induction by excess Sup35N (Derkatch et 
al., 1997). [PIN+] is required at the step of [PSI+] initial occurence but is not needed for its 
propagation. [PIN+] appears to be a prion as it passes the prion criteria that are 




























Figure 1.1 Experimental assay used to monitor presence of the yeast prion [PSI+]  
A. Sup35 protein is produced at the same level in both [psi-] and [PSI+] cells. The 
ade1-14UGA reporter system, which contains a premature stop codon, is commonly 
used to assay presence of [PSI+]. In a [psi-] cell, Sup35 remains soluble and 
therefore readily available to participate in activities related to translation 
termination. In a [PSI+] cell, Sup35 is sequestered into an aggregated form, 
increasing readthrough of nonsense codons by translating ribosomes. In contrast 
to [psi-] cells, [PSI+] cells are able to generate significant quantities of the Ade1 
product from the ade1-14UGA transcript. B. Accumulation of Ade1 is manifested in 
[PSI+] cells as growth on –Ade medium and a white color on YPD. Absence of the 
Ade1 product is indicated in [psi-] cells as absence of growth on –Ade medium and 
red color on YPD. C. The majority of Sup35 can be found in the aggregated 
(insoluble) fraction of [PSI+] cell lysates, and the soluble fraction of [psi-] cell 
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a non-mendelian manner 2) It depends on Hsp104 (chaperone discussed later) for 
propagation 3) It is cured by growth in the presence of low levels of guanidine 
hydrochloride (GuHCl) and 4) reappears in cured strains (Derkatch et al., 2000). Also  
like [PSI+] (Derkatch et al., 2000) and [URE3] (Fernandez-Bellot et al., 2000) newly 
appearing [PIN+] elements are frequently unstable. Presence of Rnq1 or Ure2 prion 
aggregates made yeast strains [PIN+] and the spontaneous appearance of [PIN+] was 
accompanied by the appearance of Rnq1 aggregates (Derkatch et al., 2001) suggesting 
that the [PIN+] factor corresponds to the prion form of Rnq1. The function of Rnq1 is not 
known. Unlike all other prions where prion forming domain (PFD) is mostly located in the 
N-terminal region of the protein, the PFD of Rnq1 is located towards the C-proximal 
region of the protein spanning aa 153 to 405 (Sondheimer and Lindquist, 2000).  
Two models were proposed to explain the dependence of [PSI+] on [PIN+]. In the first 
model, pin acts as an inhibitor, in its non-prion conformation it inhibits de novo formation 
of [PSI+]. The second model predicts that [PIN+] aggregates provide an initial nuclei 
facilitating [PSI+] appearance. Just as is seen with [PSI+], the mutant huntingtin is toxic 
and can aggregate only in the presence of [PIN+] (Meriin et al., 2002) supporting second 
model. But examples do exist where multiple prions result in antagonistic relations 
(Bradley et al., 2002; Schwimmer and Masison, 2002). 
 
Similarities between yeast prion proteins and huntingtin Htt 
The ability to form large fibrillar amyloid like structures is a feature shared by the 
poly-Q containing proteins such as huntingtin and the yeast prions. Concurrently, the 
amino-terminal huntingtin fragments form SDS-resistant aggregates similar to the yeast 
prion protein Sup35 fibrils.  
           Yeast prion proteins and candidate prion proteins are characterized by unusually 
high Gln and Asn content. The average Gln + Asn content for a yeast protein is 9% 
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(Santoso et al., 2000). The prion forming domains of yeast prions Sup35, Ure2, Rnq1 
and New1 possess Gln + Asn of 26 to 47%. The repetitive sequences of Gln (Q) and 
Asn (N) have been shown to form β-sheets and ‘polar zippers’ (DePace et al., 1998; 
Perutz et al., 1994) as seen with the poly-Q domain of Htt. Structural similarities between 
the three proteins- Htt, Sup35 and Rnq1 are shown in figure 1.2. 
                Sup35 N-terminal (N) domain is required for [PSI+] propagation (Ter-
Avanesyan et al., 1993; Ter-Avanesyan et al., 1994). Overexpression of Sup35 or 
Sup35N induces de novo formation of [PSI+] (Chernoff et al., 1992; Chernoff et al., 1993; 
Ter-Avanesyan et al., 1993; Derkatch et al., 1996). This most likely occurs due to the 
fact that the excess Sup35 increases the probability of the protein to adopt the self-
perpetuating prion isoform in the presence of already existing prion. The prion 
aggregates can self-seed the conversion of normal Sup35 into the prion form and do not 
require continued expression of Sup35 to maintain [PSI+] (Chernoff et al., 1993). 
Continued expression of Sup35 in a [PSI+] cell is toxic (Chernoff et al., 1992; Ter-
Avanesyan et al., 1993). Similarly, excess mutant huntingtin also causes toxicity in yeast 
cell (Meriin et al., 2002). The similarities between the prion proteins and huntingtin 
suggest common players in their life-cycle. 
 
Dependence of HttPoly-Q toxicity on endogenous yeast prions in the yeast model 
  Yeast model has provided significant insight into the understanding of  
neurodegenerative disorders like prion disease, Parkinson's disease, polyglutamine 
expansion disorders,etc. Genetic experiments in mice, which are indispensable for 
studying the molecular basis of neurological disorders, have certain limitations that 
include slow pace and high costs. It is therefore not surprising that in recent years 
numerous neurological diseases have been modeled in genetically tractable organisms, 




























 18     40 
Poly Q domain in exon1 
Exon 1 
Figure 1.2 Structural organization of Q-rich proteins                                         
A. Structural organization of huntingtin protein (Htt). Htt is a 350 kDa protein 
comprising 3144 amino acids. The exon 1 of Htt contains a Q-rich domain from 
amino acids 18 to 40. B. Structural organization of Sup35 Sup35 protein is a 77 
kDa protein comprising of 683 amino acids. It contains three structural domains. 
The N domain (prion forming domain) is 53% Gln (Q) -rich. It is also rich in Asn 
(N), Gly (G) and Pro (P) residues and contains multiple imperfect repeats. The 
middle domain (M) is highly charged and the C terminal domain is the functional 
domain responsible for translation termination. C. Structural organization of Rnq1. 
Rnq1 protein is 42.5 kDa comprising of 405 amino acids. The C terminal end (prion 
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have a special advantage with respect to genome-wide experimental approaches as a 
result of the completed sequencing of the genome, the availability of a collection of 
precise deletion mutants of every gene in the genome, and the rapidly evolving 
databases of yeast protein-protein interactions and gene expression patterns. These 
large and easily accessible bodies of information, coupled with the ease with which 
yeast can be manipulated genetically, have led to dissection of novel mechanisms of 
neurodegenerative disorders. 
HttPoly-Q aggregation and toxicity have been studied by using simple organisms 
such as fruit flies (Jackson et al., 1998), Caenorhabditis elegans (Faber et al., 1999) and 
yeast Saccharomyces cerevisiae. Yeast assays usually employ short constructs derived 
from the poly-Q expanded exon 1 of Htt. The GFP-tagged polypeptides from normal 
(Q25) and mutant (Q103) forms of huntingtin are expressed under galactose-inducible 
promoter (figure 1.3 A). While poly-Q aggregation has been readily observed in yeast 
(Krobitsch and Lindquist,2000; Muchowski et al., 2000; Cao et al, 2001; Kimura et al., 
2001; Muchowski et al., 2002), a yeast-based assay for poly-Q toxicity has not been 
available until recently. It turned out that efficient cytoplasmic aggregation and toxicity of 
the chimeric protein, containing the poly-Q expanded exon 1 of Htt fused to the green 
fluorescent protein (GFP), could be detected only in the yeast strains bearing an 
endogenous yeast QN-rich protein, Rnq1, in its prion form, called [RNQ+], or [PIN+] 
(Meriin et al., 2002) shown in figure 1.3 B, C. In the absence of a prion, poly-Q 
aggregates are rarely found, and toxicity is not seen. Yeast prions apparently “seeds” 
aggregation of the heterologous poly-Q protein (Figure 1.3 D). Prion form of QN-rich 
domain of the other yeast protein, New1, has also been shown to facilitate aggregation 
of poly-Q construct originated from the other mammalian protein, mutant ataxin-3 
involved in Machado-Joseph Disease (MJD), although cell toxicity of that protein was not 


















Figure 1.3 Poly-Q associated phenotypes in prion containing yeast                                      
A. Cartoon of the huntingtin construct expressed in yeast. Polypeptides from 
normal (Q25) and mutant (Q103) forms of huntingtin fused to GFP are 
expressed under galactose-inducible promoter  B. Q103 cytotoxicity depends 
on the presence [RNQ+] prion. Yeast expressing Q103 do not show growth 
on galactose selective medium in the presence of [RNQ+] prion but show 
growth in [rnq-] yeast. Q25 expressing yeast can grow on galactose
containing selective medium irrespective of the presence or absence of the 
[RNQ+] prion. C. Excess Q103GFP forms clumps while excess Q25GFP 
shows diffused fluorescence. Yeast expressing Q103 forms aggregates only 
in the presence of [RNQ+] while yeast expressing Q25 show diffused 
fluorescence irrespective of the presence or absence of the [RNQ+] prion. D. 
Model proposing the role of pre-existing prions in inducing aggregation of 




that prion-dependent toxicity of the Htt-derived poly-Q construct in yeast is associated 
with the defect of endocytosis, possibly via sequestration of some components of the 
vesicle-assembly machinery by poly-Q aggregates (Meriin et al., 2003). As subcellular  
localization of Htt in mammalian cells has led to a suggestion that it may play a role in 
vesicle trafficking (Muchowski et al., 2002), it is possible that yeast model reflects certain 
features of cell toxicity that are relevant to mammalian HD. 
 
Proteins and processes modulating the biological effects of Q-rich 
aggregates of Sup35 and Htt  
 
Molecular chaperones 
             Molecular chaperones are proteins which can recognize and bind to non-native 
(denatured, misfolded intermediates) polypeptides to facilitate them to fold to their native 
states that are specified by their primary sequences. In cytosol where protein 
concentrations are high, chaperones are required for protein folding, especially for large 
multidomain protein folding at elevated temperature. Two types of molecular chaperones 
function to facilitate protein folding- 1) Heat shock proteins (Hsp)- These are proteins 
that suppress polypeptide aggregation and promote protein folding and 2) Enzymes like 
DsbA, DsbB, PDI that catalyse or correct the disulphide bond formation. 
The major families of Hsps modulating the Q-rich aggregates are Hsp100, Hsp70 
and Hsp40. Hsp104, a member of the ClpB/Hsp100 family facilitates the ATP-dependent 
resolubilization of misfolded and aggregated proteins in conjunction with Hsp70/DnaK 
and Hsp40/DnaJ (Glover and Lindquist,1998). In yeast, Arabidopsis and maize, the 
Hsp100/ClpB play a major role in acquisition of thermotolerance ie the ability to survive 
very high temperatures (Sanchez and Lindquist, 1990; Queitsch et al., 2000; Nieto-
Sotelo et al., 2002). For eg: Yeast cells expressing Hsp104 (yeast Hsp100) are 1000- 
times more viable after exposure to temperatures ≥ 50°C or to 20% ethanol than cells 
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carrying deletions of HSP104 (Sanchez and Lindquist, 1990; Sanchez et al., 1992). This 
capacity is attributed to Hsp104’s ability to resolubilize and refold aggregated proteins 
damaged by protein-damaging stress that includes heat stress as already mentioned 
(Glover and Lindquist, 1998; Parsell et al., 1994; Goloubinoff et al., 1999). During times 
of severe stress, rate of protein aggregation exceeds the capacity of other heat shock 
proteins to prevent aggregate accumulation and Hsp104 becomes critical for survival. 
This explains why Hsp104 is not required for normal growth or even growth at higher 
temperatures but is crucial for cell survival at extreme temperatures. Hsp104 levels 
increase in late exponential and stationary phase of growth, as well as during sporulation 
(Sanchez and Lindquist, 2000; Sanchez et al., 1992). 
Hsp70 (DnaK) family functions in an ATP-dependent stabilization of hydrophobic 
regions of extended polypeptides. Yeast Hsp70 has two major subfamilies Ssa and Ssb.  
The Ssa subfamily is one of the major heat shock inducible cytosolic chaperone 
subfamilies in yeast. This subfamily has four members Ssa1, 2, 3 and 4. Presence of 
atleast one Ssa is required for vegetative growth (Werner-Washburne et al., 1989).  
while Ssb proteins are associated with translating ribosomes. The Ssb subfamily is 
composed of two nearly identical proteins Ssb1 and Ssb2, which are not essential for 
viability and not inducible by heat shock (Nelson et al., 1992). 
Hsp40 is a regulator of Hsp70 (Cyr and Douglas, 1994). The J-domain of Hsp40 
can stimulate the ATPase activity of Hsp70 in order to refold non-native polypeptides. 
Hsp40 can bind non-native polypeptides directly and deliver them to Hsp70 for folding 
(Qian et al., 2002 for example).  
 
Role of molecular chaperones in prion propagation 
Yeast prion propagation is modulated by the Hsp104/Hsp70/Hsp40 complex. 
Prion propagation operates at the level of protein folding and thus chaperone proteins 
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that assist protein folding come into the picture. Both overexpression of Hsp104 and 
deletion of Hsp104 cures [PSI+] (Chernoff et al., 1995). Infact intermediate levels of 
Hsp104 are required to maintain [PSI+]. In accordance, overproduction of Hsp104 in 
[PSI+] cells results in shift of Sup35 from the insoluble (aggregated) to soluble (non-
aggregated) fraction (Patino et al., 1996; Paushkin et al., 1996). Hsp104 is also involved 
in the propagation of other yeast prions, interestingly overexpression of Hsp104 does not 
cure  yeast prions [URE3] (Moriyama et al., 2000) or [RNQ+] (Derkatch et al., 1997; 
Sondheimer and Lindquist, 2000). 
Hsp70-Ssa1 protects [PSI+] from curing effects of excess Hsp104 (Newnam et 
al., 1999) and facilitates de novo induction of the [PSI+] prion in [psi-] cells (Allen et al., 
2004). Atleast in some [PSI+] variants, excess Ssa1 also increases phenotypic 
expression of [PSI+], detected as nonsense-suppression (Newnam et al., 1999). Ssa1 
was also shown to be important for the mitotic stability of [PSI+] (Jung et al., 2000; Jones 
and Masison, 2003). Although Ssa1 does not cure endogenous [PSI+], some chimeric 
constructs of [PSI+] were shown to be cured by Hsp70-Ssa1 and Hsp70-Ssb1 
(Kushnirov et al., 2000). In contrast to Ssa1, Ssbs antagonize [PSI+]. Excess Ssb 
increases [PSI+] curing by overexpressed Hsp104 (Chernoff et al., 1999). In the 
ssb1∆ssb2∆ strain, spontaneous [PSI+] formation in [psi- PIN+] cells is increased and 
curing of [PSI+] by excess Hsp104 is decreased (Chernoff et al., 1999). Some [PSI+] 
isolates can also be cured by excess Ssb (Chernoff et al., 1999; Kushnirov et al., 2000).  
          Hsp40-Sis1 regulates the maintenance of [RNQ+] (Sondheimer et al., 2001) and 
excess Hsp40-Ydj1 results in gradual loss of [URE3] (Moriyama et al., 2000). Some data 
also suggest a role for Hsp40 in [PSI+] propagation (Jones and Masison, 2003; 




Role of molecular chaperones in poly-Q aggregation and toxicity 
          Molecular chaperones represent one group of proteins frequently recruited to poly-
Q inclusions. Their presence in aggregates suggests that expanded poly-Q tracts are 
recognized as misfolded conformers and that cellular quality-control mechanisms are 
activated in an attempt to prevent their accumulation (Sherman and Goldberg, 2001). 
As at least some models confirm relationship between poly-Q aggregation and cell 
toxicity, chaperone proteins counteracting aggregation are well positioned as likely 
antagonists of the poly-Q disorders. Indeed, some chaperones of the evolutionary 
conserved Hsp70 and Hsp40 families counteracted poly-Q aggregation in vitro 
(Muchowski et al., 2000) and in vivo, as seen in the cultured mammalian cells, and in the 
fruit fly assays (Kazemi-Esfarjani and Benzer, 1999; Warrick et al., 1999; Chan et al., 
2000; Cummings et al, 2001; Sakahira et al., 2002).  
              In yeast, aggregates of the heat damaged proteins are solubilized and refolded 
by the complex of chaperone proteins, including Hsp104, Hsp70 and Hsp40 (Glover and 
Lindquist, 1998). Overproduction of some members of the Hsp70 and Hsp40 families 
was shown to counteract poly-Q aggregation in the yeast cells (Muchowski et al., 2000). 
Simultaneous deletion of the SSA1 and SSA2 genes, coding for the yeast proteins of the 
Hsp70 family, as well as a point mutation in Ydj1, a protein of the Hsp40 family, also 
decreased poly-Q aggregation in yeast (Meriin et al., 2002).  Hsp104 was shown to be 
essential for the aggregation of poly-Q in yeast, and its deletion or overproduction 
eliminated or reduced poly-Q aggregation at least in some assays (Krobitsch and 
Lindquist, 2000; Satyal, et al., 2000; Cao, et al., 2001; Kimura, et al., 2001).  
 
Ubiquitin-Proteasome system  
Along with molecular chaperones, Ubiquitin/Proteasome pathway is responsible 
for dealing with misfolded proteins usually by proteolysis. Proteolysis can occur in yeast 
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vacuole or in the cytosol. Protein destruction in cytosol is achieved through the action of 
proteasome complex. Proteins marked for destruction are tagged with Ubiquitin. Ub-
mediated proteolysis could play a role in prion propagation by regulating the free 
substrate available to be converted into prion aggregates. Importance of Ubiquitin 
conjugating enzyme (Ubc4) in [PSI+] propagation has been shown by K. Allen (former 
member of Chernoff Lab). 
           The finding that poly-Q inclusions stain positively for ubiquitin, 19S and 20S 
complexes suggested that the Ub-proteasome pathway may be involved in poly-Q 
pathogenesis (Cummings et al., 1998; Chai et al., 1999). There are several reports that 
formation of poly-Q inclusions is accelerated when proteasome –inhibitors are added to 
transfected cells (Cummings et al., 1998; Chai et al., 1999;). Intracellular aggregation of 
poly-Q proteins has been proposed to impair the ubiquitin-proteasome system (for 
review see Sherman and Goldberg, 2001). 
 
Cytoskeleton-associated proteins 
        Cytoskeletal assembly proteins have been shown to modulate prion propagation as 
well as play a role in poly-Q disorder like Huntington’s disease. Sla1 and Sla2 are two 
important members of the cytoskeletal family. Sla1 along with Las17 are important in 
actin patch assembly while Sla2 plays an important role in the polarization of the cortical 
actin cytoskeleton. Sla2 is a homolog of mammalian Hip1 (huntingtin-interacting protein 
1) (Holtzman et al., 1993) which is known to function in endocytic processes. Sla1 and 
Sla2 both have some domain structures reminiscent of prion-forming domains. Sla1 
contains oligopeptide repeats (Holtzman et al., 1993) and Sla2 has a region rich in Gln 
and Asn residues (Michelitsch and Weissman, 2000), but neither can form prions 
themselves. The protein Sla1 was shown to interact with Sup35N in yeast two-hybrid 
screen and [PSI+] induction by excess Sup35 was reduced in the sla1∆ background 
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(Bailleul et al., 1999). The cytoskeletal inhibitor latrunculin-A (LatA) was shown to be 
able to cure [PSI+], but not [PIN+] (Bailleul-Winslett et al., 2000). 
               Several genes required for early endocytic events and organization of cortical 
actin patches when mutated or deleted, enhanced Q103 toxicity establishing a link 
between poly-Q toxicity and inhibition of early steps of endocytosis (Meriin, et al., 2003). 
Eg: Sla1, Pan1, Sla2. Growth of cells expressing Q103 was impaired to a greater extent 
in early endocytic mutant cell background than that of wild-type cells. Sla1 was also 
shown to interact with extended poly-Q in two-hybrid screen (Bailleul et al., 1999). This 




The goal of this study was to find factors that were important in the life-cycle of 
Q-rich protein aggregates. This was achieved by studying the interaction between 
chaperone system, ubiquitin system, cytoskeletal system and Q-rich proteins causing  
some aggregation-related disorders using the yeast prion experimental model. This 
study would thus be helpful in providing valuable information towards development of 
therapy for some aggregation-related disorders and in possibly understanding the 




















 All yeast strains used in this study are listed in Table 2.1. More detailed 
descriptions of individual strains are available for some strains in the corresponding 
chapter in which the strain was used. The presence of the [PIN+] – prion form of the 
Rnq1 protein is designated [RNQ+] or [PIN+] interchangeably.  
 The most commonly used strains in this work are a set of 4 isogenic derivatives 
of yeast strain 74-D694, which differ only in their prion composition. Strain 74-D694 ([psi-  
PIN+]) is referred to as OT60. The weak [PSI+ PIN+] strain is OT55 and the strong [PSI+ 
PIN+] strain is OT56. They were independently induced by overexpression of SUP35 in 
strain OT60 (Derkatch, et al., 1996). Strong [PSI+] strain is more efficient in showing  
nonsense suppression of the ade1-14UGA mutation resulting in growth on –Ade medium 
after 3-4 days and a white/light pink color on YPD, compared to the 7-8 day incubation 
time required to see growth of weak [PSI+] cells on –Ade, and a pink color on YPD. 
GT17 is a [psi- pin-] derivative acquired by GuHCl treatment of strain OT56 as described 
previously (Derkatch, et al., 1997). 
              The other most commonly used set of isogenic strains in these studies are 
derived from the strong [PSI+ PIN+] diploid parent GT81 (Chernoff, et al., 2000). GT81 is 
a self-diploid GT81 is heterozygous by MAT locus and homozygous by all other genes. 
GT81-1C and GT81-1D are haploid meiotic segregants of opposite mating types derived 
from GT81 (Chernoff, et al., 1999). GT234 (Chernoff, et al., 1999) and GT409 (Kim Allen  
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GT17 MATa ade1-14UGA his3-∆200 leu2-3,112 trp1-289UAG ura3-52 [psi- 
pin-] 
GT81 MATa/ MATα  ade1-14/ade1-14 his3/his3 leu2/leu2 trp1/trp1 
ura3/ura3 lys2/lys2 [PSI+ PIN+] 
GT81-1C Strong [PSI+ RNQ+] MATa haploid meiotic spore clone of GT81 
GT81-1D Strong [PSI+ RNQ+] MATα haploid meiotic spore clone of GT81 
GT146 MAT a  ade1-14  his3-∆200 or 11,15  leu2-3,112  lys2  trp1-∆  
ura3-52 ssb1::HIS3 ssb2::URA3  [PSI+ RNQ+] 
GT157 [psi- PIN+] derivative of GT146 
GT159 MATa [psi- RNQ+] haploid derivative of GT81 
GT202 and GT203 [PSI+] derivatives of GT157 Induction by CEN-GAL-SUP35 
GT215-8A MAT α ade1-14  leu2-3, 112 his3-∆200(or -11, 15)   lys2 trp1-∆  
ura3-52 ∆sup35::HIS3 [SUP35Sc URA3 CEN] [PSI+]  
GT234 MATα ade1-14UGA his3-∆200  leu2-3,112 trp1-289UAG  ura3-52  
lys2 [psi- rnq-]        
GT255-2A MATα  ade1-14UGA his3-∆200 lys2 ura3-52 leu2-3,112 trp1-289UAG 
sup35∆::HIS3 [pASB2-CEN LEU2 SUP35] [psi- PIN+] 
GT310 MAT α   ade1-14  leu2-3, 112 his3-∆200(or -11, 15)   lys2 trp1-∆  
ura3-52 ∆sup35::HIS3 [SUP35NMPm-CSc URA3 ] [PSI+] 
GT349 MATa ubc4∆::HIS3 derivative of GT81-1C 
GT385 Heterozygous  ubc4∆::HIS3 ubc5∆::HIS3 derivative of GT340 and 
GT349 (isogenic to GT81) [PSI+ PIN+] 
GT385-13A MATα ubc4∆ [psi-  rnq-] haploid meiotic spore clone of GT385 
GT386 MATa ubc4∆::HIS3 [psi- PIN+] derivative of GT349 
GT387 MATa ubc4∆::HIS3 [psi- pin-] derivative of GT349 
GT393 MATα ade1-14 his3 lys2 ura3 leu2  trp1  sup35::HIS3 [PSI+] 
[pASB2] [PSI+ PIN+] 
GT490  [PSI+ pin-] derivative of OT56 
GT532 ubc4∆ / ubc4∆ diploid (GT385-13A X GT580) 
GT532-9B,-9D MATa and MATα haploid meiotic spore clones of GT532 
GT534 ubc4∆ / ubc4∆ diploid(GT385-13A X GT582) 
GT534-2A,2B MATa and MATα haploid meiotic spore clones of GT534 
GT557 GuHCl cured strain of GT310 [psi- pin-] 
GT564 MAT a  ade1-14  his3-∆200 or 11,15  leu2-3,112  lys2  trp1-∆  
ura3-52 rnq ∆: HIS3   [psi- PIN+] rnq disruptant of GT159 
GT573 AQT-2 MATa ubc4∆::HIS3 [PSI+ PIN+] anti-polyQ toxicity 
derivative of GT349 
GT574 AQT-7 MATa ubc4∆::HIS3 [PSI+ PIN+] anti-polyQ toxicity 
derivative of GT349  
GT575 AQT-9 MATa ubc4∆::HIS3 [PSI+ PIN+] anti-polyQ toxicity 
derivative of GT349  
GT579 AQT-2 MATa ubc4∆::HIS3 [PSI+ PIN+]  [pRS316GAL] 









GT581 AQT-7 MATa ubc4∆::HIS3 [PSI+ PIN+]  [pRS316GAL] 
GT582 AQT-7 MATa ubc4∆::HIS3 [PSI+ PIN+]  [pYES2-103Q] 
GT592 [psi- PIN+] derivative of GT310 obtained by WT Hsp104 treatment 
GT606 ade1-14/ade1-14  ∆ubc4::HIS3/∆ubc4::HIS3 his3-∆200(or -11, 
15)/ his3-∆200(or -11, 15) leu2-3,112/leu2-3,112  lys2/lys2  trp1-
∆/trp1-∆  ura3-52/ura3-52 [PSI+]       
GT607 AQT-9 MATa ubc4∆::HIS3 [PSI+ PIN+]  [pRS316GAL] 
GT608 AQT-9 MATa ubc4∆::HIS3 [PSI+ PIN+]  [pYES2-103Q] 
GT675 AQT-2 MATa ubc4∆::HIS3 [psi- PIN+]  
GT676 AQT-7 MATa ubc4∆::HIS3 [psi- PIN+]  
GT677 AQT-9 MATa ubc4∆::HIS3 [psi- PIN+]  
GT724/GT756 AQT-9 ubc4∆ / ubc4∆ diploid [PSI+ PIN+]  [pYES2-103Q] 
GT724-3B,-3D MATa and MATα haploid meiotic spore clones of GT724 
GT726 GT532-9B and GT532-9D [pYES2-103Q, YEP13] 
GT727 GT534-2A and GT534-2B [pYES2-103Q, YEP13] 
GT728 GT724-3B and GT724-3D [pYES2-103Q, YEP13] 
GT729 AQT-2/AQT-7 ubc4∆ / ubc4∆ diploid [PSI+ PIN+] 
GT730 AQT-7/AQT-9 ubc4∆ / ubc4∆ diploid [PSI+ PIN+] 
GT741 AQT-2/AQT-9 ubc4∆ / ubc4∆ diploid [PSI+ PIN+] 
GT769 MATa ubc4∆::HIS3 [psi- pin-] derivative of AQT-2 GT573 
GT770 MATa ubc4∆::HIS3 [psi- pin-] derivative of AQT-7 GT574 
GT771 MATa ubc4∆::HIS3 [psi- pin-] derivative of AQT-9 GT575 
GT784-8C MAT α  ade1-14  his3-∆200 or 11,15  leu2-3,112 lys2  trp1-∆ 
ura3-52  ubc4::HIS3 rnq1::HIS3 [PSI+] 
GT818 MATα ubc4∆::HIS3, rnq1∆::HIS3, leu2-3,112,lys2,trp1- ∆,ura3-
52,ade1-14 
OT37 MAT α his4 lys2 
OT38 MAT a his4 lys2 
OT55 
([PSI+]1-1-74-D694) 
Weak [PSI+ PIN+] derivative of OT60 
OT56 
([PSI+] 7-74-D694) 
Strong [PSI+ PIN+] derivative of OT60 
OT59 alias PJ69-4A MAT a trp1-901 leu2-3,112 ura3-52 his3-200 gal4∆ gal80∆ Gal2-
ADE2 LYS2::GAL1-HIS3 met2::GAL7-LaZ 
OT60 
([psi-]-74-D694) 
MATa ade1-14UGA his3-∆200 leu2-3,112 trp1-289UAG ura3-52 [psi-
PIN+] 
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from Y.O. Chernoff’s lab) are meiotic segregants of GT81, cured of [PSI+] and [PIN+] by 
GuHCl. GT159 is the [psi- PIN+] derivative of a GT81 meiotic segregant, cured of [PSI+], 
but not [PIN+], by excess Hsp104 (Chernoff, et al., 1999).  
 
Plasmids 
Table 2.2 describes most of the plasmids used in this work. Listed separately 
(Table 2.3) are the plasmids with chimeric genes and in (Table 2.4) are the basic cloning 
vectors frequently employed as “empty vector” controls. Plasmid types are described as 
either CEN (centromeric) or 2µ (high copy number). Some experiments utilized entire 
sets of specialized constructs. For example the SSA-SSB chimeric constructs, SSB 
mutants, Hsp104 mutants given by S. Lindquist and yeast 2-hybrid constructs. They do 
not appear in tables but are explained in text in this section. Plasmids that were 
constructed for this study are mentioned in the appropriate chapter.  
 The HIS3CEN based plasmids used in chapter 3 : pH28-A509Db (Hsp104-
A509D),  pH28-2nd NBFb, pH28-monitorb, pH28-AAb, pH28-GTb, pH28-
ISNBDDDb(Hsp104-C*),pH28-104b, pH28-ATPKb and pH28-A503Vb(Hsp104-A503V)  
are plasmids obtained from S. Lindquist lab from E. Schirmir. All the HSP104 mutant 
alleles are expressed under the control of GAL1 promoter. 
The yeast two-hybrid plasmids used in chapter 4 were plasmids pAS1, which 
bears the GAL4 DNA-binding domain under the ADH promoter and the TRP1 marker 
and the plasmid pACT which bears the activation domain of GAL4 under the ADH 
promoter and the LEU2 marker (Durfee et al., 1993) were kindly provided by S. Elledge. 
Plasmids pSE1111 and pSE1112 which bear the GAL4ACT-SNF1 and GAL4DNA–SNF4 
chimeric constructs respectively (Durfee et al., 1993) were used as positive control in 
these experiments and were also provided kindly by S. Elledge. PACTSSA1 and 
pACTSSB1 are SSA1 and SSB1 fused to the activation domain of GAL4. 
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Table 2.2 List and description of plasmids used in this study  
 
Protein            Plasmid                                            Type/Marker      Promoter       SourceΓ 
Hsp104 pYSGAL104        CEN/URA3        GAL1             1                   
      pH28                             CEN/HIS3          GAL1            2 
  
Hsp104-            pUK21-KT218,620                           CEN/URA3          3  
KT-218,620       pKT218,620                                     CEN/URA3                              3 
    pLA1-HSP104KT          CEN/HIS3         GAL1             3 
    pRS316GALHSP104KT      CEN/URA3        GAL1             3 
    
Hsp104-MI   pYS-GAL104-MI          CEN/URA3        GAL1 1                           
Hsp104-MII   pYS-GAL104-MII          CEN/URA3        GAL1            1                     
Hsp104-MIII      pYS-GAL104-MIII         CEN/URA3         GAL1           1           
Hsp101   pLA1-plantHsp104WT  CEN/HIS3          GAL1            4 
Hsp101-   pRS316GAL-plantHsp104MT CEN/HIS3          GAL1            4 
T499I 
 
Hsp104-     pGALHSP104-Lib   CEN/URA3        GAL1  5 
K302N 
 
Ssa1    pRS316K-SSA1   CEN/URA3       SSA1              6 
    pTEF-SSA1    CEN/URA3       TEF1   6 
    pGAL-SSA1    CEN/URA3       GAL1    2 
    pC211    CEN/HIS3         SSA2   7 
 
Ssa1-21   pRDW30    CEN/URA3       SSA1         8 
 
Ssa2    pN2     CEN/HIS3         SSA2   7 
 
Ssa3    pYCL1-GAL-SSA3                        CEN/LEU2  GAL1   9 
 
Ssa4    pYCL1-GAL-SSA3                        CEN/LEU2  GAL1   9 
    YEpGAL-SSA3   2µ/LEU2 GAL1   6 
 
Ssb1    pRS316GAL-SSB1            CEN/URA3        GAL1            10 
 
Ydj1    pRSYDJ1             CEN/HIS3         GPD               11 








Table 2.2 (continued) 
 
Protein                   Plasmid                         Type/Marker      Promoter         SourceΓ  
        
Sis1     pTVSIS1       CEN/TRP1             GPD              13 
     pRS315SIS1      CEN/ LEU2             SIS1            12 
 
Human Hsp40    Hdj1424GPD       2µ/TRP1              GPD   6 
  
Human Hsp40    Hdj2424GPD                  2µ/TRP1              GPD   6 
Hsp82     pMC3       CEN/URA3   GAL1  2  
Hsp26     p2UGPD       2µ/URA3           GPD           14 
Sla1     pFL44Sla1      2µ/URA3              SLA1           15 
     pRS316GAL-SLA1    CEN/URA3   GAL1           14 
 
Sla2     pRS316-SpSLA2    CEN/URA3   SLA2           17 
     pDD355                CEN/URA3   GAL1           18 
     pDD354      2µ/HIS3              SLA2           19   
 
Sla2∆33-359      pDD368        2µ/HIS3              SLA2           19   
  
Sla2∆360-575   pDD372                          2µ/HIS3              SLA2           19 
 
Ubc4    DO266       CEN/TRP1               UBC4            20 
    pTRPUBC4       2µ/TRP1              GAL1            20  
 
Ubc5    DO272                       CEN/TRP1               UBC4            20 
 
HttQ20             pAS1HUNQ20     2µ//TRP1    ADH            15 
 
HttQ25    pYES2-25Q       2µ/URA3                  GAL1            21    
   pYES-Q25trp                   2µ/TRP1                   GAL1           22      
        
HttQ53              pAS1HUN53       2µ//TRP1     ADH             15  
 
HttQ103            pETQ103       5 
       
    pYES2-103Q                  2µ/URA3               GAL1               21 
    pYES-Q103trp2µ/      2µ/TRP1                GAL1              22        
  
HttPro   pYES2-PRO       2µ/URA3               GAL1  22  
 
HttQ25Pro   pYES2-25QP       2µ/URA3               GAL1  22  
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Table 2.2 (continued) 
 
Protein            Plasmid                                       Type/Marker      Promoter         SourceΓ 
 
Sup35         CEN-GAL-SUP35      CEN/URA3                 GAL1              23 
         pASB2                   CEN/LEU2                 SUP35             24 
         pSTR7                                            2µ/ LEU2                   SUP35             25 
         pEMBL-yex-SUP35       2µ/ URA3LEU2         SUP35      26 
         pLA1-SUP35                              CEN/HIS3                  GAL1     27 
 
Sup35         pLSpSUP35NMGFP                      CEN/LEU2                  SUP35            28 
 
Sup35N       pLA1-SUP35N                               CEN/HIS3                   GAL1             27 
 
Sup35NM    pRS315-SpSUP35NMSc               CEN/LEU2               SUP35             29 
         pYCL1-CUP1-SUP35NMSc           CEN/LEU2               CUP1               29 
         pLSpSUP35NM-GFP                 CEN/LEU2               SUP35             28          
 
Sup35MC    pMCUP1MCSc                               CEN/URA3              CUP1                 5 
 
Sup35C       pEMBL-yex-SUP35C-del3ATG     2µ/URA3 LEU2         SUP35             29   
 
ΓSource indicates either reference wherever available, or the person who constructed or 
lab who gave gifted us the plasmid. 
1: Dr Neito-Sotelo; 2: Newnam et al., 1999; 3: Wegrzyn et al., 2001; 4: Dr Elizabeth 
Vierling; 5: This study; 6 : Dr. E. Craig; 7: Schwimmer and Masison, 2002; 8: Jung et al., 
2000; 9: Allen et al., 2004; 10: Chernoff et al., 1999; 11: Kimura et al., 1995; 12: Dr. D. 
Cyr; 13: Krobitsch and Lindquist, 2000;  14: Dr S.Lindquist;15: Bailleul et al., 1999; 16:Dr 
P. Bailleul; 17.Mike; 18: Yang et al., 1999; 19: Dr D. Drubin; 20: Dr Braun; 21: Meriin et 
al., 2002; 22: Dr M. Sherman; 23: Derkatch et al., 1996; 24:Borchsenius et al., 2001; 25: 
Broach et al., 1979; 26: Cesareni and Murray., 1987; 27: G. Newnam 28: Bailleul-









pG4BD-0-SUP35N and pG4BD-SUP35 constructed by P. Bailleul (Bailleul et al., 1999)  
each contain SUP35N and SUP35 respectively fused to the N-terminus of GAL4 DNA 
binding domain (GAL4DNA). pG4BD-1-NMSc and pG4BD-1-NMPm constructed by E. 
Lewitin (Chernoff Lab) contains the Saccharomyces SUP35NM and Pichia SUP35NM 
respectively fused to the N-terminus of GAL4DNA. pG4BD-2-Sup35Pm constructed by P. 
Bailleul (Bailleul et al., 1999) contains Pichia Sup35 fused to the N-terminus of GAL4DNA. 
Plasmids used for Ssb studies in chapter 4 were also kindly provided by Dr E. Craig. All 
the Ssb plasmids are URA3 based centromeric vectors. pSSB1-V442F carries PSSB1-




Table 2.3 List of plasmids containing chimeric genes 
Protein                                     Plasmid             Type/Marker      Promoter         Source 
HttQ20Sup35MCSc               pMCUP1Q20MCSc         CEN/URA3   CUP1    This study 
HttQ53Sup35MCSc               pMCUP1Q53MCSc         CEN/URA3   CUP1    This study                     
HttQ103Sup35MCSc             pMCUP1Q103MCSc       CEN/URA3   CUP1    This study                        
HumanSup35N-            pMCUP1NHs400MCSc   CEN/URA3   CUP1    This study                          
Saccharomyces Sup35MC 
 
HumanSup35NM            pMCUP1NMHs400CSc    CEN/URA3   CUP1    This study                         
Saccharomyces Sup35MC 
 
PichiaSup35NM-  pYCLPmSc                     CEN/LEU2  SUP35    E. Lewitin 
Saccharomyces Sup35C 
 
Pichia Sup35N-                      pMCUP1NPmMCSc        CEN/URA3   CUP1    This study                          
Saccharomyces Sup35MC   
 
Sup35NM-HumanHpr6.6 pRS315SpSup35NMScHPR6.6 CEN/LEU2  SUP35  E. Lewitin 
 
Sup35NM-HumanHpr6.6 pYCL1CUP1Sup35NMScHPR6.6 CEN/LEU2  CUP1 E. Lewitin 
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Been destroyed in the polylinker. Plasmids -pRS316∆KX-T433A-SSB1-X, pRS316∆KX-
F444S-SSB1-X, pRS316∆KX-T444I-SSB1-X, pRS316∆KX-M409A-SSB1-X, 
pRS316∆KX-F432S-SSB1-X each contain SSB1-T433A, SSB1-F444S, SSB1-T444I, 
SSB1- M409A and SSB1- F432 SSB mutant alleles expressed under SSB1 promoter 
(Pfund et al., 2001). The His-tagged C-terminal truncations were each carried on a p416-
TEF plasmid and they are called- p416-TEF-HIS-Ssb1∆488, p416-TEF-HIS-Ssb1∆499 
and p416-TEF-HIS-Ssb1∆507 carrying SSB1∆488, SSB1∆499 and SSB1∆507 mutant 
alleles expressed under TEF promoter (Pfund et al., 2001). pRS316K-SSB1 contains 
SSB1 expressed under its own promoter and pRS316 was used as an empty vector 
control. The SSA1/SSB1 chimeric gene fusions were carried on two plasmid sets. One 
was expressed under its own promoter and was pRS316K based while the other was  
 
 
Table 2.4 List of control plasmids 
Plasmid                              Type/Marker      Promoter                             Source  
pRS316GAL                      CEN/URA3            GAL1                          Liu et al., 1992 
pLA1                                 CEN/HIS3                                         Newnam et al., 1999 
pEMBL-yex                       2µ/URA3 LEU2            Cesareni and Murray, 1987  
pFL39                                CEN/TRP1                Bonneaud et al., 1991 
YEP13                              2µ /LEU2                                             Broach et al., 1979 
pYSGAL                           CEN/URA3                                                Dr Neito-Sotelo 
pYCL1        CEN/LEU2                                                           E. Lewitin 
pFL36                              CEN/LEU2                                 Chernoff Lab  




expressed under TEF promoter. Both are URA3 based centromeric vectors. Plasmid 
pRS316K-ABB contains the SSA1/SSB1 chimeric gene fusion that contains the 
promoter and ATPase domain of SSA1, then the 18K peptide binding domain and the 
10K variable domain of SSB1. Similarly, pRS316K-AAB contains the SSA1/SSB1 
chimeric gene fusion that contains the promoter, ATPase domain and 18K peptide 
binding domain of SSA1, and the 10K variable domain of SSB1. Plasmid pRS316K-BBA 
contains the SSA1/SSB1 chimeric gene fusion that contains the promoter and ATPase 
domain of SSB1, then the 18K peptide binding domain and the 10K variable domain of 
SSA1. pRS316K-BAB contains the SSA1/SSB1 chimeric gene fusion that contains the 
promoter, ATPase domain and the 10K variable domain of SSB1 and the 18K peptide 
binding domain of SSA1, pRS316K-BAA contains the SSA1/SSB1 chimeric gene fusion 
that contains the promoter and ATPase domain of SSB1 and the 18K peptide binding 
and 10K variable domain domain of SSA1. Genes on plasmids from other set all are 
expressed under TEF promoter and the combinations are same as mentioned above for 
the first set. The plasmids are pTEF-BAB, pTEF-SSA1, pTEF-BAA, pTEF-BBA, pTEF-
AAB ,pTEF-ABA, pRS316K-BAB, pTEF-ABB and pTEF-SSB1. 
 The pEMBL series vectors listed in tables 2.2 and 2.4 contain the defective 
LEU2-d allele; selection on –Leu medium leads to amplification of this plasmid (or its 
derivatives) up to about 100 copies per cell (Derkatch et al., 1996). 
 
Antibodies 
 All primary and secondary antibodies, and the concentrations in which they were 





Table 2.5 Description of antibodies used in this study 
Antibody 
designation 
Concentration of primary 
antibody for Western 
blotting 
Concentration of secondary 
antibody used for Western 
blotting 
Anti-Rnq 1:5000  1:2000 
Anti-Sup35  1:1000  1:1000  





Molecular biology techniques 
 Standard protocols were used for DNA electrophoresis, restriction digestion, 
ligation, and bacterial transformation (Sambrook and Russel, 2001). Enzymes were 
purchased from New England Biolabs and Gibco BRL.  
 
QIAgen Gel Extraction protocol  
 Fragments of DNA generated by restriction digest or PCR reaction were 
separated using standard DNA electrophoresis (Sambrook and Russel, 2001). DNA 
bands corresponding to desired products were identified using a UV transilluminator 
(Fischer Biotech 312nm Variable Intensity Transilluminator) and bands were excised 
from EtBr-stained gels using a scalpel. Separation of DNA from gel was achieved using 
the QIAgen Gel Extraction Kit and protocols supplied by the manufacturer (QIAgen). 
 
E.coli plasmid DNA isolation 
 Small-scale plasmid DNA isolation was performed using the QIAgen Quick Spin 
method or alkaline lysis method. For QIAgen Quick Spin method, protocols provided by 
the manufacturer (QIAgen) were followed.  
 33
 For large scale/maxi prep isolation of plasmid DNA, standard laboratory protocols 
were applied (Sambrook and Russel, 2001). Fresh bacterial colonies were suspended in 
250 ml of Luria broth (LB) (10g/l tryptone, 5g/l yeast extract, 10g/l NaCl, pH 7.0) 
contained in a 1 liter flask, plus an appropriate antibiotic (i.e. Ampicillin) for plasmid 
selection. Cells were grown to an optical density (OD) reading of 0.8 at 550 nm (OD550). 
Cells were transferred to sterile plastic bottles, and pellets were harvested at 7000 x g. 
Pellets were suspended in 10 ml Solution I (50 mM glucose, 10 mM EDTA, 25 mM Tris-
HCl, pH 8.0), were transferred to sterile Oak Ridge tubes, and were respun at 7000 x g.  
Pellets were resuspended in 4.5 ml of Solution I plus lysozyme (0.5 ml of 20mg/ml 
lysozyme), incubated at room temperature for 10 minutes, then were placed on ice for 
20 minutes, after which 10 ml of freshly prepared Solution II (0.2N NaOH, 1% SDS) was 
added, and cells were returned to ice bath for an additional 15 minutes. 7.5 ml of sodium 
acetate (3 M, pH 5.0) was added and incubation of cells on ice continued for 1 hour. Cell 
debris was pelleted at 27,000 x g at 4°C for 20 minutes. Supernatants were collected 
into sterile tubes, and 20 ml isopropanol was added and samples were incubated for 20 
minutes at room temperature, followed by 20,000 x g spin for 15 minutes, and a wash 
with 70% ethanol. Dried pellets were resuspended in 3.9 ml TE (pH 8.0) and were 
incubated for 30 minutes at 37°C, after which 4 ml LiCl (9 M) was added and the 
samples were transferred to -20°C for at least 20 minutes. The suspension was 
separated by centrifugation at 20,000 x g for 20 minutes, and supernatants were 
transferred to sterile tubes containing 8 ml of 95% ethanol. Tubes were placed on ice for 
1 hour, followed by collection of pellets at 12,000 g for 15 minutes. DNA pellets were 




Yeast and E.coli transformation procedures 
 All yeast transformations were performed according to lithium-treatment 
procedure (Ito, et al., 1983; Kaiser, et al., 1994). All E.coli transformations were prepared 
using chemically competent E. coli cells according to standard laboratory protocols 
(Sambrook and Russel, 2001). 
 
Standard yeast media and growth conditions 
 Yeast cultures were grown at 30°C unless otherwise noted. Standard yeast 
media and standard procedures for yeast cultivation, phenotypic and genetic analysis, 
transformation, sporulation and dissection were used (Kaiser, et al., 1994). Sporulating 
cultures were dissected using a micromanipulator Ergaval Series 10 from Carl Zeiss. 
Calculation of number of generations (G) for the time period t was calculated according 
to the following formula: G = log2(Ct/C0), where Ct is the concentration of the cells at the 
time point t, and C0 is the concentration of the cells at the starting point. Cell counts were 
performed using a hemacytometer (Brightline). Synthetic media lacking adenine, 
histidine, leucine, tryptophane, or uracil are designated as –Ade, -His, -Leu, -Trp and -
Ura, respectively. In all cases when the carbon source is not specifically indicated, 2% 
glucose (Glu) was used. The synthetic medium containing 2% galactose (Gal) or 2% 
galactose and 2% raffinose (Gal+Raf) instead of glucose was used to induce GAL 
promoter. Liquid cultures were grown with at least a 1/5 liquid/flask volumetric ratio in a 
shaking incubator (200-250 rpm). Yeast transformants were checked in all cases on 
YPG (medium containing glycerol as carbon source). Petites that are respiratory 
deficient do not grow on YPG or on medium containing galactose as sole carbon source 




Yeast DNA isolation 
 Plasmid and genomic DNA from yeast cultures was collected according to 
standard laboratory protocols (Kaiser, et al., 1994).  Briefly, cells from late log phase 
cultures were centrifuged at 7000 x g, and cell pellets were resuspended in 500 ul of 1M 
Sorbitol, 0.1 M EDTA, pH 7.5 containing 4% of a 50 ug/ml lyticase solution and were 
incubated at 37° C for approximately 3 hours. Cells were briefly spun down at 12,000 x 
g, and pellets were resuspended in 500 ul of a 50 mM Tris-HCl (ph 7.4), 20 mM EDTA 
solution. SDS was added to a final concentration of 1%, and the samples were 
incubated at 65°C for 30 minutes. 2 ml of 5 M potassium acetate was added and 
samples were placed on ice for 1 hour. Following 12,000 x g centrifugation, 0.75 ml 
isopropanol was added to the supernatants, samples were centrifuged at 12,000 x g for 
5 minutes. Supernatants were discarded and pellets were dried, resuspended in 0.4 ml 
TE (pH 7.4) plus 22 ul of a 1 mg/ml solution of RNAse A, and incubated at 37°C for 30 
minutes. DNA was precipitated with 2 volumes of 95% isopropanol. Samples were 
centrifuged at 12,000 x g for 15 minutes, and pellets were washed with 70% ethanol. 
DNA pellets were dried and resuspended in 50 ul TE (pH 7.4).  
 
Protein isolation and differential centrifugation   
 Collection and analysis of yeast total protein lysates was conducted using 
standard yeast laboratory procedures (Kaiser, et al., 1994; Sambrook and Russel, 
2001). Analysis of soluble and insoluble material of yeast total lysates (‘centrifugation’ or 
‘sedimentation’ analysis) was prepared according to previously published procedures 
(Patino, et al., 1996), with slight modification. At least 2 independent cultures (originated 
from independent transformants) were analyzed per each strain/plasmid combination. 
For Q25/Q103 blots, cells were collected by centrifugation and disrupted by 10min 
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vortexing with 600 µM acid-washed glass beads in the lysis buffer (40 mM HEPES 
[pH7.5], 50 mM KCl, 1% Triton X-100, 1 mM Na3VO4, 50mM β-glycerophosphate, 50 mM 
NaF, 5 mM EGTA, 5 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1mM benzamidine, 
and 0.2 of one proteinase inhibitor tablet, Roche, pre-dissolved in distilled water). Cell 
debris were removed by centrifugation at 800 g for 10 min. This step also precipitates 
some of Q103 and Q25 protein; fraction of protein precipitated in these conditions was 
not influenced by the chaperone composition (not shown). The resulting supernatant 
was fractionated by centrifugation at 10,000 g for 10 min. The pellets were dissolved in 
the same volume of lysis buffer as respective supernatants. Loading SDS-PAGE buffer 
with 2% SDS, was added to both pellets and supernatants. Samples were denatured by 
boiling for 5 min, ran on SDS-PAGE, transferred to nitrocellulose membrane and reacted 
to anti-GFP monoclonal antibody (Sigma), and the to the secondary antimouse antibody 
(Sigma). Horse radish peroxidase tagged to secondary antibody was detected using 
Amersham ECL detection system. Densitometry was performed on X-ray films by using 
the Kodak 1D program from a Gel Logic 200 imaging system. 
       For Sup35 and Rnq1 blots, yeast cells were suspended in centrifugation lysis buffer 
with slightly different composition (50 mM tris-HCl, pH7.5 + 10 mM KCl + 5 mM MgCl2 + 
0.1 mM EDTA + 0.1 mM DTT + 100µg/ml cycloheximide + 2 mM PMSF + 1 mM 
Benzamidine + 2µg/ml Pepstastin A + 10µg/ml Leupeptin + 100µg/ml RNase A) were 
lysed with glass beads on a vortex mixer. High concentrations of proteinase inhibitors 
were required to keep proteins stable throughout the fractionation procedure. Cell debris 
was removed by centrifugation at 3,000 x g to produce a “total lysate” fraction. Half of 
the total lysate was used as a control, while the remainder was fractionated by 
centrifugation at 12,000 x g for 15 min. The supernatant was placed into a fresh tube, 
and the pellet was resuspended in an equal amount of the lysis buffer. SDS, glycerol, 2-
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mercaptoethanol and Tris-HCl (pH 6.8) were added to every sample up to final 
concentrations of 3%, 10%, 3% and 0.15 M, respectively. Resulting samples were 
heated at 95oC for 10 min and run on the standard SDS-polyacrylamide gel. For 
performing the protein assays, gels were transferred onto Hybond ECL nitrocellulose 
membranes and reacted to the appropriate antibodies. Where required, densitometry 
measurements were obtained from exposed films using the program Alphaimager 2000, 
Alpha Innotech Corporation. 
       
Nonsense suppression assay for presence of [PSI+] 
Presence of [PSI+] was detected by its ability to suppress the ade1-14UGA mutant allele, 
as described previously (Chernoff, et al., 2000; Derkatch, et al., 1996). The [psi-] ade1-
14UGA strains are not able to grow on medium lacking adenine (-Ade) and exhibit dark 
red color on rich (YPD) medium, while [PSI+] ade1-14UGA strains are able to grow on –
Ade after 2-3 days  (‘strong’ [PSI+]) or 7-10 days (‘weak’ [PSI+]), and exhibit light-pink 
color on YPD. ‘Mosaic’ colonies containing both [PSI+] and [psi-] cells were detected as 
sectored pink/red colonies on YPD medium. In quantitative analyses, mosaic/sectored 
colonies were scored as ½ [PSI+] since when the cell was plated, [PSI+] was present, but 
was unstable in successive cell divisions. 
 
Assay to monitor for presence of [RNQ+]  
 The non-Mendelian element [PIN+] controls the ability of overproduced Sup35 to 
induce de novo formation of [PSI+] (Derkatch, et al., 1997). In all of the yeast strains 
used in this study, [PIN+] is known to be encoded by the prion form of the Rnq1 protein, 
designated [RNQ+]. The presence of [RNQ+] was monitored by one of the following 
assays depending on the strains used: 1) [psi-] strains, bearing the galactose-inducible 
plasmid pLA1-SUP35, were incubated on –His/Gal medium and velveteen replica plated 
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onto –Ade/Glu media. [RNQ+] was detected by growth on –Ade after 10-14 days of 
incubation, due to induction of [PSI+]. 2) [psi-] strains lacking pLA1-SUP35 were mated to 
the strain [psi- rnq-] GT234 bearing the multicopy SUP35 plasmid pSTR7 (or YEp13 
empty vector control, for comparison). The [RNQ+] diploids, in contrast to [rnq-] diploids, 
grew on medium lacking adenine after 10-14 days of incubation due to induction of 
[PSI+].  3) To check the [PSI+] strains for the presence of [RNQ+], cells were first cured of  
[PSI+] by galactose-inducible wild-type Hsp104 (Chernoff, et al., 1995), which does not 
cure yeast cells of [RNQ+] (Derkatch, et al., 1997). At least two independently cured [psi-] 
derivatives were usually analyzed for each [PSI+] clone, always with the same result. 
These [psi-] derivatives were either transformed individually with the multicopy SUP35 
plasmid pSTR7 (or YEp13 empty vector control, for comparison), in case of diploid 
strains, or mated to the [psi- rnq-] GT234 bearing pSTR7 (or YEp13 empty vector control, 
for comparison), in case of haploid strains. Presence of [RNQ+] in the resulting 
transformants or diploids was detected as described above. 
 
Thermotolerance assay 
To measure thermotolerance of the exponential yeast cells, yeast precultures 
were grown overnight at 25°C in the synthetic medium selective for the plasmid(s) 
containing inducer if the constructs were inducible, at a starting concentration of 2.4 x 
105 cells/ml till final concentration was 106 cells/ml was reached. The cultures typically 
took 24hrs in shaker conditions to attain this concentration. 0.5ml aliquots of each 
culture were placed on ice (control samples) or incubated for 5 to 20 mins in the 50°C 
waterbath and then on ice (heat-shocked samples). Then serial dilutions of both the 
control and heat-shocked samples were prepared and either pipetted onto the 
corresponding synthetic selective medium containing glucose, 5µl per spot or 3µl per 
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Plate assay for cytotoxicity 
To assess cytotoxicity qualitatively, yeast transformants were patched on to the 
Glu medium selective for the plasmid(s) and velveteen replica plated onto the inducer 
containing medium of the same composition eg: in order to induce the PGAL  promoter- 
galactose containing medium, to induce PCUP1- CuSO4 containing medium. This was 
followed by the second passage on inducer medium, by using either velveteen replica 
plating or spotting with a spotter from Replicatech if necessary. Differences in growth 
were better seen sometimes after the second passage. Atleast 8 independent 
transformants were tested in each case for each strain/plasmid combination. All or vast 
majority of them did usually show the same results. Typical representatives are shown 
on figures. 
 
Quantitative assay for cytotoxicity 
 To measure cytotoxicity quantitatively, yeast cultures were pre-grown overnight 
in the synthetic Glu liquid medium, selective for the plasmid(s), and inoculated at 105 
cells/ml into the liquid inducer medium eg: Gal+Raf medium of the same composition, in 
order to induce the PGAL constructs. Aliquotes were taken after various periods of 
incubation, and plated onto the Glu medium selective for plasmid(s). Colonies were 
counted after 3 days of incubation at 30°C. Two platings for each of two independent 
cultures for each strain/plasmid combination were performed at each time point. 
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Averages of four counts are shown on Figures. Standard deviations never exceeded 
35% of the value for each time-point.  
 
GFP detection by fluorescence microscopy 
 GFP fluorescence images were taken using live cultures. An aliquote of cells was 
placed onto a glass slide, it was sealed with a coverslip using nail polish. Images were 
scanned using Olympus BX41 microscope with a 100X objective, with Narrow band GFP 
filter. Typically, Cultures were grown overnight in the inducer containing medium eg 
Gal+Raf medium for genes expressed under galactose inducible promoter, as described 
above for quantitative analysis. Only cells showing fluorescence were counted and 
grouped into different classes based on the patterns observed. The excitation 
wavelength was 543 nm for the helium-neon laser (rhodamine fluorescence), and 488 
nm for the argon laser used to visualize GFP.   
 
Endocytosis assay 
 For staining with FM4-64 (Molecular Probes), mid-log phase cells grown in the 
Gal+Raf medium were concentrated 10-times and incubated with 8µM dye for 12 mins in 
the selective medium with galactose. Cells were washed two-times with the same 
medium and left for 45 min at 30°C shaker (Meriin et al., 2003). FM4-64 staining was 

































Figure 2.1 Internalization of the lipophilic dye FM4-64  in normal cells    
The dye binds the cell membrane and is internalized through the 
endocytic pathway. Red patches represent the labeled endosomes 
after 10-15 minutes of staining and distinct ring-shaped labeling of the 
vacuoles after 45 minutes of staining reflecting the fusion of 
endosomes with vacuolar membrane is an indication that endocytosis 
is not affected.  
                                          
12 minute staining 
 45 minute staining 
 42
CHAPTER 3 





The ClpB/Hsp100 proteins are conserved members of the AAA+ superfamily 
(Wickner et al., 1999). The AAA+ proteins are ATPases associated with various cellular 
activities like protein folding, membrane trafficking, organelle biogenesis, proteolysis, 
intracellular motitility and DNA replication (Neuwald et al., 1999; Vale, 2000; Ogura and 
Wilkinson, 2001). This group of proteins is found in bacteria, protozoa, fungi and plants 
and their expression is inducible by heat stress (Schirmer et al., 1996). In yeast, 
Arabidopsis and maize, the Hsp100/ClpB play a major role in acquisition of 
thermotolerance ie the ability to survive very high temperatures (Sanchez and Lindquist, 
1990; Queitsch et al., 2000; Nieto-Sotelo et al., 2002). Hsp104 (Yeast Hsp100) is also 
important in prion maintenance (Chernoff et al., 1995; Patino et al., 1996; Paushkin et 
al., 1996; DebBurman et al., 1997; Moriyama et al., 2000) and was shown to be 
essential for the aggregation of poly-Q expanded exon 1 of Htt (Q103) (Krobitsch and 
Lindquist, 2000; Cao et al., 2001; Kimura et al., 2001; Satyal et al., 2000).  
Two models have been proposed to explain the role of Hsp104 in prion life-cycle. 
The first model suggests that Hsp104 converts the cellular Sup35 protein into a partially 
unfolded intermediate, which serves as a substrate for prion conversion (Chernoff et al., 
1995). The second model suggests that Hsp104 facilitates prion conversion by 
combining partially unfolded intermediates into oligomeric complexes thus producing 
new prion ‘seeds’ initiating new rounds of prion replication (Patino et al., 1996; Serio and 
Lindquist, 2000).  
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A non-mutagenic chemical agent (GuHCl) cures all three yeast prions [PSI+],  
[URE3] (Wickner, 1994) and [RNQ+] (Derkatch et al., 1997). [PSI+] loss by GuHCl occurs 
in a strictly generation-dependent manner apparently by a “ dilution mechanism” 
blocking [PSI+] proliferation (Tuite et al., 1981; Eaglestone et al., 2000). GuHCl is a 
protein-denaturing agent, however at concentrations used (1-5mM), it is not high enough 
to cause significant protein denaturing. These concentrations however have been shown 
to inhibit ATPase activity of Hsp104 in vitro (Glover and Lindquist, 1998). This suggests 
that GuHCl cures yeast cells of prions by inactivating Hsp104 (Eaglestone et al., 2000; 
Glover and Lindquist, 1998; Ness et al., 2002; Ferreira et al., 2001; Jung et al., 2002). 
This suggestion is further supported by the finding that a point mutation at residue 184 
prevents [PSI+] curing by GuHCl, implicating Hsp104 as the major target of GuHCl in 
prion replication cycle (Jung et al., 2000).  
The functional unit of the Hsp104 is composed of six monomers each with two 
ATP binding sites (nucleotide binding domains one and two also known as NBD1 and 
NBD2). The NBDs are highly conserved (Schirmer et al., 1996) flanked by less 
conserved amino-terminal, middle, and carboxy-terminal regions (Parsell et al., 1991). In 
related proteins, the N and C-terminal regions appear to bind substrates and/or effector 
proteins (Smith et al., 1999; Barnett et al., 2000). The middle region is the most variable 
and least understood. Even though the middle domain is not conserved, its length and 
the primary and secondary structure has been conserved during evolution (Nieto-Sotelo 
et al., 1999). The middle region has a propensity to form a coiled-coil (Nieto-Sotelo et al., 
1999). Both NBDs are essential for function: substitution of critical lysine residues at 
position 218 and 620 in the Walker-A sites by threonine in either NBD eliminates 
thermotolerance (Parsell et al., 1994) and interferes with prion maintenance function 
(Chernoff et al., 1995). Careful analysis indicated that the single mutation at position 218 
(NBD1) prevents hydrolysis of ATP, not affecting the oligomerization of Hsp104, while 
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the 620 mutation impairs Hsp104 oligomerization, but not ATP hydrolysis (Schirmer et 
al., 1998; Parsell et al., 1994). The Hsp104-KT mutants are dominant-negative for [PSI+] 
curing (Chernoff et al., 1995) and thermotolerance (Wegrzyn et al., 2001). The Hsp104-
KT mutant also cures [PIN+] (Wegrzyn et al., 2001). A great degree of conservation in 
the nucleotide-binding domain and middle domain amongst plant, yeast and bacterial 
orthologs is seen. Plant Hsp101 shares 60% similarity with Yeast Hsp104. Moreover, 
expression of Hsp101 could complement the thermotolerance defect in yeast caused by 
deletion of HSP104 . 
            Ssa proteins –members of the Hsp70 family are also coinduced with Hsp104 
during heat shock, stationary-phase growth and sporulation (Kurtz et al., 1986; Werner-
Washburne and Craig, 1989). They interact with Hsp104 in thermotolerance in vivo 
(Sanchez et al., 1993) and in protein disaggregation in vivo (Glover and Lindquist, 1998).  
Ssa1 favors [PSI+] propagation. Hsp104’s role is to cause aggregate disassembly, and 
Hsp70-Ssa is proposed to promote new rounds of aggregate assembly. This concerted 
action of Hsp104 and Hsp70-Ssa results in prion proliferation. 
 In this chapter, we present a detailed study of the effects of Hsp104-wild-type 
and different mutants (NBD, Middle domain and C-terminal region) including plant 
Hsp104 (Hsp101) on Q-rich aggregates formed by Sup35, Rnq1 and Htt-Q103. We also 
present kinetics of [PSI+] and [PIN+] loss by Hsp104, Hsp104-KT and GuHCl. 
 
Materials and methods 
 
Yeast Strains 
Yeast strains used in this study are discussed in detail in Chapter 2 and Table 
2.1. The [PSI+ pin-] strain GT490 was OT56, cured of [PIN+] by expressing the dominant 
negative Hsp104 derivative Hsp104-KT218,620 (Wegrzyn, et al., 2001). For this 
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purpose, OT56-derived colonies that retained [PSI+] after pulse induction of Hsp104-
KT218,620 expression, were then cured of [PSI+] by excess wild-type Hsp104 and 
checked for retention of [PIN+] (see description of the [PIN+] assay in Chapter 2 Materials 
and Methods section). As wild-type Hsp104 usually does not cure [PIN+], those 
becoming [pin-] after excess Hsp104 treatment were identified as originating from the 
[PSI+ pin-] derivatives. Lack of the aggregated (prion) form of Rnq1 in these derivatives 
was then confirmed by differential centrifugation assay (Chernoff, et al., 2002). 
 
Plasmid constructs 
Plasmids specific to this study are described here, for all other commonly used 
plasmids refer to Chapter 2. The plasmid pUK21-KT218,620 was constructed by 
inserting XhoI-EcoRI  fragment of HSP104 obtained from plasmid pKT218,620 into XhoI-
EcoRI  digested plasmid pUK21 (Vieira and Messing, 1991). The plasmid pKT218,620  
provided by S. Lindquist contains two Lys-to-Thr substitutions at codons 218 and 620 of 
the HSP104 gene that inactivate both the ATP binding sites of Hsp104 (Parsell et al., 
1991). The HIS3-based plasmid pLA1-HSP104KT and URA3-based plasmid 
pRS316GAL-HSP104KT which express the HSP104KT218,620 mutant allele under the 
GAL promoter, were constructed by inserting the 3.2kb BamH1-SpeI fragment of mutant 
Hsp104 from pUK21-KT218,620 into BamH1-SpeI digested pLA1 and pRS316GAL 
respectively (Wegrzyn et al., 2001).  
Dr. Elizabeth Vierling’s lab kindly provided us the plasmid pAZ958. The BamHI-
XbaI fragment contains HSP101 cDNA (wild type) from Arabidopsis and plasmid 
pAZ1092 BamHI-XbaI fragment contains mutant HSP101 (hot1-4) from Arabidopsis. The 
change is a G to an A at position 1495. These fragments were cloned into yeast 
expression vectors in order to study them in yeast. The HIS3-based plasmid pLA1-
plantHsp104WT that expresses Wild-type Plant Hsp101 under the GAL promoter was 
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constructed by inserting the BamH1-Xba1 HSP101 fragment from plasmid pAZ98 into 
BamH1-Xba1 digested pLA1. Similarly, pLA1-plantHsp104MT was constructed by 
inserting BamH1-Xba1 Mutant HSP101 fragment from plasmid pAZ1092 into BamH1-
Xba1 digested pLA1.  
 
Quantitation of prion curing 
Transformants were grown in the same manner as described in materials and 
methods- quantitative assay section. Growth was monitored by counting cells and 
cultures were maintained in the exponential phase of growth by periodically diluting them 
with fresh medium. Aliquots were taken after certain periods of time and were plated 
onto synthetic plasmid-selective Glu medium. Colonies were counted and analyzed for 
the presence of [PSI+] and [PIN+] as described in Chapter 2.In addition to complete 
[PSI+] and [psi-] colonies, a fraction of the mosaic colonies that showed both light pink 
[PSI+] and red [psi-] sectoring were counted as half [PSI+] and half [psi-]. The number of 
generations (G) for the time period t was calculated according to the formula : G = log2 
(Ct / C0) where Ct is the concentration of viable plasmid-containing cells at time-point t 
and C0 is the concentration of the viable plasmid-containing cells at the starting point. 
Concentrations of viable plasmid-containing cells were determined by from the numbers 
of colonies grown on selective medium. Curing by 5mM GuHCl was quantified in exactly 
the same way except that the strains did not contain galactose-inducible plasmids, both 
cultures growing in synthetic Gal + Raf medium and in YPD medium were analyzed for 
comparison, aliquots were plated onto YPD medium, and all viable cells rather than only 






The data on Hsp104 and Ssa effects on [PSI+] is published in Wegrzyn et al., 2001. The 
data on Hsp104 effects on poly-Q toxicity has been submitted for publication to the 
Journal of Biological Chemistry as a part of Gokhale et al., 2005 manuscript. 
 
 
Comparison of the kinetic parameters of prion curing by excess Hsp104 Wild-type, 
mutant Hsp104-KT and GuHCl 
 
GuHCl, an agent that blocks [PSI+] proliferation (Eaglestone et al., 2000) 
presumably does so by inactivating Hsp104 (Eaglestone et al., 2000; Glover and 
Lindquist, 1998). To check this, we compared kinetics of [PSI+] loss by wild-type 
Hsp104, mutant Hsp104-KT and GuHCl in the [PSI+PIN+] strains GT81-1C (Figure 3.1 
A), OT55 (Figure 3.1 B) and OT56 (Figure 3.1 C). As wild-type and mutant Hsp104 were 
induced in synthetic Gal + Raf medium, the GuHCl induced curing of [PSI+] was also 
studied in both YPD and Gal + Raf medium. Although GT81-1C and OT56 were more 
resistant to [PSI+] curing effect of GuHCl in Gal + Raf medium than in YPD medium, it 
did not change the general picture. In all cases, no statistically significant [PSI+] loss was 
observed for the first 4 to 5 (strong [PSI+] cultures- Figure 3.1 A, C) or 3 to 4 (weak [PSI+] 
culture-Figure 3.1 B) cell divisions in the presence of GuHCl, confirming the existence of 
a lag period apparently required for dilution of [PSI+] replicating units. In contrast cultures 
overexpressing either Wild-type or mutant Hsp104 did not exhibit this lag. The weak 
[PSI+] strain OT55 was more sensitive to the curing effect of wild-type Hsp104 but not to 
the curing effects of mutant Hsp104 than was the isogenic strong [PSI+] strain OT56 
(Figure 3.1 B, C). This further confirms a difference between the mechanisms of [PSI+] 
curing effects of wild-type Hsp104 and mutant Hsp104-KT. Quantitation of [PIN+] curing 
in the [psi- PIN+] strain OT60 demonstrates that [PIN+] loss by GAL-HSP104KT is very  
 
Figure 3.1 Kinetics of [PSI+] and [PIN+] loss                                              
A, B and C. Comparison of kinetic parameters of [PSI+] curing by WT 
Hsp104, Hsp104-KT and GuHCl  in the yeast strains A. GT81-1C , B. 
OT55 and C. OT56. Curing conditions included induction of GAL-
HSP104 (Hsp104), induction of GAL-HSP104-KT (Hsp104-KT), growth in 
the presence of 5 mM GuHCl in rich medium (YPD + 5 mM GuHCl) or in 
synthetic Gal + Raf medium (Gal + Raf + 5mM GuHCl). See materials 
and methods for procedures. D. Quantitation of [PIN+] curing in the [psi-
PIN+] OT60 by Hsp104-KT. Expression of GAL-HSP104KT was induced 
on –Ura/Gal medium. Cells were plated onto –Ura medium after various 
periods of time. Presence of [PIN+] in resulting colonies was determined 
in a cross to the tester strain GT234/pSTR7 as described in Materials 




































Table 3.1 Distribution of [PIN+] among [PSI+] and [psi-] colonies obtained after excess 
Hsp104 or excess Hsp104-KT treatment 
 
Strain       Induced         No. of                                       Distribution of  
               construct    Generations                  [PSI+]                                 [psi-] 
                                                          No. (%)      Total no of        No. (%)      Total no of 
                                                          [PIN+]    [PSI+] analyzed    [PIN+]    [PSI+] analyzed    
 
OT55   GAL-HSP104        0.4             NT                                     8 (100)           8 
                                         2.3         8 (100)              8                   8 (100)           8                                  
                                         7.3              NT                                     8 (100)           8      
 
OT55  GAL-HSP104KT    1.2         16(80)             20                     1 (33)           3    
                                         4.0             2(8)             24                      1 (6)           16 
                                         8.0              NT                                         0                 3 
                                         9.0              NT                                         0                 5 
 
OT56  GAL-HSP104        2.0         8 (100)              8                   8 (100)           8                                  
                                         7.0              NT                                     8 (100)           8      
                                         7.5              NT                                     8 (100)           8      
 
OT56  GAL-HSP104KT    0.5              NT                                      2 (29)            7 
                                         4.3          5 (21)             24                         0              26 
                                         7.9          5 (21)             24                         0              21 
 




rapid and is nearly complete by third generation (Figure 3.1 D). The [pin-] cells were 
detected as early as in the first generation after Hsp104-KT induction (Table 3.1).  
Quite remarkably [PIN+] appeared to be more frequently retained in cells remaining 
[PSI+] than in cells becoming [psi-]; in strain OT56, [PIN+] was still retained by  
some [PSI+] cells after eight generations, yet it was entirely lost from [psi-] cells after four 
generations (Table 3.1). This is in agreement with preferential coretention and coloss of 





Mutant Hsp104-KT interferes with the activity of wild-type Hsp104 
One possible mechanism of Hsp104-KT to cure [PSI+] is by interfering with Wild-
type Hsp104 by inhibiting assembly of functional Hsp104 hexamers. That is indeed the 
case with K620T as it impairs Hsp104 oligomerization in vitro. It is likely that in vivo, the 
interaction between mutant and wild-type Hsp104 leads to the formation of 
heteromultimeric complexes so that the formation of functional Hsp104 hexamers 
becomes inefficient. If so, this effect should be partly overcome by increasing 
concentration of wild-type Hsp104. Similarly, Hsp104-KT show partly ameliorate the 
[PSI+] curing effect of excess Wt Hsp104. To check this, we overexpressed GAL-
HSP104 and GAL-HSP104KT constructs separately and together in [PSI+] strain OT56. 
[PSI+] curing by wild-type or mutant Hsp104 alone proceeded with similar rapid kinetics 
such that less than 60% of cells remained [PSI+] one generation after galactose 
induction and less than 10% of cells remained [PSI+] after four generations (Figure 3.2 
A). In contrast, more than 80% of cells remained [PSI+] after one generation and more 
than 40% remained [PSI+] after 4 generations when both mutant and wild-type were 
expressed together (Figure 3.2 A). This indicates that wild-type and mutant Hsp104 
interfere with each other’s [PSI+] curing effects as would be expected if Hsp104-KT acts 
by inactivating wild-type Hsp104. 
 
Interactions of Hsp70-Ssa with wild-type and mutant Hsp104 
Hsp70-Ssa protects [PSI+] curing by excess wild-type Hsp104 (Newnam et al., 
1999). In order to examine whether it does so with mutant Hsp104-KT, we expressed 
GAL-SSA1 construct with either wild-type HSP104 or mutant HSP104-KT in the [PSI+] 
strain OT56. Hsp70-Ssa did not protect [PSI+] curing by excess mutant Hsp104-KT 
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Figure 3.2 Interactions of wild-type Hsp104, mutant Hsp104-KT and Hsp70-Ssa 
A. Antagonistic interaction between mutant and wild-type Hsp104 in [PSI+] 
curing. Yeast strain was transformed with pH28 (Hsp104), pLA1-HSP104KT 
(Hsp104-KT), a combination of both plasmids or controls. Cultures were 
induced in liquid –Ura-His/Gal + Raf medium (see materials and methods) and 
plated onto YPD medium at various time points to detect [PSI+] curing. Both 
wild-type and mutant Hsp104 proteins cure [PSI+] completely by fourth 
generation of growth. Coexpression of wild-type and mutant Hsp104 reduces 
[PSI+] curing. B. Effects of Hsp104 and Ssa on [PSI+] curing Yeast strain was 
transformed with plasmids pH28 + pRS316GAL (Hsp104), pH28 + pGAL-SSA1 
(Hsp104 + Ssa), pLA1-HSP104KT + pRS316GAL (Hsp104-KT) and pLA1-
HSP104KT + pGAL-SSA1(Hsp104KT + Ssa). Cultures were induced in liquid –
Ura-His/Gal + Raf medium. Excess Hsp70-Ssa protects [PSI+] from curing by 
excess Hsp104 but not from excess Hsp104-KT. C. Effects of Hsp70-Ssa on 
[PSI+] curing by color assay. In addition to the plasmids used in legend 4.2B , 
were combinations pGAL-SSA1(Ssa1) and pLA1 (control). Transformants were 
grown on solid –Ura-His/Gal medium and velveteen replica plated onto YPD 
medium. Lighter color is indicative of intense suppression. Results confirm that 
excess Hsp70-Ssa decreases the [PSI+] curing effect of excess Hsp104 but 
increases the PSI+] curing effect of excess Hsp104-KT                                     
Yeast strain used: OT56 [PSI+ PIN+]
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efficient in the presence of excess Ssa. Yeast cultures expressing Hsp70-Ssa and wild-
type Hsp104 simultaneously exhibited lighter color on YPD medium compared to  
cultures overexpressing Hsp104 alone. This corresponds to higher retention of [PSI+] 
mediated nonsense suppression in the presence of excess Hsp70-Ssa. However 
efficiency of [PSI+] mediated nonsense suppression was reduced in cultures that  
underwent simultaneous overexpression of Hsp70-Ssa and Mutant Hsp104KT compared 
to that of the cultures expressing Hsp104-KT alone. This reduction resulted in a more 
intense red color on YPD medium (Figure 3.2 C) Thus Hsp70-Ssa exhibits opposite 
effects on [PSI+] curing by overproduced wild-type and mutant Hsp104. 
 
Effects of the mutant alleles of yeast Hsp104 and plant Hsp101 on [PSI+] and [PIN+] 
 Overproduction of the yeast chaperone Hsp104 is known to eliminate [PSI+] 
(Chernoff et al., 1995) but not [PIN+] (Derkatch et al., 1997). The double K-to-T 
substitution at aa positions 218 and 620 of Hsp104 (Hsp104-KT) inactivates both 
nucleotide binding domains of Hsp104 (NBD1 and NBD2) and disrupts the function of 
wild-type Hsp104 in a dominant negative fashion (Chernoff et al., 1995; Schirmer et al, 
1998). In contrast to overproduced wild-type Hsp104, mutant Hsp104-KT cures yeast 
cells not only of [PSI+] (Chernoff et al., 1995) but also of [PIN+] (Wegrzyn et al., 2001).  
Hsp104-K302N (refer below for the description of how K302N was isolated) has a 
mutation in its nucleotide binding domain. It cures both [PSI+] and [PIN+] prions (Table 
3.2). 
Next, we checked if Hsp104 mutants previously isolated in a genetic screen at S. 
Lindquist laboratory (Schirmer et al., 2004) affect [PSI+] and [PIN+] (see Table 3.2). 
Some of the mutations were in the nucleotide binding domain (Hsp104-NBDDA) –cured 
[PSI+] (Table 3.2) while some in the middle domain (Hsp104-A503V, Hsp104-
A503VA509D and Hsp104-A503V) did not cure [PSI+] and [PIN+] except for Hsp104-
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A509D (Table 3.2) and C-terminal domain (Hsp104-C* where C* indicates several 
substitutions from negatively charged residues to positively charged ones) of Hsp104did 
not cure [PSI+] and [PIN+](Table 3.2). Some mutant alleles had mutations in more than  
 
 
Table 3.2. Effects of different Hsps on yeast prions                      
Overexpressor                           Tested for [PSI+]          Tested for [PIN+]      
combinations                                       ____________        ____________                            
                                    [PSI+]   [psi-]    Total      [PIN+]   [pin-]  Total  
 
Control                                        48          0           48          48        0        48      
↑ WT Hsp104          0            48         48          48        0        48           
↑ Library Hsp104 (Hsp104-K302N)  0            48         48          0          48      48          
↑ Hsp104-A509D      21          27    48      18         30      48 
↑ Hsp104-A503V          Not applicable*                48         0        48    
↑ Hsp104-A503VA509D       45   3    48      48         0     48 
↑ Hsp104-NBDDA         0            48         48           Not tested                      
↑ Hsp104-Internal deletion at C-terminal   3   45    48       45        3     48 
↑ Hsp104-C*     36   12         48           48       0        48  
↑ Hsp104-G217ST499I         0            48         48          Not tested                      
↑ Hsp104-A392TT499I P679KK620T 5   43    48        45       0        48 
↑ Hsp104- L421KI424DI428K (MI)    15          33    48        48       0        48      
↑ Hsp104- L445RA448DL455K (MII)    14          34         48            0        48      48      
↑ Hsp104- A479DL483KL486R (MIII)                                     Not applicableδ            
↑ Plant WT Hsp104          48          0           48            48       0       48      
↑ Plant Hsp104-A499T                48          0           48            48       0       48      
                            
* Hsp104-A503V is toxic to [PSI+] 





one domain eg Hsp104-G21ST499I –cured [PSI+] and Hsp104-
A392TT499IP679KK620T cured [PSI+] but not [PIN+] while one mutant allele had internal 
deletion in C-terminal domain that also cured [PSI+] but not [PIN+] (Table 3.2).  Hsp104-
A503V by itself was toxic to the [PSI+] strain (see in more detail below) and did not cure 
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[PIN+] (Table 3.2) The Hsp104-A503V derivative was also previously shown not to 
antagonize thermotolerance (Schirmer et al., 2004).  
Amongst the mutant alleles of Hsp104 with triple aminoacid substitutions in 
amphipathic α-helices of middle domain that has a propensity to form a coiled-coil 
(Schirmer et al., 1996), MI ( mutations affecting helix 1) and MII ( mutations affecting 
helix 2) both cured yeast prion [PSI+] though not completely, with only MII curing [PIN+] 
as well (Table 3.2). MIII (mutations affecting helix 3) remains toxic in the strain 
background tested. Mutations that changed the amphipathic character on helices 2 (MII) 
and 3 (MIII), but not those on helix 1(MI) caused the loss of function of Hsp104 
suggesting that helices 2 and 3 play an important role in the maintenance of a coiled-coil 
structure. Moreover, these mutations abolished the hexamer formation and changed the 
protein stability (Neito-Sotelo et al., unpublished results).  
Plant Hsp101 shares the domain architecture of middle domain with the yeast 
Hsp104. As in yeast, Hsp101 plays a major role in the acquisition of thermotolerance ie 
the ability to survive high temperatures, following acclimation to mild heat shock 
treatments (Sanchez and Lindquist, 1990; Queitsch et al., 2000; Nieto-Sotelo et al., 
2002). The T499A mutation falls in the coiled-coil linker between the two NBDs and 
corresponds to yeast position 502. This mutant failed to develop thermotolerance to 
45°C providing an evidence for an essential role of this structural domain. When 
checked for their effects on yeast prions, both Wild-type and mutant Plant Hsp104 did 
not cure either [PSI+] or [PIN+] (Table 3.2). In all cases, 12 subclones from 4 independent 





[PSI+]-specific toxicity of Hsp104-A503V  
As mentioned above, expression of Hsp104-A503V by itself inhibited growth of 
the [PSI+  PIN+] strain OT56 and [PSI+ pin-] strain GT490. Such an effect was not seen in 
the isogenic [psi- PIN+] strain OT60, confirming that it is specific to [PSI+] rather than to 
any prion (Figure 3.3 A, B). The severity of the toxic effect of Hsp104-A503V depended 
on the variant of [PSI+]. The [PSI+ PIN+] strain OT55, which is isogenic to OT56 but 
bears a “weak” variant of [PSI+], characterized by the larger proportion of the Sup35 
protein remaining in the soluble fraction (Allen et al., 2004; Derkatch et al., 1996), was 
not inhibited by expression of Hsp104-A503V to such an extent as was OT56 (data not 
shown). One possibility is that toxicity of Hsp104-A503V is due to increased 
sequestration of the soluble Sup35 protein by prion aggregates. As Sup35 is an 
essential protein working in termination of translation, such sequestration may inhibit 
growth of the “strong” [PSI+] variants where amount of the remaining soluble Sup35 is 
already low. To test this hypothesis, a high-copy plasmid expressing only the Sup35C 
domain was introduced into the [PSI+] strain together with the Hsp104-A503V expression 
construct. Sup35C is completely functional in translation, but is not sequestered by the 
[PSI+] prion aggregates, as it lacks the Sup35N prion domain. As expected, Sup35C 
counteracted toxicity of Hsp104-A503V in the [PSI+] background (Figure 3.3 C). 
 Next we checked whether Hsp104-A503V influences the size of the Sup35 prion 
aggregates. These experiments employed the construct containing the Sup35N (prion) 
and M (middle) domains fused to GFP. Inclusion of this tagged protein into the prion 
aggregates makes them detectable by fluorescence microscopy (Chernoff et al., 2002). 
In the [PSI+] cells, Sup35NM-GFP, expressed under the endogenous PSUP35 promoter, 
usually shows diffused fluorescence pattern (Bailleul et al., 2000; Wegrzyn et al., 2001), 
due to the fact that the Sup35PSI+ aggregates are usually so small in these conditions 
that they can hardly be recognized. However, in the presence of Hsp104-A503V, the  
[PSI+ PIN+]
↑ Hsp104-A503V
↑ Hsp104-A503V + ↑ Sup35C
↑ Sup35C
Control
Figure 3.3 [PSI+] dependent toxicity of the Hsp104-A503V mutant derivative 
A. Expression of Hsp104-A503V inhibits growth of the [PSI+] cells while expression 
of Hsp104-G217ST499I is toxic regardless of the prion background. Plates were 
photographed after 3 days of incubation (second passage) on the -His/Gal medium, 
used to induce the Hsp104 constructs. Data  for [PSI+ PIN+] and [psi- PIN+](shown) 
and [PSI+ pin-] (not shown) was same as [PSI+ PIN+] . B. Quantitative assay 
demonstrating growth inhibition of [PSI+] cells expressing Hsp104-A503V. Cultures 
were grown in the liquid -His/Gal+Raf medium to maintain and induce the Hsp104-
A503V and control constructs. Growth rate of the [PSI+] culture overexpressing
Hsp104-A503V is statistically different from growth rate of all other cultures; 
differences between other cultures are statistically insignificant. C. Hsp104-A503V
toxicity is ameliorated by overproducing Sup35C in [PSI+ PIN+] cells. Cultures 
contained the PGAL-HSP104-A503V plasmid, high-copy SUP35C plasmid and 
empty controls in all possible combinations. Plates were photographed after 4 days 
of incubation (second passage) on the -Ura-His/Gal medium, which is selective for 
both plasmids and induces the Hsp104-A503V construct. D. Effect of Hsp104-
A503V on the Sup35NM-GFP aggregation. Cultures were grown in the Gal+Raf
medium, which is selective for both PGAL-HSP104-A503V (or control) and PSUP35-
SUP35NM-GFP plasmids, and induces the PGAL-HSP104-A503V construct. All cells 
expressing Sup35NM-GFP alone show diffused fluorescence, while cultures co-
expressing Hsp104-A503V with Sup35NM-GFP contain cells with detectable 
clumps and dots. Numbers of cells are the averages of two counts, with at least 
100 cells counted in each case. 
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same PSUP35-SUP35NM-GFP construct produced large detectable clumps or dots (Figure 
3.3 D). Thus, expression of Hsp104-A503V increased the size of Sup35 aggregates. 
Possibly, increased Sup35 aggregation contributes to cell toxicity. Such an effect of  
Hsp104-A503V would be similar to consequences of Sup35 (or Sup35N/NM) 
overproduction in the [PSI+] background, which results in both appearance of large 
detectable Sup35 clumps (Patino et al., 1996) and cell toxicity (Chernoff et al., 1992;Ter-
Avanesyan et al., 1993; Derkatch et al., 1996).  
 
Effects of the yeast prion [PSI+] and chaperone Hsp104 on Q103 toxicity 
The poly-Q extended (Q103) exon 1 of human Htt fused to GFP is toxic when 
expressed under the galactose-inducible (PGAL) promoter in the yeast strain containing 
endogenous QN-rich protein Rnq1 in the prion form, but not in the isogenic strain lacking 
a prion (Meriin et al., 2002). We have now demonstrated that [PSI+], prion form of 
another protein with a QN-rich domain, release factor Sup35 (Chernoff, 2001; Chernoff 
et al., 2002), also promotes Q103 toxicity (Figure 3.4 A). This data was generously 
provided by G. Newnam (Chernoff Lab). Effects of [PIN+] and [PSI+] on Q103 toxicity 
appear to be additive (data not shown).  
 Overproduction of the yeast chaperone Hsp104 is known to eliminate [PSI+] 
(Chernoff et al., 1995) but not [PIN+] (Derkatch et al., 1997). In agreement with these 
data, we have shown that overproduction of wild-type Hsp104 counteracts Q103 toxicity 
only in a [PSI+] background and not so when [PSI+] is absent (Figure 3.4 B).  
 
Mutant alleles of Hsp104 counteract Q103 toxicity 
The double K-to-T substitution at aa positions 218 and 620 of Hsp104 (Hsp104-
KT) inactivates both nucleotide binding domains of Hsp104 (NBD1 and NBD2) and 
disrupts the function of wild-type Hsp104 in a dominant negative fashion (Chernoff et al.,  
Figure 3.4 Effects of yeast prions and Hsp104 on Q103 toxicity
A. Presence of either [PSI+] or [PIN+] prion is required and sufficient for Q103 
toxicity. Medium is selective for plasmid (-Ura) and contains galactose to 
induce the poly-Q constructs. Plates were photographed after 3 days of 
incubation (second passage). B. Excess Hsp104 ameliorates poly-Q toxicity 
only in [PSI+] cells but not in [psi- PIN+] cells. Strains contained the HIS3
marked Hsp104 overexpressing plasmid (WT Hsp104) or empty control, in 
addition to a poly-Q construct. Plates were photographed after 7 days of 
incubation (second passage) on the -Ura-His/Gal medium, which is selective 
for plasmids and induces poly-Q and Hsp104 constructs. In both A and B, no 
differences in growth were detected on the glucose (Glu) medium (data not 
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1995; Schirmer et al, 1998). In contrast to overproduced wild-type Hsp104, mutant 
Hsp104-KT cures yeast cells not only of [PSI+] (Chernoff et al., 1995) but also of [PIN+] 
(Wegrzyn et al., 2001). As expected, expression of Hsp104-KT counteracts Q103 toxicity  
not only in the [PSI+] strains but also in the [psi- PIN+] strains, apparently by curing cells 
of prions (data not shown), thus reproducing an effect of the hsp104 deletion (Meriin et 
al., 2002).  Single dominant negative NBD mutants KT218 and KT620 also exhibit anti-
toxicity (data not shown).  
Surprisingly, we have isolated a presumably wild-type HSP104 clone from a 
widely used cDNA yeast library, that counteracted Q103 toxicity in both [PSI+] (not 
shown) and [psi- PIN+] (Figure 3.5 A) backgrounds. DNA sequencing revealed that this 
clone of HSP104 actually contained a G-to-C substitution at the nucleotide position 906, 
resulting in K-to-N substitution at the aa position 302 within NBD1. It was found to inhibit 
the thermotolerance function of Hsp104 in a dominant-negative fashion like Hsp104-KT 
(Figure 3.5 B) and cure endogenous prions (Table 3.2).       
Next, we checked whether HSP104 mutant alleles obtained from S. Lindquist 
and checked previously for endogenous prions afffect poly-Q toxicity. Indeed, mutant 
alleles of HSP104 with substitutions in the middle region and C-terminal region, 
counteracted Q103 toxicity with varying degrees depending on the prion background 
(Figure 3.6 A). While expression of Hsp104-G217ST499I is toxic regardless of the prion 
background, this mutant could not be studied for poly-Q toxicity (Figure 3.3 A and table 
3.2). Mutant alleles of Hsp104 like HSP104-A503V and HSP104-C*  counteracted Q103 
toxicity in the [psi- PIN+] strain (figure 3.6 A, B) without curing yeast cells of prions in the 
absence (Table 3.2) and presence of poly-Q (Table 3.3). Hsp104-C* could counteract 
Q103 toxicity in [PSI+] background too (Figure 3.6 A).  
As A503V mutation counteracted poly-Q toxicity without curing [PIN+], we have 









Figure 3.5 Effects on the HSP104 clone isolated from the yeast cDNA
library on A. Q103 toxicity and B. thermotolerance of WT Hsp104
A. Strains contained the URA3-based Hsp104 plasmid (as shown) or 
empty control, in addition to the TRP1 poly-Q constructs. Plates were 
recorded after 3 days of incubation (second passage) on the -Ura-
Trp/Gal medium, which is selective for plasmids and induces both 
Hsp104 and poly-Q constructs. The HSP104 clone isolated from the 
yeast cDNA library (Library Hsp104) reduces Q103 toxicity in the [psi-
PIN+] background, in contrast to wild-type Hsp104. 
B. [psi- pin- ] strain GT17 was transformed with the URA3-based WT 
Hsp104, Hsp104K302N, Hsp104-KT or empty control. 10 fold serial 
dilutions of the heat-shocked samples (50°C for 10 mins) and control 
samples on –Ura medium is shown. Samples before heat-shock are 
also shown (see materials and methods for more details on the 
procedure). Hsp104K302N like dominant negative Hsp104-KT mutant 
affects the thermotolerance function of WT Hsp104.
[psi- PIN+]
↑ Q103 + ↑ Library Hsp104
↑ Q25




Figure 3.6 Effect of mutant derivatives of Hsp104 (Lindquist Lab) on Q103 
toxicity                                                        
A. Antitoxic effect of the mutant alleles of Hsp104 vary depending on the 
prion background. Strains contained the HIS3-based Hsp104 plasmid (as 
shown) or empty control, in addition to the URA3 poly-Q constructs. Plates 
were photographed after 7 days of incubation (second passage) on the -
Ura-His/Gal medium, which is selective for the plasmids and induces both 
Hsp104 and poly-Q constructs. Amongst all the HSP104 alleles tested,only 
HSP104-A503V and HSP104-C* antagonized Q103 toxicity without the 
curing of prions [PSI+] and [PIN+] (seeTables 3.2 and 3.3) B. Quantitative 
assay confirming the antitoxic effect of the HSP104-A503V and HSP104-C* 
in [psi- PIN+] strain OT60: Cultures were grown in the liquid –Ura-His 
medium containing galactose and raffinose (Gal+Raf) to induce poly-Q and 
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Table 3.3 Effect of Hsps on yeast prions in the presence of poly-Q 
  Overexpressor                         Tested for [PSI+]          Tested for [PIN+]    
   combinations                    _________________   _________________                                              
              [PSI+]   [psi-]    Total      [PIN+]   [pin-]  Total  
 
↑ Q103                     48        0          48           48        0        48      
↑ WT Hsp104  + ↑ Q103            0         48        48           48        0        48           
↑ Hsp104-A509D + ↑ Q103      21        27    48       18       30       48 
↑ Hsp104-A503V + ↑ Q103         Not applicable*            48        0        48    
↑ Hsp104-A503VA509D     3          45        48          40        8        48 
+ ↑ Q103           
                            




background. Normally, Q103 forms large “clumps” in about 40% of the [psi- PIN+] cells, 
and either “dots” or both small clumps and dots in the rest of them (Figure 3.7 A, B). In 
contrast, cells co-expressing either Hsp104-A503V or Hsp104-C* with Q103 showed 
essentially no large clumps, instead most of them contained dots (Figure 3.7 B). This  
shows that expression of Hsp104-A503V and Hsp104-C* decreases size of Q103 
aggregates, suggesting a possible mechanism for anti-toxicity.  
Prion-dependent Q103 aggregation in yeast is associated with a defect of 
endocytosis, that is one of the likely causes for Q103 toxicity (Meriin et al., 2003). We 
have monitored the effect of Q103 aggregation on endocytosis by using the lipophilic 
fluorescent dye FM4-64 (see materials and methods for more details). This dye binds to  
the cell membrane and is internalized through the endocytic pathway. In cells with 
normal endocytosis, FM4-64 forms a distinct ring around the vacuole at 45 min after dye 
addition, reflecting the fusion of dye-stained endosomes with the vacuolar membrane. In 
contrast, cells with large Q103 clumps, and about 50% of cells with both small clumps 
and dots contained no such fluorescent rings, indicating a defect in endocytosis. Cells   
 
Figure 3.7 Effects of the Hsp104-A503V and Hsp104-C* mutant derivatives on 
Q103 aggregation and endocytosis. 
A. Types of aggregates observed in Q103 overexpressing cells. Cultures were 
grown in the liquid Gal+Raf medium to induce the poly-Q construct. Three distinct 
classes of cells with aggregates were observed:     - cells containing large clumps;      
- cells containing dots;     - cells containing both clumps and dots. B. Expression of 
Hsp104-A503V and Hsp104-C* decreases proportions of cells with clumps and 
increases proportion of cells with dots. Average number from 2 repeats for each of 
2 independent cultures is given in each case. Error bars indicate standard 
deviations. C and D. Clumps but not dots block endocytosis. Ring-like staining of 
the vacuole with FM4-64 is a marker of normal endocytosis. Majority of cells with 
dots show rings, while majority of cells with clumps and 50% of cells with both 
clumps and dots do not, indicating a defect in endocytosis. Note that partial 
leakage of GFP fluorescence through red filter occurs in the cells with large 
clumps. Data were homogenous for all plasmid combinations. Error bars indicate 
standard deviations.E. Expression of Hsp104-A503V and Hsp104-C* increases 
proportion of soluble Q103 protein.Proteins were isolated after 24 hrs of growth in 
synthetic Gal+Raf medium selective for plasmids, and fractionated as described in 
materials and methods. No differences in the proportion of Q103 precipitated at 
800 g were seen (not shown). Proportions of Q103-GFP protein in pellet (P) and 
supernatant (S) fractions obtained at 10,000 g were determined by densitometry. 
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with dots usually exhibited FM4-64 rings confirming that in the absence of large 
aggregates, endocytosis was not affected (Figure 3.7 C, D). As expression of Hsp104-
A503V and Hsp104-C* increased proportion of cells with dots and almost eliminated 
large clumps, defect of endocytosis was essentially not seen in these cultures. 
Differential centrifugation assay confirmed that co-expression of Hsp104-
A503V/Hsp104-C* with Q103 shifted a portion of the Q103 protein from the fraction 
pelletable at 10,000 g to the supernatant fraction (Figure 3.7 E). At higher centrifugation 
speed (200,000 g) essentially all Q103 was precipitated independently of the presence  
or absence of the mutant Hsp104 proteins, while non-expanded Q25 control remained 
soluble (data not shown). These results are in agreement with the fluorescence  
microscopy data and show that expression of Hsp104 mutants does not solubilize Q103 
aggregates but leads to a decrease in aggregate size, so that higher speed is needed for 
the efficient precipitation of aggregates. As total levels of Q103 were not affected by 
mutants (data not shown), decrease in aggregate size should be accompanied by an 
increase in the number of aggregated units. Taken together, our data confirm that 
Hsp104-A503V and Hsp104-C* ameliorates Q103 toxicity by counteracting formation of 
the large aggregates, which inhibit endocytosis. 
Amongst the middle domain mutant alleles of Hsp104 that carried triple 
aminoacid substitutions and were checked previously for effects on yeast prions-
HSP104-L445R,A448Asp,L455K (MII) counteracts poly-Q associated toxicity in strains 
irrespective of the presence or absence of either prions [PSI+] (Figure 3.8 A) or [PIN+] 
(data not shown). MII thus showed poly-Q anti-toxicity because of loss of endogenous 
prions [PIN+] and [PSI+] (Table 3.2). Strains expressing HSP104-A479Asp,L483K,L486R 
did not grow  regardless of the prion background (Figure 3.8 A)  as seen before (Table 
3.2) and therefore its effects could not be tested for anti-toxicity.  
A
↑ Q103
↑ Q103 + ↑ Plant Wt Hsp104
↑ Q103 + ↑ Plant Hsp104A499T
↑ Q25
B
Figure 3.8 Effect of middle domain mutants of yeast and plant Hsp104 on 
Q103 toxicity 
A. MIII is toxic while MII is able to counteract poly-Q toxicity regardless of the 
prion background. Yeast strains (mentioned below) were transformed with 
plasmids “Q25”- pYES-Q25trp + pRS316GAL, “Q103”- pYES-Q103trp + 
pRS316GAL, “WT Hsp104 +Q103 “- pYSGAL104 + pYES-Q103trp, “MI 
+Q103” – pYSGAL104-MI + pYES-Q103trp, “MII + Q103” - pYSGAL104-MII 
+ pYES-Q103trp, “MIII +Q103”- pYSGAL104-MIII + pYES-Q103trp. 
Transformants were grown on –Ura-Trp and spotted onto –Ura-Trp/Gal to 
induce the constructs.Plate is photographed after 5 days of incubation. See 
materials and methods for details on mutant plasmids. B. Both plant 
Hsp104-wild-type and middle domain mutant cannot counteract poly-Q 
toxicity regardless of the prion background. Yeast strains (mentioned below) 
were transformed with plasmids “Q103”- pYES2-103Q + pLA1 , “Q103 + 
Plant Wt Hsp104”-pYES2-103Q + pLA1- plantHsp104Wt , “Q103 + Plant 
Hsp104A499T”-pYES2-103Q + pLA1- plantHsp104MT, “Q25” – pYES2-Q25 
+ pLA1. Transformants were grown on –Ura-His and velveteened onto –Ura-
His/Gal + Raf. Plates were photographed after 5days of incubation. For both 
A and B, typical representatives of [PSI+ PIN+] are shown. [psi- PIN+]- OT60 
and [PSI+ pin-] –GT490 data not shown was similar.
↑ Q103
↑ WT Hsp104 + ↑ Q103 
↑ MI + ↑ Q103
↑ MII + ↑ Q103





Figure 3.9 Domain architecture of the Hsp104 protein showing 
locations of mutations exhibiting an anti poly-Q toxicity effect         
NBD1 and NBD2 - nucleotide binding domains 1 and 2, respectively; 
















Both Plant Wild-type and mutant Hsp104 containing G to A substitution at 
position 1495-corrosponding to A499T did not antagonize poly-Q toxicity when tested in 
[PSI+ PIN+] (Figure 3.8 B), [psi- PIN+] and [PSI+ pin-] strains (data not shown). Here, 
irrespective of no loss of endogenous yeast prions [PSI+] and [PIN+] (Table 3.2), yeast  
Hsp104 –both wild-type and mutant were not able to overcome Q103 toxicity. Location 




Comparison between prion-curing effects of Hsp104 inactivation 
[PSI+] loss by GuHCl follows a slow generation dependent kinetics with a long lag 
period required to decrease the average copy number of prion aggregates. Based on the 
calculation of kinetics of GuHCl–induced loss, [PSI+] strain used in that work contained 
about 60 proliferating Sup35PSI+ units per cell (Eaglestone et al., 2000) . Kinetics of [PSI+]  
curing in our strains (see Figure 3.1) was generally similar to those reported previously 
(Eaglestone et al., 2000), although weak [PSI+] was lost faster than strong [PSI+] as 
expected (see Figure 3.1). However, [PSI+] loss induced by Hsp104-KT did not show a 
significant lag period and followed rapid kinetics, strikingly different from that of GuHCl-
induced loss in the same conditions (Figure 3.1). These differences contradict the 
previous model suggesting that GuHCl cures yeast cells of [PSI+] (and possibly other 
prions) by inactivating Hsp104 (Eaglestone et al., 2000; Glover and Lindquist, 1998).  
[PSI+] loss cannot be therefore explained to occur by simple dilution in cell divisions. 
Alternative explanation could be that, in addition to the proliferation defect, Hsp104 
inactivation affects the state of preexisting prion units or that GuHCl mediated 
inactivation of Hsp104 is incomplete and is sufficient only for blocking [PSI+] proliferation 
but not for altering the parameters of preexisting Sup35PSI+ aggregates.Moreover, [PIN+] 
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loss after Hsp104 inactivation was even more rapid than [PSI+] loss (Figure 3.1 D and 
Table 3.1).  
 
Interaction of Hsp104 and Hsp70-Ssa in prion maintenance 
Hsp70-Ssa1 protects [PSI+] from curing by excess Hsp104 (Newnam et al., 
1999). Excess Ssa1 also increases nonsense suppression by [PSI+] (Newnam et al., 
1999) while mutation in SSA1 decreases [PSI+] stability and eliminates [PSI+] in 
combination with deletion of another member of the Hsp70 family-SSA2 (Jung et al., 
2000). The data indicates that Ssa1 favors [PSI+] propagation. However, excess Ssa1 
failed to protect [PSI+] by curing with hsp104 deletion (Newnam et al., 1999) or by 
Hsp104-KT (Figure 3.2 B). Moreover the anti-[PSI+] effect of Hsp104-KT was enhanced 
by excess Ssa1 (Figure 3.2 C). Based on the model proposed for Hsp104-Hsp70Ssa 
concerted action, inactivation of Hsp104 leads to slowing of the disaggregation process 
leading to monomerization. In contrast increased levels of Ssa result in intensified 
assembly of new aggregates. This could result in accumulation of large aggregates 
losing prion activity.  
 
Role of endogenous prions in poly-Q aggregation and toxicity  
            
             Our data confirms previous observations showing that the presence of 
endogenous yeast QN-rich proteins in a prion form promotes poly-Q aggregation (Meriin 
et al., 2002; Osherovich and Weissman 2001) and toxicity (Meriin et al., 2002), and 
demonstrate that [PSI+], a prion form of Sup35, is promoting toxicity of the Htt-derived 
poly-Q construct in the same way as does [PIN+], a prion form of Rnq1 (Figure 3.4 A). 
These results, implicating endogenous QN-rich prions as susceptibility factors in the 
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poly-Q disorders, could be relevant to mammalian cells, containing a lot of proteins with 
potentially prionogenic QN-rich domains (see Michelitsch and Weissman, 2000). 
 Prion domains of Sup35, and possibly of Rnq1 are composed of “aggregation 
modules”, or QN-rich stretches, and “propagation modules” - in case of Sup35, 
oligopeptide repeats (Chernoff, 2004; Osherovich et al, 2004). QN-rich stretches form 
stable intermolecular β-sheets, leading to generation of aggregates with fibrillar 
morphology (Perutz, 1999), characteristic for both prions and poly-Q proteins such as 
Htt. It is possible that QN-rich prion aggregates serve as aggregation “seeds” for the 
poly-Q derivatives of Htt (Meriin et al., 2002). “Propagation modules” are reguired for 
propagation of aggregates in the cell divisions via repetitive cycles of the chaperone-
mediated aggregate “shearing”, generating new “seeds” (Chernoff, 2004; Osherovich et 
al, 2004). Poly-Q fragments of Htt apparently lack propagation capabilities on their own 
(Osherovich et al, 2004), so that in the absence of endogenous prions, poly-Q 
aggregates are not only rarely formed but also incapable to persist in the yeast cells. 
Possibly, association with prions confines a self-perpetuating capability to the whole 
prion/poly-Q complex. Direct biochemical assays confirm that aggregated Q103 is 
associated with Rnq1 in the yeast cells (Meriin et al., 2003).   
 
Role of the chaperone Hsp104 in poly-Q aggregation and toxicity  
Numerous previous studies have shown that the presence of Hsp104 is required 
for poly-Q aggregation in yeast (Krobitsch and Lindquist,2000; Cao et al., 2001; Kimura 
et al., 2001; Meriin et al.,2002). Hsp104 overproduction reduced poly-Q aggregation at 
least in some yeast strains (Krobitsch and Lindquist, 2000) and in the heterological 
model of C. elegans (Satyal et al.,2000). However, Hsp104 is required for propagation of 
all known endogenous yeast prions, including [PSI+] (Chernoff et al., 1995) and [PIN+] 
(Derkatch et al., 1997).  Apparently, it serves as a major factor promoting aggregate 
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“shearing” (Chernoff, 2004). Therefore, previously reported effects of Hsp104 on poly-Q 
aggregates could be mediated by its effects on the endogenous prions. 
 Indeed, the dominant negative Hsp104 derivatives with mutations in NBDs (both 
the previously described Hsp104-KT218, 620 and newly found Hsp104-K302N) or in the 
middle region of Hsp104 (Hsp104-A509D and Hsp104-L445RA448DL455K-MII)  
inhibited both poly-Q toxicity and Hsp104 function in prion maintenance (Figure 3.5 A, 
3.6 A, 3.8 A and Table 3.2). Loss of poly-Q toxicity was accompanied by a loss of the 
endogenous prion(s), implicating prion elimination as a major cause of the toxicity relief. 
In contrast, overproduction of Hsp104, which is known (Chernoff et al., 1995, Derkatch 
et al., 1997) and confirmed to solubilize and eliminate [PSI+] but not [PIN+], reduced poly-
Q toxicity only in the [PSI+] strains but not in the [psi- PIN+] strains (Figure 3.4 B), 
confirming that excess Hsp104 influenced poly-Q via prion elimination. 
 However, in the case of Hsp104-A503V and Hsp104-C* mutants, toxicity relief 
(Figure 3.6 A, B) was not accompanied by elimination of a prion (Tables 3.2 and 3.3) or 
loss of a thermotolerance function of Hsp104 (Schirmer et al., 2004). Anti-toxicity effect 
by these mutants was apparently due to decreased size of poly-Q aggregates (Figure 
3.7 B): expression of mutant Hsp104 reduced proportion of the cells with large poly-Q 
clumps (Figure 3.7 B), which exhibit a defect in endocytosis (Figure 3.7 C, D), a 
landmark of prion-dependent poly-Q toxicity in yeast (Meriin et al., 2003). Thus, our data 
provide the first evidence that at least some mutant derivatives of Hsp104 are capable of 
modulating poly-Q aggregation without eliminating yeast prions.  
 
Differential effects of Hsp104-A503V on poly-Q and [PSI+] aggregates 
 Quite remarkably, expression of the mutant Hsp104-A503V protein was 
incompatible with the presence of the strong variant of [PSI+] prion (Figure 3.3 A, B). 
This effect was counteracted by simultaneous expression of the Sup35C region, 
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incapable of aggregation due to lack of prion domain (Figure 3.3 C). Thus, 
incompatibility between Hsp104-A503V and [PSI+] was most likely due to shortage of 
functional Sup35.  
Indeed, fluorescence microscopy confirmed that size of the Sup35 aggregates is 
increased in the [PSI+] strain expressing Hsp104-A503V (Figure 3.3 D). This could occur 
due to either promotion of aggregation or defect in aggregate “shearing”. For instance, 
underexpression of Hsp104 or expression of the dominant negative Hsp104 allele 
(Hsp104-KT218,620) in the [PSI+] strains also resulted in increased size of the Sup35 
clumps, apparently due to defect in “shearing” (Wegrzyn et al., 2001). However, cell 
growth was not inhibited in these cases, probably due to the fact that shearing-defective 
Sup35 aggregates were quickly lost from the population. This apparently does not occur 
in case of the Hsp104-A503V mutant, indicating that this mutation probably makes 
Hsp104 capable of promoting aggregate growth by facilitating prion conversion rather 
than by inhibiting aggregate shearing. Indeed, increased rate of prion conversion would 
facilitate sequestration of the newly synthesized Sup35 by prion aggregates and in this 
way may inhibit growth. Such an explanation also agrees with data showing that Hsp104 
promotes in vitro Sup35 aggregation in certain assays (Shorter and Lindquist, 2004). 
Observations that Hsp104-A503V remains functional in thermotolerance (Schirmer et al., 
2004) and does not antagonize [PIN+] (Table 3.2 and Table 3.3) also support gain-of-
function (rather than impairment of function) model of its action. 
 Schirmer et al. have previously reported that the Hsp104-A503V and double 
Hsp104-A503V, A509D mutants inhibit growth of some yeast strains at 37oC. The prion 
status of the strains used in that paper was not reported, but at least in the case of 
double mutant, growth inhibition probably did not depend on [PSI+], as it was not 
counteracted by Sup35C, in contrast to our data. Our [psi-] strain, coming from a 
 72
different genotypic background, did not show temperature sensitivity with Hsp104-
A503V.  
 
Possible molecular mechanisms of the Hsp104-A503V effects  
            According to the previous data of S. Lindquist lab (Cashikar et al., 2002), the 
A503V mutant exhibits increased background ATPase activity but can not further 
increase ATP hydrolysis of NBD1 in response to substrate binding at the C-terminus. We 
propose that these alterations of the Hsp104 function have different consequences, 
depending on the type of aggregates Hsp104 is dealing with. In case of non-
perpetuating poly-Q aggregates, increased background ATPase activity may lead to 
increased aggregate shearing, and therefore, to decreased aggregate size. Hsp104 
interaction with the self-perpetuating (prion) aggregates of Sup35 is more complex. One 
possibility is that inability of the mutant Hsp104 to undergo fine tuning of the NBD results 
in shifting the balance between its “shearing” and “conversion-promoting” activities, that 
facilitates aggregate growth and sequestration of the newly synthesized Sup35 protein 




























The Hsp70 group of chaperones have been implicated in numerous cellular 
processes some relevant to this study are regulation of heat shock response, protein 
translocation, cytosolic protein folding (for review see Craig et al., 1999) and translation 
(Horton et al., 2001). The Ssa subfamily is one of the major heat shock inducible 
cytosolic chaperones in yeast and consists of four proteins (Ssa1, Ssa2, Ssa3 and 
Ssa4). Ssa1 and Ssa2 share 97% identity, and the more distantly related Ssa3 and Ssa4 
share 80% identity to each other and Ssa1 (Craig et al., 1985). Ssa2 is constitutively 
expressed at high levels during steady state growth. Ssa1 is present at a lower level 
during steady state growth, but is highly induced during heat-shock along with Ssa3 and 
Ssa4. Members of the Hsp70-Ssa family together with Hsp104 provide thermotolerance 
in vivo (Sanchez et al., 1993) and in protein disaggregation in vitro (Glover and 
Lindquist, 1998). Along with the known effects of Hsp70 on yeast prions, Hsp70 was 
shown in vitro to interact with fragments of Htt containing the poly-Q tract and inhibit the 
ordered assembly of SDS-resistant HD exon-1 fibrils. The Hsp70/Hsp40 system was 
also shown to mitigate the neurotoxicity of polyQ expanded proteins in a Drosophila 
disease model (Warrick et al., 1999; Kazemi-Esfarjani and Benzer, 2000). Inhibition of 
poly-Q aggregation in vivo was in some cases associated with anti-toxicity. 
Members of the Hsp70-Ssb proteins (Ssb1 and Ssb2) make up the second 
subfamily of cytosolic Hsp70s that share 99% sequence identity. Ssbs are non-essential 
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proteins that are constitutively expressed during steady-state growth. Ssbs share 60% 
aminoacid identity to the Hsp70-Ssa subfamily (Craig and Jacobsen, 1985). Ssbs of 
Saccharomyces cerevisiae are ribosome-associated molecular chaperones, which can 
be cross-linked to nascent polypeptide chains. Close association of Ssb with translating 
ribosomes makes the strain carrying deletions of SSB1 and SSB2 sensitive to translation 
inhibiting drugs like aminoglycoside, paromomycin (Pars) and Hygromycin (HygS) 
(Nelson et al., 1992). In addition they also are cold sensitive and osmosensitive. ssb1,2∆ 
also produces sensitivity to GuHCl (Ghcs) (Chernoff et al., 1999). In contrast to Ssa1, the 
Ssbs consistently act as [PSI+] antagonist, while with Htt-Q103, there hasn’t been any 
reporting of Ssb effects.         
   Hsp70 has two major functional domains: an ATPase domain and a substrate 
binding domain. Ssb in particular is structurally composed of three domains: highly 
conserved 44-KDa ATPase domain (amino acids 1-400), followed by a polypeptide-
binding domain that is less conserved (amino acids 401-507) and a variable extreme C-
terminal domain (amino acids 507-613). An intact peptide-binding domain is essential 
and an alteration of a conserved residue in the peptide-binding cleft (V442) affects its 
function (Pfund et al., 2001).  
 
Hsp40  
Hsp40 regulate Hsp70 ATPase activity (Cyr and Douglas, 1994) and can also 
present unfolded peptides to Hsp70 (Qian et al., 2002). Members of the Hsp40 family 
have been shown to regulate prions.Like Hsp70, Hsp40 can also modulate other 
abnormal non-prion Q-rich protein aggregates like Htt.  
In this chapter, we have systematically examined the effects of various yeast 
chaperones of the Hsp70/Hsp40 complex along with other yeast chaperones Hsp82 
(Hsp90 family) and small yeast chaperoneHsp26 on poly-Q aggregation and toxicity in 
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the series of isogenic yeast strains that differ only by prion composition. We also study 
the effects of Hsp70-Ssa/Ssb on [PSI+].   
 
Materials and methods 
 
Yeast strains 
  Yeast strains unique to this study are described here. Other commonly used 
strains are described in Chapter 2 and Table 2.1. GT146 is [PSI+ PIN+] ssb1,2 ∆ , GT157 
is [psi- PIN+] ssb1,2 ∆ , GT202 and GT203 are [PSI+] derivatives of GT157 obtained by 
overexpression of Sup35N. They exhibit decreased non-sense suppression in the 
presence of wild-type Ssb1 protein (Chernoff et al., 1999). GT310 is the “Sup35PS-only” 
[PSI+]PS strain as described in Chernoff et al., 2000.The Pichia-Saccharomyces prion is 
designated as [PSI+]PS and Sup35PS indicates that the prion forming domain of Picha 
Sup35 is fused to the MC domain of Saccharomyces Sup35. The strain PJ69-4A alias 
OT59 (James et al., 1996) was used for yeast two-hybrid assays. 
 
Plasmid constructs 
Some plasmids specific to this study are described here, for all other commonly 
used plasmids refer to Chapter2. Sequence analysis of the plasmid pRDW30 carrying 
PSSA1-SSA1-21 (Jung et al., 2000) revealed a base change resulting in a substitution of 
tryptophan for leucine at amino acid residue 483 (L483W).  
pACT-SSB1 was constructed by ligating the BamH1 XhoI fragment containing 
SSB1 from pTEF-SSB1 to pACT cut with the same enzymes. pACT-SSA1 was 
constructed by ligating the BamH1 fragment of pTEF-SSA1 to pACT cut with BamH1. 
This construction was done with the help of an undergraduate student Heather Vanpelt 
(Chernoff Lab).   
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Medium used for Ssb studies  
Complete medium YPD with 0.2mg/ml paromomycin, YPD + 35µgm/ml 
Hygromycin and YPD + 5mM GuHCL were used to monitor drug sensitivity of SSB 
mutants. Similarly, synthetic selective media –Ura + above mentioned addition of drugs 
was used to monitor sensitivity. 
 
Two-hybrid assay 
In vivo reconstitution of the split Gal4 activator as a result of physical interaction 
between proteins fused to different Gal4 domains was detected by growth on –Ade 
medium due to activation of the GAL2::ADE2 reporter construct in the strain PJ69-4A as 
described previously (Bailleul et al.,1999 and references therein). The Ade+ 
transformants in which GAL2::ADE2 was activated presumably by physical interaction 
between two proteins (Ssa1 and Sup35Sc- from this study) were screened for activation 
of GAL1::HIS3 by growing the transformants on –trp-leu-his medium in the presence of 
1mM aminotriazole (AT) to eliminate the possibility of mutations that could activate 
transcription of the ADE2 gene in a Gal4-independent fashion. 
 
Results 
The data on Hsp70 and Hsp40 effects on poly-Q toxicity is submitted for publication to 











Effects of yeast Hsp70 family and other small chaperones Hsp82 and Hsp26 on 
Q103 toxicity 
 
          Yeast Hsp70 proteins of the Ssa subfamily aid in propagation of the yeast prion 
[PSI+] (Newnam et al., 1999; Allen et al., 2003; Jung et al., 2000), and exhibit differential 
effects on the other yeast prion, [URE3] (Schwimmer and Masison, 2002; Roberts et al., 
2004). The amino acid substitution of tryptophan for leucine at residue 483 (L483W) of 
the Ssa1 protein (also referred as Ssa1-21) results in reduced [PSI+] stability 
characterized by decreased nonsense suppression, reduced prion ‘seed’ number, high 
mitotic loss of [PSI+]. When Ssa1-21 is the only source of Ssa in cell ie in ssa1∆ssa2∆ 
background, cells show [PSI+] no more phenotype (Jung et al., 2000). Proteins of the 
other cytosolic Hsp70 subfamily, Ssb, consistently antagonize [PSI+] in various assays 
(Allen et al., 2004;Chernoff et al., 1999; Chacinska et al., 2001). In contrast, Hsp26 and 
Hsp90 chaperones did not show any detectable effects on [PSI+] (Newnam et al., 1999).  
 We have checked the effects of the individually overproduced Hsps on the prion-
dependent Q103 toxicity in yeast. Among all yeast Hsp70 proteins tested (Ssa1, 2, 3 and 
4, Ssa1-21 and Ssb1) (Figure 4.1 A, B, C), only overproduction of Ssa4 counteracted 
Q103 toxicity in the [PSI+ PIN+] strain (Figure 4.1 B), although it exhibited no detectable 
anti-toxicity in the [psi- PIN+] or [PSI+ pin-] backgrounds, and did not cure [PSI+] at a 
significant level (Allen et al, 2004 and data not shown). Overproduction of Hsp26 or 
Hsp90 (Hsp82) did not exhibit any antitoxic effect on Q103 independently of which 
prions were present (Figure 4.1 D). 
 
Differential effects of the Hsp40 chaperones on Q103 toxicity 
Hsp40 and Hsp70 chaperones cooperate with Hsp104 in solubilization and 
refolding of heat-damaged proteins (Glover and Lindquist, 1998). One of the major yeast 
Hsp40 chaperones, Sis1, is also involved in [PIN+] propagation (Sondheimer and  
Figure 4.1 Effect of Hsp70, Hsp82 and Hsp26 chaperones on Q103 toxicity 
A. pGAL1-SSA1, pGAL1-SSA2, pGAL1-SSB1, pSSA1-SSA1-21 none exhibit 
anti-poly-Q toxicity effect. Medium used is selective for the plasmids -Ura-
Trp/Gal + Raf and contains galactose to induce the poly-Q and chaperones 
that are under gal promoter. Plates were photographed after 10 days of 
incubation (second passage). Result for OT56 is shown. Data with OT60 and 
GT490 was similar and is not shown. Ssa1 expressed under TEF promoter 
also did not show any anti poly-Q toxicity effects (data not shown).  B. 
Excess Ssa4 counteracts poly-Q toxicity only in [PSI+  PIN +] strain. Medium 
used was selective for plasmids and contained galactose to induce poly-Q 
and chaperones under gal promoter (-Ura-Leu/Gal + Raf). Plates were 
photographed after 7 days of incubation. pGAL1-SSA3, pGAL1-SSA4, 
pSSA1-SSA1 and pGAL1-SSA4 from a 2µ plasmid were used. None of the 
Ssa constructs counteracted poly-Q toxicity in the isogenic [psi- PIN +] and 
[PSI + pin -] background (data not shown). C. Ssa1 and Ssa2 do not 
counteract poly-Q toxicity when expressed from SSA2 promoter.  Medium 
used was selective for plasmids and contained galactose to induce the poly-
Q constructs (-Ura-His/Gal + Raf). Plate was photographed after 8 days of 
incubation. Data for OT60 and GT490 was similar and is not shown. D. 
Chaperones Hsp26 and Hsp82 do not counteract poly-Q toxicity. Medium 
selective for plasmids and containing galactose was used to induce poly-Q 
and chaperone constructs. Plate is photographed after 10 days of incubation. 
Data for OT60 and GT490 was similar and is not shown. Typical 
representatives are shown. See materials and methods for procedural details 
and plasmids used.
Strains  used: [PSI+  PIN+] (OT56) , [psi- PIN+] (OT60) and [PSI+ pin-] (GT490)
BA
↑ Q25
↑ Ssa1 + ↑ Q103
↑ Ssa2 + ↑ Q103
↑ Ssb1 + ↑ Q103
↑ Ssa1-21 + ↑ Q103
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↑ Q25
↑ Ssa3 + ↑ Q103
↑ Ssa4 + ↑ Q103
↑ Ssa1 + ↑ Q103
↑ Ssa4 (2µ) + ↑ Q103
↑ Q103
[PSI+  PIN +]
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Ssa2 + ↑ Q103
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Lindquist, 2001), while overproduction of the other Hsp40 chaperone, Ydj1, has been 
shown to antagonize poly-Q aggregation in some yeast models (Muchowski et al.,  
2000). The Hsp40 chaperones Ydj1 and Sis1 did not affect Q103 toxicity at any 
detectable level in the [PSI+] strains, but exhibited opposite effects on Q103 toxicity 
when overproduced in the [psi- PIN+] strain. Extra-copy of YDJ1, expressed from either 
the strong constitutive PGPD promoter (Figure 4.2 A,C) or endogenous PYDJ1 promoter 
(Figure 4.4 A), increased Q103 toxicity. In contrast, extra copy of SIS1, expressed from 
either PGPD (Fig. 4.2 B, D) or endogenous PSIS1 promoter (Figure 4.4 A), counteracted 
Q103 toxicity.  
             Figure 4.3 A shows different kinds of aggregates seen in [psi- PIN+] cells. Q103 
forms large “clumps” in about 40% of the [psi- PIN+] cells, and either “dots” or both small 
clumps and dots in the rest of them. Fluorescence microscopy analysis confirmed that 
co-expression of Ydj1 with Q103 in the [psi- PIN+] background increased proportion of 
the endocytosis-defective cells with large Q103 clumps (Figure 4.3 B). Likewise, 
proportion of the Q103 protein which is insoluble and pelletable at 10,000 g was 
increased in the presence of excess Ydj1 (Figure 4.3 D). In contrast, the [psi- PIN+] 
cultures co-expressing Sis1 with Q103 exhibited a decrease in proportion of the 
endocytosis-defective cells with large clumps, in comparison to those expressing Q103 
alone. This was accompanied by an increase in proportion of the cells with dots, or with 
both dots and small clumps (Figure 4.3 C), and by decrease in proportion of the Q103 
protein pelletable at 10,000 g (Figure 4.3 E). Neither excess Ydj1 nor excess Sis1 
affected total levels of Q103 (data not shown). Excess Sis1 did not lead to any  
detectable loss of [PIN+], confirming that effect of Sis1 is not due to loss of a prion. 
Taken together, these data suggest that excess Ydj1 exacerbates toxic effect of Q103 
by increasing size of Q103 aggregates, while excess Sis1 counteracts toxicity by 
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Figure 4.2 Effects of Hsp40 chaperones on Q103 toxicity         
A and C - Excess Ydj1 increases Q103 toxicity in [psi- PIN+] background. 
B and D – Excess Sis1 decreases Q103 toxicity in [psi- PIN+] background. 
A and B – Plate Assay: The –Ura-His/ Gal (Ydj1) and –Ura-Trp/ Gal (Sis1) 
medium were used to select for plasmids and to induce the poly-Q 
constructs. Plates were photographed after 7 days of incubation (second 
passage) for Ydj1 and after 3 days of incubation (second passage) for 
Sis1. Differences in media composition reflects the difference in Q103 
control. No effects of Ydj1 or Sis1 on toxicity were detected in the [PSI+]
background (not shown). C and D – Quantitative Assay. Average numbers 
from 2 repeats of each of two independent transformants are shown in 
each case. Cultures were grown in liquid respective selective medium 
containing galactose and raffinose. Standard deviation did not exceed 
27% of the value for each time-point. Differences between Q103 cultures 
and cultures expressing Ydj1 or Sis1 were statistically significant after 3 
days and 6 days respectively. Differences in media composition reflects 
the difference in Q103 control and is consistent with plate assay. Q103 
control grows much more slower in –Ura-Trp/Gal than in –Ura-His/Gal 
medium.Strains used same as mentioned in legend 4.1.
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Figure 4.3 Effects of Hsp40 chaperones on Q103 aggregates       
A.Types of aggregates observed in Q103 overexpressing cells. [psi- PIN 
+] cultures were grown in liquid –Ura-His/ Gal + Raf medium to induce 
poly-Q. Three distinct classes of cells with aggregates were observed –
1) cells containing large clumps, (   ) 2)cells containing dot-like structures 
(   ) and 3)cells containing both clumps and dots (   ). B and C - Excess 
Ydj1 increases proportion of cells with Q103 clumps while excess Sis1 
decreases it. Error bars indicate standard deviation. Cultures were grown 
in liquid –Ura-His/Gal + Raf (Ydj1) and in –Ura-Trp/Gal + Raf (Sis1) 
overnight. D and E – Excess Ydj1 decreases proportion of soluble Q103 
(D) and excess Sis1 decreases it (E). Proteins were isolated in the [psi-
PIN +] strain after 24 hours of growth in synthetic Gal + Raf medium 
selective for plasmids and fractionated as described in Materials and 
Methods (Chapter 2). Pellet (P) and Supernatant (S) fractions at 10,000 g 
are shown. Proportion of Q103-GFP protein in P and S are determined 
by densitometry. For strain and plasmids used, see 4.2 Figure legend. 
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Figure 4.4 Modulation of Ydj1 and Sis1 effects on Q103 toxicity 
A. Single copy Ydj1 increases and single copy Sis1 decreases Q103 toxicity in 
[psi- PIN+] strain. Medium used is –Trp-Leu/ Gal selective for plasmids and 
containing galactose to induce the poly-Q constructs. Plate was photographed 
after 8 days of incubation. Plasmids used: “↑ Q103 “: pYES-Q103trp, “ Sis1” –
pRS315Sis1, “Ydj1”- pRS315Ydj1 . Control plasmid used is pRS315. B. 
Mammalian homolog of Ydj1 and Sis1 do not have any effects on Q103 toxicity. 
Medium used is selective for plasmids and contains galactose to induce poly-Q 
constructs (-Ura-Trp/Gal). Plate is photographed after 14 days of incubation. 
Plasmids used: “↑ Q103” – pYES2103Q, “↑ Hdj1 “-Hdj1424GPD; “↑ Hdj2” -
Hdj2424GPD , “↑ Q25” – pYES225Q. Control plasmid used is pFL39. OT60 data 
is shown. GT490 and OT56 show similar results and is not shown. C. Ssa1 
eliminates the Sis1’s Q103 toxicity compensatory effect. Medium used is selective 
for plasmids and contains galactose to induce poly-Q constructs (-Ura-His-
Trp/Gal).Plate is photographed after 7 days of incubation. Plasmids used “↑ Q103 
“: pYES2-103Q, “ Sis1” – pTVSIS1,”Ssa1”: pN2 . Control plasmids used are 
pRS316GAL, pLA1 and pFL39. D. Ssa1 does not have any effect on Ydj1’s ability 
to increase Q103 toxicity. Medium used is same as in 4.4C. Plate is photographed 
after 3 days (second passage). 
Plasmids used are “↑ Q103 “: pYES-Q103trp, “Ydj1”- pRSYDJ1, “↑ Ssa1”: 
pGALSSA1.                                                       
Strains  used: [PSI+  PIN+] (OT56) , [psi- PIN+] (OT60) and [PSI+ pin-] (GT490)
[psi- PIN+]
↑ Q103 
↑ Q103 + ↑ Ydj1






Since Hsp40 are considered to be co-chaperones of Hsp70, we checked the 
effects of Hsp70-Ssa1 and Hsp40-Sis1 or Hsp40-Ydj1 simultaneously. Ssa1 did not  
change the already observed effects of Sis1/Ydj1 on poly-Q toxicity (Figure 4.4 C, D). 
We also checked the effects of mammalian homologs of Sis1 and Ydj1 known as Hdj1  
and Hdj2 respectively on poly-Q toxicity. Neither showed any observable effect 
irrespective of the prion background (Figure 4.4 B).  
  
Effect of mutations in the peptide-binding domain and C-terminal truncations of 
SSB1 on drug sensitivity 
 
The [psi- PIN+] and [PSI+] ssb1,2∆ strains, GT157 and GT146 respectively were 
transformed with SSA-SSB chimeras (Figure 4.5) and checked for compensation of Pars, 
Hygs,, and Ghcs phenotypes by K. Allen (Chernoff Lab). Her studies showed that that the 
peptide-binding domain of Ssb in combination with at least one other domain of Ssb 
origin were capable of compensating for sensitivity to paromomycin and GuHCl in our 
strains background (Allen et al., 2004), while only complete Ssb was compensating for 
Hygromycin sensitivity (Allen et al., 2004). In this chapter, we extend this study by 
testing several point mutations in the peptide binding domain and C-terminal truncations 
of Ssb (Pfund et al, 2001) on drug sensitivity in the [psi- PIN+] and [PSI+] ssb1,2∆ strains 
mentioned above. Full length SSB1, point mutant alleles of SSB1: SSB1-M409A, SSB1-
V432S, SSB1-T443A, SSB1-F444S, SSB1-F444I, compensated the drug sensitivity of 
ssb1,2∆ strains when tested on both complete medium and synthetic medium with all  
three drugs, Paromomycin, Hygromycin and GuHCl (Figure 4.6 A, B). Ssb1-V442F 
showed complete Hygs , while partial Pars  and Ghcs on complete medium (Figure 4.6 A). 
On the contrary such an effect was not detected on synthetic medium (Figure 4.6 B). 
Ssb1-∆488 showed drug sensitivity when tested on complete medium and synthetic 
medium, with the exception of GuHCl on synthetic medium (Figure 4.6 A, B). Ssb1-∆499  
Figure 4.5 Schematic representation of Hsp70 Ssa-Ssb chimera proteins 
A. Hsp70 family proteins share three distinct functional domains: The N-
terminal ATPase domain, the 18-kDa peptide-binding domain, and the C-
terminal 10-kDa variable domain. B. Recombinant DNA technology was used 
to generate two sets of expression vectors encoding Hsp70 Ssa-Ssb protein 
chimeras (James et al., 1997; Pfund et al., 2001). One set was placed under 
the TEF1 promoter while the other set was placed under the HSP70 promoter 
corresponding to the source of the ATPase domain. In this study, each
plasmid is designated according to the promoter or the plasmid backbone, 
and the chimeric combination it encodes. For example, pTEF-ABA and 
pRS316K-ABA encode ABA chimeric proteins under the TEF1 promoter and 




















































Figure 4.6 Drug sensitivity of SSB mutants in ssb1,2∆ [PSI+ PIN+] on 
A. complete medium YPD and B. synthetic medium SD + 13  
Transformants were velveteened onto medium containing additions of 
drugs as mentioned in materials and methods. Ssb-V442F causes 
complete sensitivity to Hygromycin and partial sensitivity to GuHCl and 
paromomycin seen at detectable levels only when tested on YPD 
(complete medium). Ssb1-∆488 shows sensitivity to all three chemicals on 
YPD medium while only with hygromycin and paromomycin on synthetic 
medium. Ssb1-∆499 and Ssb1-∆507 shows sensitivity to hygromycin only 
on YPD medium.  [psi- PIN+] data is similar and not shown.                  
Strains used: ssb1,2∆ [PSI+ PIN+]: GT146 , ssb1,2∆ [psi- PIN+]: GT157  
Plasmids used: pRS316 based SSB1 wild-type allele, mutant alleles and 




and Ssb1- ∆507 showed Hygs only on complete medium, while these truncations could 
otherwise compensate drug sensitivity of other drugs on complete medium and synthetic  
medium (Figure 4.6 A, B). Presence or absence of [PSI+] did not affect the final 
outcome. 
 
Effect of mutations in the peptide binding domain and C-terminal truncations of 
SSB1 on Hsp104’s ability to cure [PSI+]  
 
Ssa proteins – member of the Hsp70 family are coinduced with Hsp104 during 
heat shock, stationary-phase growth, and sporulation (Kurtz et al., 1996; Werner-
Washburne et al., 1987; Werner-Washburne et al., 1989). Ssa1 –member of the SSA 
family was shown to protect [PSI+] from Hsp104-mediated curing (Newnam et al., 1999). 
On the other hand, Ssb1 overproduction increased [PSI+] curing by excess Hsp104 
(Chernoff et al., 1999) and infact Ssb1 overproduction by itself could also cure [PSI+] 
(Chacinska et al., 2001). Here we wanted to study if the ability of Ssb1 to increase  
[PSI+] curing by excess Hsp104 is affected by any of the mutations in the peptide-
binding domain or C-terminal truncations. None of the mutations/truncations in Ssb1 
affected [PSI+] suppression by itself when checked in [PSI+] strains GT146, GT202 and 
GT203 (data not shown). Peptide-binding domain of Ssb1 was shown to be essential for 
its activity (Pfund et al., 2001). However none of the mutations in this domain affected 
Ssb’s ability to cure [PSI+] by excess Hsp104 (Figure 4.7). Infact, Ssb lacking the 
complete variable C-terminal domain (Ssb1-∆507) interfered with its ability to increase  
[PSI+] curing by excess Hsp104 (Figure 4.7) and the Ssb lacking the variable C-terminal 
domain and the C-terminal portion of the peptide binding domain containing the two last 
β strands 7 and 8 (Ssb1-∆488) partially affected Ssb’s ability to cure [PSI+] (Figure 4.7). 
Strangely enough (Ssb1-∆499) lacking only the last β strand 8 of peptide binding domain  
 
Figure 4.7 Effect of mutations in peptide binding domain and C-terminal 
truncations of Ssb on Hsp104’s ability to cure [PSI+]  
Transformants were grown on medium selective for plasmids (-Ura-His) 
velveteened onto -Ura-His/Gal to induce the Hsp104 construct by growing for 
about 3 days and then velveteened onto YPD (color) and –ura-his-ade 
(suppression) to check for [PSI+]. –Ade plate was photographed after 10 
days of incubation and YPD plate was photographed after 2 days of growth 
at 30°C and 2 days of refrigeration at 4°C for color development. Ssb1-∆488 
followed by Ssb1-∆507 affect Hsp104’s ability to cure [PSI+].                     
Strain used: OT56 [PSI+ PIN+]
↑ Hsp104
↑ Hsp104 + Ssb1- M409A
↑ Hsp104 + Ssb1- V432S
↑ Hsp104 + Ssb1- ∆ 488
↑ Hsp104 + Ssb1- ∆ 499
↑ Hsp104 + Ssb1- ∆ 507
↑ Hsp104 + Ssb1
↑ Hsp104 + Ssb1-T443A
↑ Hsp104 + Ssb1- F444S
↑ Hsp104 + Ssb1- F444I
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↑ Hsp104 + Ssb1- V442F
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and the complete C-terminal domain did not compromise Ssb’s ability to cure [PSI+] 
(Figure 4.7). 
 
Effect of chimeric SSA-SSB’s on [PSI+]PS 
Effect of Hsp70-Ssa and Ssb was also studied on [PSI+]PS. Ssa does not affect 
suppression by [PSI+]PS and Ssb cures [PSI+]PS. Ssa was shown to increase 
Saccharomyces [PSI+] suppression (Allen et al., 2004) while Ssb was shown to increase 
Hsp104’s ability to cure Saccharomyces [PSI+]. Because Pichia-Saccharomyces [PSI+]  
is very unstable, heterogeneity in color was observed. But in general in majority of 
transformants, when the chimeric protein contained any two domains of Ssb1- either the 
ATPase domain or the peptide-binding domain, or the variable domain, the protein had a 
curing effect on Pichia [PSI+] (Figure 4.8 A). On the other hand, when the chimeric 
protein contained any two domains of Ssa1, it did not affect suppression by Pichia-
Saccharomyces [PSI+]  (Figure 4.8 A). 
When the mutations in the peptide-binding domain and C-terminal truncations of 
Ssb1 were tested with Pichia-Saccharomyces [PSI+], two mutations F444S and F432S 
affected [PSI+]PS  to a larger extent than the wild-type Ssb1 alone. Strangely enough, the 
curing effect of Ssb1 on [PSI+]PS were not strong enough to see effects of mutations 
affecting the curing (Figure 4.8 B). 
 
Interaction between Ssa/Ssb and Saccharomyces/Pichia Sup35 
We employed two-hybrid approach to test if an interaction between Sup35 from 
either S cerevisiae or P methanolica and Ssa or Ssb exists . Interaction between 
Sup35Sc and Ssa was seen as growth on –Ade medium by the activation of GAL2-
ADE2 reporter (Figure 4.9 A). Ssa did not show 2-hybrid interaction with Sup35Pm 
(Figure 4.9 A). This interaction was confirmed by the activation of another reporter  
Figure 4.8 Effect of Ssa and Ssb on  [PSI+]PS
A. Effect of chimeric Ssa-Ssb proteins on [PSI+]PS. Medium used is –Ura 
selective for the plasmid. The transformants were velveteened onto YPD to 
check for the presence of [PSI+]  by color. Lot of heterogeneity is observed in 
terms of color partly because  [PSI+]PS is unstable. SSA1 does not affect 
suppression by [PSI+]PS and SSB1 cures [PSI+] PS in contrary to SSA1 
increasing suppression by Saccharomyces [PSI+] (Allen et al., 2004) and 
SSB1 only increasing curing effect by excess Hsp104 but not by itself 
(Chernoff et al., 1999). No particular domain of SSA or SSB seems to be 
responsible for the shift between [PSI+] maintenance and curing. See 
materials and methods for details on what the chimeric ABB etc stand for. 
Note that this chimeric proteins were expressed under their own promoter. 
Data for chimeric proteins expressed under TEF promoter did not show sharp 
color differences and is not shown.  B. Effect of peptide-binding domain 
mutations in SSB1 on [PSI+]PS suppression. The transformants were grown on 
medium selective for plasmid (-Ura) and velveteened onto –Ura-Ade to check 
for suppression. Plate is photographed after 6 days. All the mutations and 
truncations in Ssb1 do not affect suppression by Pichia [PSI+] PS with the 
























Figure 4.9 Yeast two-hybrid assay to check for interaction between 
Ssa/Ssb and Sup35 of Saccharomyces cerevisae (Sc) and Pichia 
methanolica (Pm)
A. Activation of GAL2-ADE2 detected as growth on –Ade indicating yeast 
two-hybrid interaction. Depicted is growth seen after 9 days of incubation a
by spotting on medium selective for plasmids and lacking adenine (-Trp-
Leu-Ade). Plasmid bearing the GAL4 DNA-binding domain under the ADH
promoter is TRP1 marked and the plasmid (pACT) bearing the activation 
domain of GAL4 under the ADH promoter is LEU2 marked. Plasmids
containing SNF1 and SNF4 are used as a positive control. Weak 
interaction between Ssa1 and Saccharomyces Sup35 is seen as 
papillatory growth compared to the strong growth seen by the interaction 
between Snf4 and Snf1. Sup35 alone also shows non-specific interaction 
seen as weak papillatory growth with pACT + Sup35 combination. B. 
Activation of GAL1-HIS3 detected as growth on –His confirming yeast two-
hybrid interaction. Depicted is growth on –Trp-Leu-His + 1mM 
aminotriazole seen after 5 days of incubation. See materials and methods 
on principle and working of yeast two-hybrid method and the plasmids and 
strains used. SNF1, SUP35Sc,SUP35NSc,SUP35NMSc, SUP35NMPm, 
SUP35Pm are all fused to the GAL4 DNA-binding domain, while SNF4, 



































system GAL1-HIS3 as growth on –His medium (Figure 4.9 B). Physical interactions in 
vitro and in vivo were seen between Sup35Sc and Ssa (Allen et al., 2004). However Ssb  
did not exhibit two-hybrid interaction with either the full length or N/NM portions of 




 Do Hsp70/Hsp40 chaperones influence poly-Q toxicity?  
Both yeast Hsp40 proteins influencing poly-Q toxicity, Sis1 and Ydj1, are thought 
to be co-factors of the Hsp70 chaperones of Ssa subfamily (Bukau and Horwich, 1998). 
Yeast Ssa1 was shown to suppress the formation of insoluble poly-Q aggregates in the 
yeast cells (Muchowski et al., 2000; Cummings et al., 2001). However, simultaneous 
depletion of the two members of Ssa subfamily, Ssa1 and Ssa2, decreased prion-
dependent Q103 aggregation in our system (Meriin et al., 2002), and excess Ssa 
promoted rather than decreased aggregation of the yeast prion protein Sup35 in our 
hands  (Allen et al., 2004; Newnam et al., 1999).  
One could suggest that Hsp40 chaperones act on poly-Q aggregates via 
modulating activity of their Hsp70 interacting partners. However, our data show that only 
one of the 4 members of the S. cerevisiae Ssa subfamily, Ssa4, counteracts Q103 
toxicity when overproduced. Moreover, antitoxic effect of Ssa4 could be seen clearly 
only in the yeast strains containing both prions, [PIN+] and [PSI+] simultaneously (Figure 
4.1 B). Differential effects of various members of the Hsp40 and Hsp70 families on Q103 
confirm that chaperone interactions with poly-Q aggregates are of highly specific nature, 
and suggest caution in interpreting the previous data where only some members of the 
family were studied. For example, effect of the ssa1/2 deletion (Meriin et al., 2002) could 
be not due to elimination of Ssa1 and Ssa2 per se, but due to increased fraction of Ssa4 
 92
in the total Ssa pool. Interestingly, while all Ssa proteins act in the same direction on 
[PSI+] (Allen et al., 2004), Ssa1 and Ssa2 differ from each other in their effects on the 
other yeast prion, [URE3] (Schwimmer and Masison, 2002). Further investigations are 
needed in order to establish molecular basis of the differential effects of Ssa chaperones 
on protein aggregates. 
 
Differential effects of Hsp40 chaperones on poly-Q aggregation and toxicity  
 
              Yeast Sis1 and Ydj1, functionally distinct heat shock proteins of the Hsp40 
family, are homologs of the human Hsp40 proteins Hdj1 and Hdj2, respectively. In the 
Drosophila model of a poly-Q disease, both proteins suppressed neurodegeneration but 
Hdj1 had a stronger effect than Hdj2 (Chan et al., 2000). Interestingly, overexpression of 
Hdj2 increased inclusion formation by Htt in the mammalian COS7 cells (Wyttenbach et 
al., 2000). Neither when tested however in yeast showed any effect on poly-Q toxicity 
(Figure 4.4 B) suggesting the requirement of a specific environment that cannot be 
created in yeast. Yeast Ydj1, a homolog of Hdj2, has previously been shown to suppress 
rather than increase formation of insoluble aggregates of polyQ-expanded exon 1 of Htt 
in yeast (Muchowski et al., 2000; Cummings et al., 2001). Effect of Sis1 on poly-Q 
aggregation in yeast has not previously been studied. 
 In our system, excess Sis1 decreased Q103 aggregate size (Figure 4.3 C, E) 
and counteracted Q103 toxicity (Figure 4.2 B, D), similar to the effect of its mammalian 
homolog Hdj1 in the other models. Intact Sis1 is required for the maintenance of [PIN+] 
prion (Sondheimer et al., 2001), however excess Sis1 did not cure cells of [PIN+], ruling 
out a possibility that anti-toxicity was due to loss of a prion. In contrast to Sis1, excess 
Ydj1 increased Q103 aggregate size (Figure 4.3 B, D), similar to the effect of its 
mammalian homolog Hdj2 at least in some assays (Wyttenbach et al., 2000), and 
increased Q103 toxicity (Figure 4.2 A, C). This agrees with the previous observation that 
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Q103 aggregation is decreased in the strain carrying ydj1-159 mutation (Meriin et al., 
2002). Interestingly, our preliminary data indicate that Sis1 and Ydj1 also differ from 
each other in regard to their effects on the yeast prion [PSI+] (S. Müller, J. Patterson and 
Y. Chernoff, unpublished data). Differences between our results and previous reports on 
the effects of yeast Ydj1 on poly-Q (Muchowski et al., 2000; Cummings et al., 2001) are 
probably due to differences in the poly-Q constructs employed, yeast strains and/or prion 
compositions. For instance, our plate assay has not detected any effects of Hsp40s on 
poly-Q toxicity in the presence of both [PSI+] and [PIN+] prions simultaneously, possibly 
because toxicity was too strong to see an effect clearly (data not shown). As Hsp40s’ 
effects observed in our [psi- PIN+] strain parallel observations in higher eukaryotic 
systems, one could argue that the yeast assay used in our work better reproduces 
patterns of interactions between poly-Q aggregates and chaperones in the homologous 
mammalian systems. The co-operative effect of Hsp40 and Hsp70 however could not be 
detected in this system. 
Effect of Ssa-Ssb’s on [PSI+]S and  [PSI+]PS      
The Ssa and Ssb Hsp70 families of S cerevisiae share 60% amino acid identity 
and reside in cytosol (Craig and Jacobsen, 1985) yet each have distinct, non-
overlapping functions in vivo –Ssa proteins function in protein translocation into 
organelles and regulate the heat shock response (Craig and Jacobsen, 1985) while Ssb 
proteins are associated with translating ribosomes (Nelson et al., 1992). They have 
opposite effects on Saccharomyces [PSI+] –Ssa favoring maintenance while Ssb 
favoring curing. Deletion of both Ssb-encoding genes, Ssb1/2∆, causes sensitivities to 
some translational inhibitors. It was shown that constructs containing the peptide-binding 
domain and atleast one other domain of Ssb was able to complement some drug 
sensitivity (Allen et al., 2004), we tested which of the mutations in the peptide binding 
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domain and C-terminal truncations of Ssb is responsible for the drug sensitive 
phenotype. Interestingly, the C-terminal truncations had the most dramatic effect on drug 
sensitivity, while only one mutation in peptide-binding domain V442F showed drug 
sensitivity (Figure 4.6). Interestingly, the C-terminal truncation of Ssb1 affected ability of 
Hsp104 to mediate [PSI+] curing implicating that the C-terminal domain of Ssb1 seems 
to be important in Ssb’s function in relation to drug sensitivity in our strain prion  
background and [PSI+] curing. Surprisingly the chimeric protein BBA (containing Ssa’s 
C-terminal variable domain) does not affect Ssb’s function in showing drug resistance 
(Pfund et al., 1997).                                                                                                     
Excess Ssa1 was shown to increase [PSI+] formation by overproduced Sup35N from the 
same species (Allen et al., 2004), and also by heterologous Sup35NM protein derived 
from an evolutionarily distant yeast, Pichia methanolica (K Allen, unpublished results). It 
was shown that construct carrying all three domains of Ssa (AAA) was able to increase 
non-sense suppression in the weak [PSI+] strain OT55, (Allen et al., 2004), we observed 
that the construct with any two Ssa domains (AAB, ABA, BAA) were able to maintain 
[PSI+]PS just as with AAA. Infact peptide-binding domain of Ssb1 was shown to be 
necessary and sufficient for the inhibition of [PSI+] mediated suppression (Allen et al., 
2004), we observed that any two domains of Ssb1 (ABB, BAB) were equally effective as 
BBB in curing [PSI+]PS. The construct BBA showed 50% curing of [PSI+]PS, and the 
unstable nature of [PSI+] PS made it difficult to intepret this result. Our data showing a 
two-hybrid interaction between Saccharomyces Sup35 and Ssa goes hand in hand with 
the observation that Ssa co-localized with Sup35-GFP clumps in vivo (Allen et al., 2004) 
and it was also capable of interacting with Sup35NM in the affinity chromatography 
assays in vitro (Allen et al., 2004).  
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CHAPTER 5 




Ubiquitination and QN-rich protein aggregates 
During the past decade, it has become apparent that a set of ostensibly 
unrelated neurodegenerative diseases, including Alzheimer’s, Parkinson's, Huntington's 
and prion diseases, that involve protein misfolding and aggregation and which result in 
inclusion bodies and other aggregates within cells are linked to the Ubiquitin (Ub)-
proteasome system (Tran and Miller, 1999; Mayer, 2003; Ciechanover, 2003). This link 
is because of the fact that these aggregates often contain ubiquitin, which is the signal 
for proteolysis by the 26S proteasome. The link between the ubiquitin-proteasome 
system and neurodegeneration has been strengthened by the identification of disease-
causing mutations in genes coding for several ubiquitin-proteasome pathway proteins in 
Parkinson's disease (reviewed in Ross and Pickart, 2004). It has been suggested that 
protein aggregates can impair the function of the Ub-proteasome system (Bence et al., 
2001). 
        The Ub-proteasome pathway regulates a wide variety of biological processes 
(Hershko and Ciechanover,1998). The degradation of abnormal or damaged proteins 
occurs, at least in part by the Ub-proteasome pathway. Proteins targeted for degradation 
via this pathway require conjugation of Ub through an isopeptide bond joining the C-
terminal glycine of Ub to a side-chain amino group of lysine (K) in the target protein. Ub 
polymerization occurs by linkage of the K at position 48 of the proximal Ub to the C-
terminal glycine of another Ub. This reaction requires the sequential action of three 
enzymes: Ub-activating enzymes (E1), Ub-conjugating enzymes (E2) and/or Ub-ligase 
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(E3) (Hershko and Ciechanover,1998). Ubiquitination is a reversible process facilitated 
by Deubiquinating (DUB) enzymes that disassemble Ub-conjugates releasing free Ub 
(Wilkinson, 2000). Ub-substrates bind to the 19S regulatory particle of 26S proteasome, 
are unfolded and translocated to the 20S proteasome core, where protein is degraded 
by proteinases (Finley, 2002).  
Depletion of Ubp6 and Doa4 (DUBs) that result in Ub depletion has been shown 
to cause defects in phenotypic expression and de novo formation of the yeast prion 
[PSI+] (Chernova et al., 2003). K. Allen (Chernoff lab) in her thesis work also found that 
the deletion of one of the major Ub-conjugating enzymes, Ubc4, results in an increase in 
spontaneous [PSI+] formation. She also saw that excess Sup35/Sup35N related toxicity 
in [PSI+] cells was reduced in ubc4∆ cells while ubc4∆ cells expressing Htt-Q103 
showed intense papillation. Recall that Q103 toxicity is seen in the wild-type yeast cells 
containing endogenous prions (Meriin et al., 2002 and this study). The papillations 
indicated that a change has occurred in a subset of cells that enabled them to overcome 
Q103 toxicity. Here, we present a detailed characterization of such mutants. 
 




Yeast strains that are unique to this study are described below. Other commonly 
used strains are described in Chapter 2, and Table 2.1. GT349 is MATa ubc4∆::HIS3 
derivative of GT81-1C [PSI+ PIN+]. GT386 is a [psi- PIN+] derivative of GT349 obtained by 
Hsp104 treatment (pGAL104). GT387 is a [psi- pin-] derivative of GT349 obtained after 3 
successive passages on 5mM GuHCl. GT573, GT574 and GT575 are AQT-2, AQT-7 
and AQT-9 strains respectively. These are GT349 [PSI+ RNQ+] ubc4∆ papillae. GT675, 
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GT676 and GT677 are [psi- PIN+] versions of GT573, GT574 and GT575 respectively. 
They were obtained by Hsp104 treatment (pLH105). GT769, GT770 and GT771 are [psi-  
pin-] versions of GT573, GT574 and GT575 respectively obtained after GuHCl treatment 
(see above). In cases, where [psi-] is made from [PSI+], [psi-] status is verified by the 
absence of growth on –ade medium (see materials and methods for more details on 
prion detection). GT385-13A is a MATα ubc4∆ [psi-  rnq-] haploid meiotic spore clone 
obtained through the dissection of the GT385 diploid. UBC4+/ubc4∆ diploids were 
obtained by mating GT81-1D with Q103 and empty plasmid transformants of GT573, 
GT574 and GT575. The Q103 and empty plasmid transformants of GT349 mated with 
GT81-1D served as a control for this experiment. These diploids were used to check 
UBC4+ dependence for AQT toxicity. The Q103 (pYES2-103Q) transformants of GT573, 
GT574 and GT575 are strains GT580, GT582 and GT608 respectively. The empty 
plasmid (pRS316GAL) transformants of GT573, GT574 and GT575 are strains GT579, 
GT581 and GT607 respectively. The ubc4∆ / ubc4∆ diploid were obtained by mating 
GT385-13A with GT573, GT574 and GT575 Q103 and empty plasmid transformants. 
They are called GT532, GT534 and GT756/GT724 respectively. The diploid GT349 
mated with Gt385-13A also called GT606 served as a control for this experiment. AQT-
2, 7 and 9 homozygous diploids were obtained by mating the seggregants of opposite 
mating type from AQT heterozygous diploids. Eg: AQT-2 homozygous diploid GT726 is 
a cross between GT532-9B and GT532-9D. Diploid selection is done by transforming 
one partner with LEU2 empty plasmid and the other with pYES2-103Q (URA3) and 
selecting on a –ura-leu medium. Similarly, AQT-7 homozygous diploid GT727 is a cross 
between GT534-2A and GT534-2B. AQT-9 homozygous diploid GT728 is a cross 
between GT724-3B and GT724-3D. To conduct the Allelism experiment, AQT-2/7, AQT-
2/9 and AQT-7/9 diploids were made. GT729 is a cross between poly-Q transformant of 
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GT573 and GT534-2B (AQT-2/7), GT741 is a cross between poly-Q transformant of 
GT573 and GT724-3B (AQT-2/9) and GT730 is a cross between poly-Q transformant of 
GT575 and GT534-2B (AQT-7/9). The strain GT784-8C, [PSI+ PIN+] MAT α ubc4∆ rnq1∆ 
is a haploid meiotic spore clone obtained from the diploid GT784. GT818 is the [psi- pin-] 
derivative of GT784-8C obtained by 5mM GuHCl treatment. Some of the strains 
mentioned were were made by undergraduate student Charles Kubicek (Chernoff Lab). 
 
Plasmid constructs  
The commonly used plasmids are listed in Chapter 2. Plasmids unique to this 
study are described here. The centromeric LEU2 based genomic library plasmids used 
were p366 (control) and p366 library pools #1, #2, #3 and #4.  
 
Diploid selection 
Diploids were made by mixing two haploid strains of opposite mating type ie one 
parent has A mating type and the other has α mating type. This was done on complete 
medium like YPD. YPD was incubated at 30°C for a day and then some cells were taken 
from the patch and streaked out on selective medium. To ease the selection of diploids 
usually one parent was transformed with LEU2 based plasmid and the other with a 
URA3 plasmid. The diploids were then selected by growth on –ura-leu. Note that this 
was possible with only if the strains are auxotrophs for that particular aminoacid. The 
plasmids were chosen depending upon what the diploid was used for. Eg polyQ (URA3) 
plasmid was used while making diploids if they were to be checked for anti-toxicity or 
empty plasmid (URA3) was used if the diploid was to be used for other purposes. In 
case where diploid selection by this means was not possible, patch was streaked out on 
YPD again, single colonies were selected, patched and mated to strains OT37 (α his4 
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lys2) and OT38 (a his4 lys2) kindly provided by S. Liebman. Diploids cannot mate with 
these strains while haploids can. All the strains used in the experiment are from GT81 
series that are lys auxotrophs. So diploid selection is most cases was to mate the single 
colonies to OT37 lawn or OT38 lawn on YPD. Incubate the plate for a day or two at 
30°C. Velveteen the plate onto SD + lys. Single colonies that were haploid depending 
upon their mating type will show growth either on OT37 or OT38 lawn while the diploid 
single colonies will not show growth on either plate. 
 
Chromosomal DNA isolation for preparing the AQT DNA library 
QIAGEN Genomic-tip 500/G kit was used . It isolates upto 100µgm high 
molecular weight DNA. Advantages of using this kit is that the procedure is very gentle 
and results in negligible DNA shearing. DNA purified with Qiagen Genomic-tips is sized 
up to 150 kb with an average length of 50-100kb. DNA is free of all contaminants like 
RNA, protein and other metabolites and has A260/A280 ratios between 1.7 and 1.9.  
 
Preparation of chromosomal DNA for pulse-field electrophoresis 
Agarose embedded yeast DNA was prepared using the BioRAD Kit. Plugs were 
loaded onto a pulse field certified agarose gel (1.2%) at 6V/cm gradient. The samples 
were run for 42hrs to get a good separation between 600kb and 1Mb. 
 
Testing of RNQ1 –likely candidate gene  
The [psi- PIN+] ubc4∆ strain and the AQT [psi- PIN+] ubc4∆ strain were crossed 
with [psi- pin-] ubc4∆ rnq∆ (control) respectively. If AQT = rnq1* all 4 spores were 
expected to be non-toxic and if AQT is not rnq1* than diff types of tetrads were expected  
(2:2, 3:1 and 4:0). While the control cross was expected to give 2 RNQ+(toxic): 2 rnq∆ 
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nontoxic. From the 8 mutant tetrads tested, 3 show 4:0 anti-toxicity:toxicity, 3 show 3:1 
and 2 show 2:2. Thus this shows that AQT mutation is not in the RNQ1 gene. The wild-
type cross showed 2:2 anti-toxicity: toxicity as expected.  
 
Results 
Note: AQT strains are in the ubc4∆ background and these strains are [PSI+ RNQ+] 
unless otherwise stated. 
 
Effect of ubc4∆ on Q103 toxicity 
 
The poly-Q extended (Q103) exon 1 of human huntingtin fused to GFP is toxic 
when expressed under galactose-inducible promoter in the  [PSI+ RNQ+] UBC4+ 
background but when expressed in cells in which Ubc4 is deleted (ubc4∆ ) showed 
numerous papillations indicating that a subset of cells were able to counteract Q103 
toxicity (Figure 5.1 A). 2 papillae from 12 independent ubc4∆ transformants were colony-
purified and re-tested along with the original transformants from which they emerged for 
the anti-toxicity phenotype. Individual papilla was then re-tested for anti-toxicity. Q103 
plasmid was lost and then re-introduced to test the anti-toxicity. Presence of [PSI+] and 
[PIN+] was tested from the 3 re-transformed papillae that continued to show anti-toxicity 
and were designated as “ AQT” strains (AQT-2, AQT-7 and AQT-9) and further 
investigated (Figure 5.1 B). Q103 toxicity in yeast depends on the presence of [PSI+] 
(Chapter 3) and [PIN+] (Meriin et al., 2002). So it was important to check that this anti-









Figure 5.1 Origin of the AQT mutants                                                        
A. Papillation in ubc4∆ background in the presence of poly-Q: The [PSI+
RNQ+] strain, GT81-1C (UBC4+) and GT349 (ubc4∆) were transformed 
with pYES2-103Q encoding huntingtin Q103 and the empty vector 
control, pRS316GAL. Medium was selective for the plasmid (-Ura) and 
contained galactose (Gal) to induce the Q103 construct. Plates were 
photographed after 3 days of incubation. No differences in growth were 
seen on glucose (-Ura) medium (data not shown). Q103 toxicity is seen 
as growth inhibition on –Ura/Gal in the UBC4+ background. Papillation is 
an indication that a subset of cells from the ubc4∆ background show anti-
toxicity. B. “ AQT” strains are papillae originating in the ubc4∆
background. 2 papillae from 12 independent ubc4∆ Q103 transformants 
were streaked out (only 2 are shown) and were checked for [PSI+] loss, 
[RNQ+] loss, plasmid retention and plasmid rearrangements (see text). 3 
papillae that retained [PSI+] and [RNQ+] were designated as “ AQT”





[PIN+]. AQT strains showed the presence of [PSI+] and [PIN+]. (See Kim D. Allen’s thesis 
for more details on obtaining AQT strains).  
To confirm the observation that the Q103 anti-toxicity effect was dependent on  
the absence of Ubc4, we checked if Q103 toxicity could be restored by the introduction 
of Ubc4. Both extra-copy chromosomal UBC4 (Figure 5.2 A) and multi copy episomal 
Ubc4 (Figure 5.2 B) were able to restore the Q103 toxicity seen in the ubc4∆ 
background with the exception that the AQT-9 anti-toxicity phenotype was not 
completely overcome by the chromosomal copy of UBC4 (Figure 5.2 A).   
 
Characterization of the anti-toxicity phenotype of AQT mutants  
Poly-Q Anti-toxicity effect of AQT strains was seen on solid medium containing 
galactose as growth which is more of a qualitative nature. We carefully analyzed this 
effect by conducting the experiment in liquid medium in a more quantitative manner. The 
AQT-2 strain overexpressing Q103 grew better than its ubc4∆ isogenic strain and UBC4+ 
isogenic strain (Figure 5.3 A). The growth of AQT strains with the empty plasmid was 
better than its ubc4∆ isogenic strain but lesser than its UBC4+ isogenic strain (Figure 5.3 
A) implying that AQT strains in general grew better than their ubc4∆ isogenic control in 
selective synthetic medium. Suprisingly, the growth of ubc4∆ strain was better in the 
presence of Q103 than its absence but it remained lot lesser than the AQT-2 strain 
expressing Q103 (Figure 5.3 A). Trends for AQT-7 and AQT-9 were similar and are not 
shown. 
When the AQT strains were transformed with Q103 expressed under Copper 
inducible promoter and checked on medium containing copper to induce the constructs, 
these strains grew equally well as their control strains (Figure 5.3 B). When checked on  
 
Figure 5.2 Anti-toxicity is ubc4∆ dependent                                                  
A. UBC4+/ubc4∆ diploids show Q103 toxicity while ubc4∆ /ubc4∆ diploids 
do not. The AQT ubc4∆ strain is mated with UBC4+ isogenic strain to 
obtain UBC4+/ubc4∆ diploids. The AQT ubc4∆ strain is mated with ubc4∆
isogenic strain to obtain ubc4∆ /ubc4∆ diploids. See materials and 
methods for more details. Diploids were selected on –Ura-His and spotted 
onto galactose selective medium to induce the expression of Q103. Plates 
are photographed after 8 days of incubation on –Ura-His/Gal (second 
passage). B. Multi copy suppression of Q103 toxicity by UBC4. AQT
strains -2,-7 and -9 GT573, GT574 and GT575 respectively along with the 
control strains GT349 (ubc4∆ Wild-type) and GT81-1C (UBC4+ Wild-type)
were transformed with control plasmids “Control”- pRS316GAL(URA3) and 
pFL39 (TRP1), ”Ubc4”- pTRP-UBC4 and pRS316GAL;” ↑ Q103”- pYES2-
103Q and pFL39 ;” ↑ Q103 + ↑ Ubc4” - pYES2-103Q and pTRP-UBC4 . 
Transformants were grown on –Ura-Trp/Glu selective for the plasmids and 
then spotted onto –Ura-Trp/Gal+ Raf to induce the constructs. Plates were 
photographed after 10 days of incubation.
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Figure 5.3 Anti-poly-Q toxicity phenotype of AQT mutants 
A. Quantitative assay demonstrates Q103-anti-toxicity effect of AQT strains. AQT
strains along with their controls were transformed with plasmids pYES2-103Q 
encoding Q103 and the control pRS316GAL. Transformants were grown in –
Ura/Gal+ Raf to induce the Q103 construct. See materials and methods for more 
details. Data for AQT-7 and AQT-9 show similar trends and is not shown. B. 
AQT strains do not exhibit anti-Q103-toxicity phenotype when Q103 is expressed 
under CUP promoter. The AQT strains and the controls were transformed with 
the plasmid pMCUP-103Q-GFP encoding Q103 and the control plasmid
pMCUP1. Transformants grown on –Ura were replica plated onto –Ura + 100µM 
CuSO4 with and without Gal. Plate was photographed after 8 days (second 
passage). C. Dominance of anti-toxicity in AQT mutants.  AQT mutants along 
with the isogenic ubc4∆ control were mated with isogenic ubc4∆ control of the 
opposite mating type and were transformed with plasmids pYES2-103Q 
encoding Q103 and the control pRS316GAL. These ubc4∆ /ubc4∆ diploids were 
selected on -Ura-His. To check for anti-toxicity effect, they were spotted onto –
Ura-His/Gal + Raf to induce the Q103 construct. Plate was photographed after 6 
days of incubation. D. Effect of [PSI+] on anti-toxicity mediated by AQT strains.
AQT strains along with their controls were compared to their [psi-] derivatives 
GT675, GT676, GT677 and their controls GT386 and GT159 for Q103 anti-
toxicity. Plasmid used was pYES2-103Q encoding Q103. Spotted onto -
Ura/Gal+Raf to induce the construct and plates were photographed after 10days. 
AQT-7 shows an increase in anti-toxicity followed by AQT-9 in the absence of 
[PSI+] while AQT-2 shows no change in anti-toxicity irrespective of [PSI+]. 
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copper containing galactose medium, growth of control strains with and without Q103 
was impaired. The AQT strains with and without Q103 continued to show good growth  
(Figure 5.3 B). No differences in growth were detected on glucose medium irrespective 
of the presence of CuSO4 (data not shown). This data implies that the Q103 toxicity of 
control strains is galactose dependent. Differences in the expression levels of Q103 
when expressed under galactose promoter and copper inducible promoter could account 
for this effect. 
           Next, we tested if the anti-toxicity trait is dominant or recessive. This was checked  
in diploids by mating each AQT strain with and without Q103 to its isogenic ubc4∆ strain. 
The diploids overexpressing Q103 continued to show anti-toxicity while the control wild-
type ubc4∆ diploid overexpressing Q103 was not able to show growth as expected on 
galactose containing medium proving that the AQT Q103 anti-toxicity phenotype is 
dominant (Figure 5.3 C). Tetrad analysis of these diploids indicated that in most of the 
tetrads, spores showed 2:2 anti-Q103-toxicity: toxicity pattern of segregation (Table 5.1). 
2:2 pattern of segregation indicates a mendelian trait. AQT phenotypes thus exhibit a 
mendelian (chromosomal) and not non-mendelian (epigenetic) pattern of inheritance as 
seen with prions.    





  Table 5.1 Tetrad analysis of AQT phenotype showing mendelian inheritance 
 Cross    4:0 3:1 2:2 1:3    0:4 Total 
AQT-2 X ubc4∆     0 0 5 0      2   7 
AQT-7 X ubc4∆    0 0 10 0      3 13 






different genes. In order to test that, AQT-2/AQT-7, AQT-2/AQT-9 and AQT-7/AQT-9  
 
diploids were made by crossing one AQT strain with the other. These diploids were then  
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Table 5.2. Results of Allelism showing mostly 4:0 pattern of segregation of AQT anti-
Q103- toxicity phenotype            
Crosses Number of Tetrads tested Anti-toxicity: Toxicity 
2/7 7 6 (4:0) 
1 (3:1) 
2/9 8 8 (4:0) 




Since Q103 toxicity in yeast is dependent on the presence of prions, we further 
investigated if AQT strains that showed anti-polyQ toxicity also showed such 
dependence on [PSI+]. [psi- PIN+] strains were transformed with Q103 along with their 
isogenic [PSI+ PIN+] strains. The absence of [PSI+] increased the growth of AQT-7 strain 
significantly and the growth of AQT-9 strain only slightly. But AQT-2 strain did not exhibit 
any increase in growth (ie increase in anti-toxicity) in the absence of [PSI+] (Figure 5.3 
D). The 3 strains differed in their ability to show anti-toxicity in the absence of [PSI+] 
suggesting that differences could exist in the nature of mutation even though it appears 





Characterization of growth of AQT strains 
Growth of AQT mutants was monitored in complete medium to check if in general 
ie in the absence of poly-Q they grew better than their control strains. AQT strains grew 
better than its ubc4∆ isogenic control while UBC4+ isogenic strain grew the best (Figure 
5.4 A) just as seen previously in synthetic selective medium with strains transformed 
with empty plasmid (Figure 5.3 A).  
AQT strains were also checked for temperature-sensitivity. Growth was 
monitored at different temperatures- 25°C, 37°C and 39°C on complete medium YPD. 
The growth of ubc4∆ wild-type control was affected at 39°C, while AQT strains continued 
to grow at 39°C along with its UBC4+ wild-type strain (Figure 5.4 B). We also checked if 
prion background had any influence on temperature-resistance seen with the [PSI+ PIN+] 
AQT strains. [PSI+ PIN+], [psi- PIN+] and [psi- pin-] versions of AQT strains were tested. In 
case of AQT-7 and AQT-9, the [psi- PIN+] versions showed temperature-sensitivity at 
39°C (Figure 5.4 C). Thus AQT-7 and AQT-9 [psi- PIN+] strains behaved differently than 
AQT-2 [psi- PIN+] strains in both temperature-resistance and dependence of anti poly Q 
toxicity on [PSI+]. In the majority of cases, anti polyQ toxicity corresponded to 
temperature-resistance at 39°C. When checked if this temperature-resistance phenotype 
is dominant or recessive, the diploids same as used for checking if anti-poly-Q toxicity 
was dominant grew poorly at 39°C than the AQT haploid strains and their growth was 
not significantly better than its isogenic ubc4∆ diploid (Figure 5.4 D) indicating that the 
temperature-resistance phenotype is recessive. 
 
Effects of the AQT mutations on Sup35/Sup35N toxicity 
           Overexpression of Sup35 or Sup35N (the prion forming domain of Sup35) in 




















Figure 5.4 Growth characteristics of AQT mutants 
A. Growth of AQT mutants in complete medium. AQT [PSI+] mutants along with 
their controls were grown in YPD medium and their growth was monitored over 30 
hrs (see materials and methods - Quantitative analysis for details). B. AQT
mutants display temperature resistance at 39°C. 10-fold dilutions of equal number 
of cells (AQT [PSI+] mutants and their controls) was spotted onto YPD and 
synthetic medium SD + 13 (data not shown). YPD plates were photographed after 
3 days of incubation at 39°C. As a control, plate made in the same way was kept 
at 30°C where all strains grew (data not shown). C. AQT-7 and AQT-9 [psi- PIN+] 
versions show temperature-sensitivity at 39°C. Temperature-sensitivity of all three 
versions [PSI+ PIN+], [psi- PIN+] and [psi- pin-] of AQT strain and its isogenic control 
ubc4∆ are compared. 10-fold dilutions of equal number of cells spotted onto 2 
YPD plates- the 30°C plate serves as a control for 39°C plate. Plates 
photographed after 10 days of incubation at 39°C. Control strain remains 
temperature-sensitive (data not shown). D. Recessiveness of AQT by 
temperature-resistance. The AQT ubc4∆/ ubc4∆ diploids were compared in their 
temperature-resistance to their haploid parents as well as controls Wild-type 
ubc4∆/ ubc4∆ diploid and to its homozygous diploid AQT ubc4∆/ AQT ubc4∆. 
GT606 (Wild-type ubc4∆/ ubc4∆ diploid), AQT-2,-7 and -9 ubc4∆/ ubc4∆ diploids 
–GT532,GT534 and GT756 respectively. The homozygous diploid AQT ubc4∆/ 
AQT ubc4∆- 2,7 and 9 are GT726, GT727 and GT728 (see materials and 
methods for more details). 10-fold dilutions of equal number of cells were spotted 
onto YPD and plates were photographed after 4 days of incubation at 39°C. AQT
[PSI+ PIN+] strains 2, 7, 9 are GT573, GT574 and GT575 respectively along with 
its isogenic control ubc4∆ GT349 and isogenic control UBC4+ GT81-1C. AQT [psi-
PIN+] strains 2,7,9 are GT675, GT676 and GT677 and AQT [psi- pin-] strains 2, 7 
and 9 are GT769, GT770 and GT771. The [psi- PIN+] and [psi- pin-] versions of 
GT349 are GT386 and GT387.
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Figure 5.5 AQT mutants decrease toxicity of ↑ Sup35/Sup35N                                  
A. Plate Assay. Strain GT349 and the three AQT strains AQT-2 GT573, AQT-
7 GT574 and AQT-9 GT575 were transformed with plasmids pRS316GAL 
(control), CEN-GAL-SUP35 (Sup35) and pRS316GALSUP35N (Sup35N), 
grown on selective medium containing glucose (–Ura/Glu) and equal numbers 
of cells were then spotted onto selective medium containing galactose and 
raffinose (-Ura/Gal+Raf) in 10-fold serial dilutions to induce the expression of 
the Sup35 constructs.Plates were photographed after 10days of incubation at 
30°C. B. Quantitative Assay. The same transformants were precultured as 
given in Materials and Methods. AQT-7 and AQT-9 showed similar trend as 


















Overproduction of Sup35 increases the probability for the accumulation of misfolded 
aggregation-prone Sup35 intermediates to adopt the prion form. We investigated if the 
AQT mutants that are able to overcome poly-Q toxicity would do so with another QN rich 
protein that shares the aggregation-prone property with poly-Q. Indeed we saw that AQT 
mutants can overcome Sup35/Sup35N toxicity with the exception that AQT-9 strain did 
not overcome Sup35N toxicity (Figure 5.5 A). Quantitative analysis confirmed our 
observation (Figure 5.5 B). Data for AQT-2 strain expressing full length Sup35 is only  
shown. Trends were similar for AQT-2 and AQT-9 expressing Sup35/Sup35N and are 
not shown.  However, when AQT mutants were tested with Sup35/Sup35N expressed  
under its own promoter on a LEU-2d based multicopy vector, no such anti-toxicity effect 
was observed (Figure 5.6 A). The difference in expression levels as indicated before for 
Cup-huntingtin construct could explain this effect. We also checked the effects of AQT 
mutants on  [PSI+] suppression. AQT-9 showed better [PSI+] suppression followed by 
AQT-7 than its ubc4∆ isogenic control and AQT-2 (Figure 5.6 B) on –ade medium. AQT-
9 and AQT-7 continued to show better [PSI+] suppression when Sup35 was present at 
high levels ie when checked on –leu-ade medium. Level of [PSI+] suppression in AQT-2 
was same as its ubc4∆ isogenic control in both –ade and –leu-ade medium (Figure 5.6 
B). 
 
Effect of AQT mutants on poly-Q aggregation and endocytosis 
The next logical step was to study the effects on poly-Q aggregation in AQT 
strains. In the yeast system, toxicity of Q103 appears to be directly associated with its 
aggregation (Meriin et al., 2001). Proposed theories are that aggregates themselves are 
toxic to cell or that the aggregates could sequester important essential proteins and thus 
could be cause of toxicity. In this case anti-toxicity could result if the interaction between 
aggregates and proteins is impaired and the proteins still remain available for function.  
Figure 5.6 Effect of AQT mutants on Sup35 toxicity and suppression without 
the involvement of galactose                                                       
A. AQT mutants do not counteract Sup35 toxicity. AQT [psi- RNQ+] strains 
AQT-2 GT673, AQT-7 GT674, AQT-9 GT675 and GT386 –control strain 
were transformed with pEMBL-YEX (control) and pEMBL-SUP35 (Sup35). 
Transformants were grown on medium selective for the plasmid containing 
glucose (-Leu). Images photographed after 15 days of incubation. B. AQT
[psi- RNQ+] strains same as mentioned in A. show better [PSI+] suppression 
over its control. Transformants grown on -Leu were velveteen replica-plated 
onto –Ade and –Leu-Ade medium. Growth on –Ade medium shows 
suppression in the presence of moderate copies of SUP35 and growth on –
Leu-Ade medium is an indication of growth with high levels of SUP35 (See 
materials and methods for pEMBL constructs). At least 8 independent
transformants were tested in each case for each combination. Typical 
representatives are shown.-Ade plate is photographed after 7 days of 
incubation and the –Leu-Ade plates photographed after 15 days and 24 























Thus one would expect that in cells showing anti-toxicity effect, the Q103 clumps 
would be broken down. In case of AQT mutants, difference in pattern of aggregation was 
observed. From ~ 200 cells observed with each mutant, around 60% of AQT 2 cells 
expressing Q103 showed dot-like structures while clumps were seen in the rest of them 
(Figure 5.7 A).  40% of AQT-7 cells expressing Q103 diffused fluorsescence while 
clumps were seen in the rest of them. In almost all AQT-9 cells expressing Q103, 
clumps were seen, some infact showed even an increased size than its isogenic wild-  
type controls (Figure 5.7 A). This suggests that atleast in AQT-2 and AQT-7 decrease of 
Q103 aggregates could be a possible mechanism of anti-toxicity.  Q103 aggregation in 
yeast was shown to be associated with defect of endocytosis and has been implicated 
as one of the likely causes of Q103 toxicity (Meriin et al., 2003). The effect of Q103 
aggregates on endocytosis was monitored using lipophilic dye FM4-64 (See materials 
and methods-chapter 2 Endocytosis section for more details). This dye binds to the cell 
membrane and is internalized through endocytic pathway. Cells where endocytosis is 
not affected show a distinct ring around the vacuoles after 45 mins of staining indicating 
the fusion of dye-stained endosomes with vacuolar membrane. In contrast, all the cells 
showing Q103 clumps contained no such rings indicating a defect in endocytosis. AQT-2 
and AQT-7 showed ring like structures inspite of the presence of clumps, while in AQT-
9, no such rings were observed in the presence of Q103 clumps (Figure 5.7 B). AQT-2 
and AQT-7 strains do not show a defect in endocytosis in cells with clumps and that 
could be one of the reasons why this strains show anti-toxicity. While AQT-9 continues 







~ 60 % ~ 40%
~ 60 %~ 40 %
A
B
AQT-2  ↑ Q103
AQT-7  ↑ Q103
AQT-9  ↑ Q103
UBC4+ ↑ Q103
ubc4∆ ↑ Q103
GFP    FM4-64
AQT-2 ↑ Q103
AQT-7  ↑ Q103
AQT-9  ↑ Q103
UBC4+ ↑ Q103
ubc4∆ ↑ Q103
Figure 5.7. Effects on aggregation state of Q103 and endocytosis in AQT
mutants 
A. Types of aggregates in Q103 overexpressing AQT strains. Strain GT349 
ubc4∆-control for AQT strains, three ubc4∆ AQT strains AQT-2 GT573, 
AQT-7 GT574 and AQT-9 GT575 and GT81-1C UBC4+ strain were 
transformed with plasmid pYES-103Q. The strains are [PSI+ RNQ+]. 
Transformants were grown in the liquid –Ura medium containing galactose
and raffinose (Gal+Raf) to induce the Q103. Distinct types of aggregates 
were observed with different strains. B. AQT-2 and AQT-7 (but not AQT-9) 
compensate for the endocytosis defect  caused by Q103. Transformants 
grown in –Ura/Gal+Raf were checked for endocytosis using FM4-64, a
lipophilic dye that enters vacuolar system via endocytic pathway. It stains 
the vacuolar membrane when endocytosed showing a ring like structure. 
AQT-2 and AQT-7 cells showing Q103 aggregates show ring indicating no 
defect in endocytosis while AQT-9 cells with Q103 aggregates do not show 
a ring, indicating a defect in endocytosis. Both the controls show no rings in 
cells with Q103 aggregates showing a defect in endocytosis (See Materials 
and methods –Fluorescence Microscopy Section for details). Note that 
residual fluorescence of cells with large clumps in the red (FM4-64) filter 
results from leakage of GFP fluorescence through red filter.
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Figure 5.8 Pulse-field gel electrophoresis of chromosomal 
DNA of AQT-2 strain GT573 and its control WT GT349    
The strains are [PSI+ RNQ+] ubc4∆. The DNA from AQT-2
strain shows different pattern of bands than its wild-type 
control – the chromosome 13 band is missing and a intense 
band at chromosome position 16 could indicate 
amplification of some parts of chromosome 13 
corresponding to a jump in the migration pattern.This data 






















Pulse-field gel electrophoresis detected difference in DNA pattern of AQT mutant 
and its ubc4∆ isogenic control  
 
 Pulse-field gel electrophoresis is used for the seperation of large chromosomal 
DNA. When the chromosomal DNA from the AQT-2 strain and its ubc4∆ strain were run 
side by side, it revealed differences in DNA pattern (See figure 5.8). The seperation was 
good in the range 600 kb-1Mb and it separated out chromosomes 7, 15, 13 and16 very 
well. The band corresponding to chromosome 13 was missing from AQT-2 strain’s DNA  
and instead there was a high intensity band at position 16. This indicates a complex 
rearrangement. The migration pattern of chromosome 7 and 15 was a bit off than its  
wild-type control but nevertheless, the bands existed. Increase in size of chromosome 7 
was also seen with AQT-7 (data not shown). The band corresponding to chromosomes 
2, 14 and 10 migrated as one single band in both the strains. Following was the band 
corresponding to chromosome 11 followed by a band corresponding to chromosome 5 
followed by chromosome 8 (see figure 5.8). All the other chromosome sizes were out of 
range of seperation of the setup and could not be very well resolved. The identification of 
chromosomes is preliminary, as our strain chromosome profile is different from 





Role of Ubc4 in poly-Q mediated toxicity 
Absence of the major Ubiquitin-conjugating enzyme Ubc4 in yeast gave rise to a 
subset of cells able to overcome poly-Q associated toxicity. Together with Ubc5, Ubc4 is 
responsible for the majority of ubiquitin-dependent targeting of proteins for degradation 
via the proteasome. Deletion of Ubc5 however did not have any effect on poly-Q 
associated toxicity. Infact even excess of Sup35/Sup35N mediated toxicity was lowered 
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in the ubc4∆ background (See Kim D. Allen’s thesis for more information). These results 
implicate that Ubc4 either directly or via interaction or regulation of other proteins favors 
the poly-Q associated toxicity seen also with another QN-rich protein Sup35. This result 
actually contradicts the conventional thinking where the absence of Ubc4 would be  
expected to have an effect on ubiquitination of proteins marked for degradation and will 
therefore lead to an excess of misfolded proteins causing an increase in toxicity. Yet, 
another thinking would be that cytotoxicity is due to the efficient recruitment of Ubiquitin-
proteosome components (UPS) to protein aggregates in order to effect their elimination. 
This results in their titration (functional depletion). In concert with this proposal, the  
efficient targeting of excessive amounts of misfolded proteins and/or aggregates may 
overwhelm the proteasome, inhibiting its activity. Indeed, impairment of the UPS by 
protein aggregation has been demonstrated in mammalian cells (Bence et al., 2001). 
Such toxicity would be expected to be overcome by: 1) the elimination of protein 
aggregates; 2) compensation of depletion by overexpression of titrated components; and 
3) a decrease in the efficiency of targeting substrates for degradation and/or the 
recruitment of chaperone and UPS components to targeted substrates. Thus ubc4∆ 
ameliorating toxicity is consistent with this model.   
Summarizing the results, the poly-Q antitoxcity phenotype of AQT mutants is 
ubc4∆ dependent. The anti-toxicity phenotype of AQT mutants seen with both Q103 and 
Sup35/Sup35N is galactose dependent. Anti-Q103-toxicity phenotype is dominant and is 
of a mendelian nature. Genetic analysis revealed that the mutations are on the same 
gene AQT mutants show temperature-resistance at 39°C and this temperature-
resistance phenotype is recessive. Interestingly, [psi- PIN+] versions of AQT-7 and AQT-
9 show some similar trends with repect to Q103 anti-toxicity, temperature-sensitivity at 
39°C and levels of [PSI+] suppression. In some fraction of AQT-2 and AQT-7 mutants 
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Q103GFP clumps are not seen and the remainder that show clumps show absence of 
endocytosis defect. This could possibly be the mechanism for anti-Q103-toxicity. AQT-9 
mutant however continues to show clumps and defect of endocytosis in cells containing 
clumps and the mechanism of anti-toxicity in this strain remains unclear. Chromosomal 
DNA of the AQT-2 strain shows a different pattern than its wild-type ubc4∆ control. The 
absence of band corresponding to chromosome 13 and an increase in intensity of band 
corresponding to chromosome number 16  could indicate that chromosome 13 has 
undergone some complex rearrangment likely to be amplification of the portion of 
chromosome 13 accounting for the increase in size and jump in the migration pattern of 
DNA.  
In the meanwhile, we also engaged in checking some candidate genes most 
likely to have mutations and which were easily testable. RNQ1 was tested in a way 
described in materials and methods. It was tested by a mating approach, and the results 
stated also in materials and methods indicated that it was not the causative gene. 
Amongst the other candidates checked were Sla1 and Sla2. The rationale behind 
checking these proteins was that all three have Q rich regions that could serve as nuclei 
for Q103 aggregation. 
            Based on the recessive nature of temperature-sensitive phenotype of AQT 
strains, we tried cloning the gene by library complementation of this phenotype. 
However, since the temperature-resistance of AQT strains was not observable on 
synthetic medium and due to the mitotic instability of the temperature resistance 
phenotype, this approach failed. Another approach was to make a library from one of the 
AQT strains and transform the ubc4∆ strain to select antitoxic clones. Our pulse-field 
electrophoresis data indicating complex rearrangment of possibly chromosome 13 and 
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an increase in size of chromosome 7 obtained in colloboration with Dr Lobachev’s 
laboratory indicates that this approach might not work.  
As effects are ubc4∆ dependent, increase in copy number of some of the genes 
on chromosome 13 (if this rearrangement were to be responsible for AQT phenotype) 
that are components of ubiquitination/protein degradation system could be the likely 
candidates. Indeed such genes like BUL2, CUE4, CUE1, PRE8, PRE5, UFO1, UBC7, 
ASI1 and SEL1 are present on chromosome 13. Bul2 is a component of the Rsp5 E3-Ub 
ligase complex involved in mono-Ubiquitination and poly-Ubiquitination. Cue4 is a 
protein of unknown function but has a CUE domain that binds to ubiquitin, which may 
facilitate intramolecular ubiquitination. Cue1 is involved in ubiquitination and degradation 
at endoplasmic reticulum surface. Pre8 and Pre5 are subunits of 20S proteasome and 
are involved in Ub-dependent protein catabolism.  Ufo1 is a component of Skp1-Cdc53-
Fbox receptor (SCF) E3 Ub-ligase that is involved again in Ub-dependent protein 
catabolism.  Ubc7 is an E2 conjugation enzyme, AsiI is a putative integral membrane E3 
Ub ligase and Sel1 has an Ub regulatory X domain (UBX) that is responsible for 
degradation of an ubiquitilated model substrate. A change in expression levels of any of 
these genes could explain ubc4∆ dependent anti-toxicity phenotype in the AQT strains. 
Identification of such a gene whose amplification is responsible for the AQT phenotype 













Prion forming potential of Q-rich region of huntingtin 
The prion proteins that are otherwise unrelated, share a common feature of prion 
conversion ie ability to form β-sheet rich amyloid aggregates. In the two best-
characterized yeast prions [PSI+] and [URE3], prion properties depend on glutamine- 
and asparagine-rich (Q/N rich) domains at the amino terminus of each protein (Serio and 
Lindquist, 1999; Wickner et al., 1999). The prion domains are dispensable for the normal 
function of their proteins and are modular, conferring the ability to aggregate when 
transferred to other proteins (Wickner et al., 2000). Genomic searches for Q/N rich 
domains similar to Sup35 prion domain led to the identification of prion domains in two 
uncharacterized proteins, New1p and Rnq1p (Michelitsch and Weissman, 2000; Santoso 
et al., 2000; Sondheimer and Lindquist, 2000). When Q/N rich regions of these proteins 
were fused to the C-terminal translation termination domain of Sup35, the resulting 
fusion proteins could reversibly aggregate to form stable heritable prion states called as 
[NU+] and [RNQ+] which emulated the [PSI+] nonsense suppression phenotype.                                        
Similarly, the mutant form of huntingtin with expanded poly-Q responsible for causing 
Huntington’s disease forms self-seeding amyloid fibrils in vitro (Scherzinger et al., 1999). 
This commonality inspired us to carry out Huntingtin chimeric Studies and explore if the 
Q rich regions of Htt when fused to C-terminal domain of Sup35 could emulate the [PSI+] 
nonsense suppression phenotype just as seen with New1p and Rnq1p.      
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Evolution of Sup35p from yeast to humans 
 Sup35 (erF3) is a well conserved eukaryotic protein. Southern hybridization at 
low stringency, using SUP35C as a probe uncovered SUP35 homologs from yeast to 
humans. Infact, SUP35 from Pichia methanolica (Kushnirov et al., 1990), Homo sapiens 
(Jean-Jean, et al., 1996) and Xenopus laevis have been cloned and sequenced. Distinct 
Sup35 domains were seen to exhibit different rates of evolution (Figure 6.1 B). The 
Sup35C region was conserved from Saccharomyces to Pichia (76%) and to humans 
(57%) (Figure 6.1 B). Pichia SUP35 could complement a deletion of the S cerevisiae 
sup35. In contrast, the Sup35N region is highly variable, even between two yeast 
genera. They exhibit only 36% homology although Pichia Sup35N of 161aa versus 
Saccharomyces Sup35N of 123aa remains QN-rich (Kushnirov, et al., 1990; Santoso, et 
al., 2000) (see figure 6.1 B, C). The Pichia Sup35 PFD-corresponding region is also 
followed by a portion of the protein, which like S cerevisiae Sup35M, is rich in glutamic 
acid and lysine residues. The [PSI+] determinants of Saccharomyces Sup35 are the Q/N 
rich N-terminus (De Pace et al., 1998) and the region of imperfect oligopeptide repeats 
(Kushnirov et al., 1995; Cox, 1994) that are localized in the 114 N-terminal amino acids 
of the Sup35 protein (see figure 6.1 A). Although human Sup35N has no significant 
homology with the corresponding Saccharomyces or Pichia domains, the first (PFD-
corresponding) half of the human Sup35 contains a high percentage of proline (12%) 
and glycine (26%) residues, which underlies a high probability of turns. Interestingly, the 
highest similarity was found in the portion corresponding to the S cerevisiae Sup35N 
oligopeptide repeats. However, instead of the regular oligopeptide repeats found in the 
yeast Sup35 regions, human Sup35 contains long poly-glycine stretches. The second 
half of the human Sup35N region is enriched in glutamic acid residues (26%) like the 
Saccharomyces and Pichia Sup35M. Thus Sup35N domains from different origins show  
Figure 6.1 Similarities between Sup35 domains of Saccharomyces 
cerevisiae (yeast used in the lab study), distantly related yeast Pichia 
methanolica and the human Homo sapiens 
A. Structure of Sup35 revealing important prion determinant features- QN-
rich domain and region of imperfect oligopeptide repeats. B. Overall similarity 
in different domains of Sup35 indicated by percentage between the three 
species. The C-terminal domain is conserved while the N domain is variable 
but still shows some homologous regions. Dark regions indicate region of 
homology and light regions indicate non-homologous regions. C. Amino acid 
Composition of the Sup35N Regions. Glycine-richness of all three Sup35N 
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high potential of structural flexibility. Chimeric Sup35 (Sup35PS) containing the Sup35NM 
region of Pichia fused to MC region of Saccharomyces Sup35 could be turned into a 
prion in S cerevisiae by overproduction of identical Pichia Sup35NM (Santoso, et al., 
2000; Chernoff, et al., 2000; Kushnirov, et al., 2000) as well as complete P. methanolica 
Sup35 protein (Zadorskii, et al., 2000). This chimeric Pichia-Saccharomyces prion is 
designated as [PSI+]PS. Prion formation by the chimeric Sup35 proteins containing the 
Sup35N (or NM) regions from the other yeast genera such as Candida, Kluyveromyces, 
etc. (Santoso, et al., 2000; Nakayashiki, et al., 2001) has also been reported. In each 
case, prion formation was induced by overproduction of the identical Sup35N (or NM) 
domain of the same origin, the approach used previously to induce do novo formation of 
[PSI+]S (Chernoff, et al., 1993; Derkatch, et al., 1996). In this chapter, we explore if N or 
NM portion of Human Sup35 have such a prion forming potential. 
Interspecies prion transfer 
Prion state is efficiently transmitted between the cells or organisms of one 
and the same species via extracellular infection (in mammals) or cytoplasmic 
exchange (in fungi), the efficiency of interspecies prion transmission is greatly 
reduced, that is referred to as a “Species Barrier” in prion transmission (Prusiner, 
1997; Kocisko, et al., 1995; Hill, et al., 2000). Even evolutionary related 
mammals (e.g., various species of rodents) exhibit a strict “species barrier”. This 
barrier could be reproduced in the in vitro conversion experiments, indicating that 
it is determined by the differences in protein sequences (Kocisko, et al., 1995). 
However, interspecies prion conversion was observed in certain combinations of 
mammalian species. For example, PrPSc  transmission from sheep to cattle is 
believed to be responsible for the BSE epidemics in Europe, while PrPSc  
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transmission from cattle is suspected to cause CJD in humans (see Prusiner, 
1997). It should be noted that in all cases where interspecies prion infection was  
detected, the PrP proteins involved were highly homologous to each other and 
differed only by a few amino acid (aa) positions. Pre-existing [PSI+]S prion of S. 
cerevisiae was not able to induce conversion of the Sup35N domain of different 
origin into a prion state, indicating existence of the strict species barrier in the 
yeast system (figure 6.2) (Santoso, et al., 2000; Chernoff, et al., 2000; Kushnirov, 
et al., 2000).  
Here, we report that the Saccharomyces-Pichia barrier is asymmetric, as pre-
existing [PSI+]PS prion is able to cause conversion of the complete S. cerevisiae Sup35 
protein (Sup35S) into a prion form, albeit less efficiently.  
 
Materials and Methods 
 
Yeast strains 
The S. cerevisiae strains used in this work originated from the GT81 series 
(Chernoff et al., 2000). The haploid segregants that contained the complete deletion of 
the chromosomal SUP35S gene (sup35::HIS3) were kept viable with an episomal copy of 
the endogenous (pASB2: CEN LEU2 SUP35) or chimeric SUP35 gene on the 
centromeric plasmid as described below.  GT393, GT255-2A and GT394 are [PSI+], [psi- 
PIN+] and [psi- pin-] derivatives with deletion of chromosomal copy of Sup35, kept viable 
with an episomal copy of endogenous Sup35. These strains were used for Human and  
huntingtin  chimeric studies. 
Strain GT310 is [PSI+]PS sup35::HIS3 [SUP35NMPmCSc, URA3]. GT592 is a 
[psi- PIN+] derivative of GT310 obtained after WT Hsp104 treatment. GT557 is the [psi-  
 
Figure 6.2 Species Barrier                                      
The prion state of Saccharomyces cerevisiae endogenous Sup35 
cannot be transmitted to next generations via heterologous Sup35p or 
Sup35N/NM, originating from the distantly related yeast species Pichia 
methanolica




















pin-] derivative of GT310 obtained after GuHCl treatment. Strain GT215-8A is 
Saccharomyces [PSI+] ∆ sup35::HIS3 [SUP35Sc, URA3]. 
GT564 is isogenic to strain GT159 except that the RNQ1 ORF has been replaced 
by the S. pombe HIS5 gene. A 1.4 kb PCR product containing the S. pombe HIS5 gene 
flanked by regions of homology to the RNQ1ORF was generated from the plasmid 
template pFA6a-His3MX6 using the specially designed primers RNQ1FOR 
(5’CTGAAATGGATACGGATAAGTTAATCTCAGAGGCTGAGTCCGGATCCCCGGGT 
TAATTAA)  and RNQ1REV (5’CAAAGGATAGAAGGCGAACTGAATCATCGTTCAGT 
AGCGGGAATTCGAGCTCGTTTAAAC) where underlined regions are homologous to 
regions within and surrounding the S cerevisiae RNQ1 ORF and non-underlined regions 
are homologous to the plasmid pFA6a-His3MX6 (Pringle). Linear PCR products 
generated were transformed into GT159 (psi- PIN+) strain. Chromosomal DNA from the 
resulting HIS+ transformants were checked for successful transplacements using the 
primers RNQ1TESTFOR (5’ ATACCCAAGCAAGCTACACG) and RNQ1TESTREV (5’ 
TGAATCATCGTTCAGTAGCGG). Wild-type parental strain was expected to produce 
1.31 kb product, while strains carrying the deletion (GT564) produce 1.48 kb band. This 
strain was transformed with pUCSUP35NMPmCSc and mated with GT310. The haploid 
segregant from the cross that had deletions in both the genes SUP35 and RNQ1 were 
selected and saved as GT591.  
 
Plasmid constructs 
The plasmid pMCup1Q20MCSc was constructed by a two-step strategy. Step1 
involved ligating the 260bp PCR-amplified Q20 region from plasmid pAS1HUN20 using 
forward primers, Hun-ForKav (5’ TGGGATCCGCATGGCGAC CCTGGAAAAGCT) and 
reverse primer, Hun-RevKav (5’TTAGATCTCTCAGCCACAGCCGGGCCGGG) into 
PCR2.1 cloning vector using enzymes, BamH1 and Bgl II. Primers were designed in a 
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way so that they were complementary to the beginning and end of the Q20 region and 
contained the BamH1 and Bgl II sites (underlined) respectively. Step 2 involved excising 
the BamH1 Bgl II fragment from PCR 2.1 cloning vector and ligating into 
pMCup1NPmMCSc cut with BamH1. Construction of pMCUp1Q53MCSc was done is a 
similar way by inserting the 360bp PCR amplified Q53 region of pAS1HUN53 using 
same set of primers Hun-ForKav and Hun-RevKav into PCR2.1 using BamH1 and Bgl II. 
Second step is same as second step for pMCup1Q20MCSc. The plasmid 
pMCUP1Q103McSC was constructed by cloning the BamH1 Bgl II Q103 fragment from 
pET-Q103 and ligating to pMCup1NPmMCSc cut with BamH1. Exon 1 of huntingtin 
gene containing 103 Glutamine residues is in frame with MC region of Saccharomyces 
Sup35.  
 400bp fragment from plasmid p56G (Hoshino et al., 1989) containing the entire 
human SUP35 was PCR amplified using using primers Sup35NHs-F (5’ 
AAAGATCTAATCATGGATCCGGGCAGT ) and primer, Sup35NHs-R( 5’ 
GGGAGATCTGCTAACAGCTGAATTTGA ) into PCR cloning vector kit (intermediate 
step). The primers were designed with Bgl II sites (underlined). This construct was cut 
with Bgl II and ligated into pMCUP1MSc cut with BamH1. The final construct 
pMCUP1NHs400MCSc has the N portion of Human SUP35 fused to MC portion of 
Saccharomyces SUP35 in frame was confirmed by sequencing facility of Athens. pYCL- 
CupNHs400MCSc was constructed by ligating the Xho1 Sac1 fragment of 
pMCup1NHsMcSc(400) and ligated to pYCL-Cup cut with the same enzymes. This is a 
LEU2 based Human chimeric SUP35 construct. Similarly, the NM portion of Human 
SUP35 (600bps) was fused to MC portion of Saccharomyces SUP35 in frame. A 600bp 
fragment was PCR amplified from plasmid p56G using the existing primers 
SUP35HsATG-F    (5’CCAGATCTATCGATGGATCCGGGCAGTGGC) and 
SUP35Hs"ATG3"-R  (5’GGAGATCTTGGCGGTGCAACCACAGAC). Here again the 
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primers were designed with Bgl II sites (underlined). The remaining strategy for 
construction is same as that mentioned for pMCUP1NHs400MCSc. (However this 
construct could not be completely confirmed as sequencing failed to read sequence 
beyond 400bp from the primer). 
 Construction of the chimeric SUP35PS gene in which SUP35NMS region coding 
for the first 253 aa was substituted with the first 254 aa of SUP35NMP was described 
previously (Chernoff et al., 2000). The chimeric SUP35PS gene in which only the 
SUP35NS region was substituted with the corresponding SUP35NP region was also 
constructed and used in the shuffle experiments, and produced results similar to those 
observed in case of the SUP35NM substitution. Unless otherwise stated, the designation 
SUP35PS in the figures and table refers to the SUP35NMP-SUP35CS construct. In all 
experiments, the SUP35PS and SUP35S genes were located on the single copy 
(centromeric) shuttle vectors as described previously (Chernoff et al., 2000). These 
genes were placed under the control of the endogenous SUP35S promoter. Plasmid 
pASB2 is a centromeric LEU2 based vector containing full length Saccharomyces 
SUP35 (Borchsenius et al., 2000).  Plasmid pYCL-Pm-Sc also a centromeric LEU2 
based vector contains SUP35NM region of Pichia methanolica fused to SUP35C region 





Can Human chimeric Sup35 be turned into a prion by existing S cerevisiae [PSI+]? 
 
The haploid S. cerevisiae strains contained complete deletion of chromosomal 
SUP35S gene and possessed both SUP35HS and SUP35S constructs. SUP35HS was 
expressed under the control of CUP1 promoter. When the [SUP35S] [PSI+]S strain was 
transformed with the [SUP35HS] plasmid, the resulting transformants lost suppression 
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only with 600bp of N-terminal sequence of Human Sup35 as described previously 
(Chernoff, et al., 2000), (Figure 6.3B) and maintained suppression with 400bp of N-
terminal sequence of Human Sup35 (figure 6.3 A). In the first case, antisuppression 
increased with increasing concentration of Copper in the medium, indicating that the 
effect was caused by Human chimeric Sup35 (Figure 6.3 B). The isogenic [psi-] strains 
remained Ade- in either case, confirming that conversion of Sup35S into a prion state is 
directed by the pre-existing Sup35S prion isoform (data not shown). Loss of the [SUP35S] 
plasmid in such a strain showed suppression (see figure 6.3 C) in case of 
NHs600MCSc. However, the Ade+ phenotype was not curable by guanidine 
hydrochloride (GuHCl), agent shown previously to cure [PSI+].  
 
Can glutamine repeats of huntingtin exon 1 substitute for prion forming domain of 
S cerevisiae Sup35 ie can this fusion be turned into a prion? 
 
The haploid S. cerevisiae strains contained complete deletion of chromosomal 
SUP35S gene and possessed both Q20/Q53/Q103MCSc and SUP35S constructs. The 
Q20/Q53/Q103MCSc construct was under the control of CUP1 promoter. In [PSI+] 
strains, suppression decreased with increasing concentration of CuSO4 and the highest 
level of antisuppression was seen with Q103MCSc (Figure 6.4 A). The isogenic [psi- 
PIN+] strains also showed antisuppression with Q53/Q103MCSc while Q20MCSc 
showed suppression (Figure 6.4 B). The expectation here was to see the chimeric 
Sup35 containing Q53 and Q103 domains that are aggregation-prone to increase [PSI+] 
suppression. On the other hand, they showed antisuppression in [PSI+] cells (figure 6.4 
A). This result suggests that these chimeras are non-prion and could efficiently terminate 
translation. [PSI+] induction by Sup35Sc was also inhibited by Q53 and Q103 chimeras.   
While on the other hand chimeric Sup35 containing Q20 domain that does not aggregate 
was expected to should antisuppression, and it infact did not (figure 6.4 A). [PSI+]  
Figure 6.3 Can chimeric Sup35NHsMCSc protein be turned into a prion by pre-
existing S cerevisiae [PSI+]? 
A. NHs400MCSc does not affect suppression by Sup35Sc as seen as growth on 
selective –ade medium for all concentrations of copper (data not shown for 10, 50, 
100 µM CuSO4). Plate is photographed after 7 days of incubation. B. NHs600MCSc 
shows antisuppression which increases with increasing concentration of CuSO4. 
Plate is photographed after 5 days of incubation. In both A and B, transformants of 
the sup35∆ containing a combination of SUP35Sc (on the LEU2 plasmid) and 
chimeric gene (on the URA3 plasmid) were grown on selective medium –Ura-Leu, 
velveteened onto selective –ade medium containing different concentration of 
copper to induce the human chimeric construct. Selective –ade medium without 
copper serves as a control for non-inducing conditons. The [psi- PIN+]  and [psi- pin-] 
transformants with chimeric gene did not exhibit growth on –Ura-Leu-Ade even after 
20days (data not shown). C.Yeast containing only Human chimeric Sup35 continue 
to show suppression but is not prion related. Ura+ Leu- from [PSI+] NHs600MCSc 
transformants were selected and checked for suppression on –Ade and -Ade + 
10/50/100/150uM CuSO4 (data not shown for all). Plate is photographed after 4 
days of incubation. The Ade+ were GuHCl non-curable (data not shown).
Strains used: GT393 [PSI+], GT255-2A [psi- PIN+] , GT394 [psi- pin-]. All are sup35∆
strains kept alive with the plasmid pASB2 (CENLEU2SUP35Sc). 
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Figure 6.4 Effects of huntingtin chimeric Sup35 on [PSI+] maintenance and induction                  
A. Q20MCSc and Q53MCSc show suppression in the presence of pre-existing [PSI+] 
while Q103MCSC shows antisuppresion that increases with increasing concentration 
of CuSO4. B Q20MCSc shows [PSI+] induction while Q53MCSc and Q103MCSc do 
not support [PSI+] induction C. None of the huntingtin chimeras show suppression in 
[psi- pin-] strain. Medium selective for both the plasmids Sup35Sc and huntingtin 
chimeras (-Ura-Leu) is used with different concentration of CuSO4 to induce the 
huntingtin chimeric constructs.                                                     






induction by Sup35Sc was not affected by Q20 chimera. None of the chimeric plasmids 
showed suppression in [psi- pin-] strain (figure 6.4 C). Strains containing only Huntingtin  
chimeric constructs could not be obtained. This could be due to the fact that these 
chimeric constructs were not functional and therefore strain could not be kept alive in the 
absence of SUP35S construct. 
 
 [PSI+] induction takes place when SUP35NM is fused to HPR6.6  
Hpr6.6 is a human progesterone receptor protein studied in Dr Choi’s laboratory 
that contains a transmembrane domain. Sup35C also contains a transmembrane 
domain. It was interesting to check if this transmembrane domain of Sup35C had any 
role to play in [PSI+] induction and this was tested indirectly by replacing the Sup35C 
with Hpr6.6 protein forming a chimeric protein Sup35NMHpr6.6 
The HPR fusion constructs indeed showed [PSI+] induction when expressed 
under its own promoter and when expressed under the control of CUP1 promoter ie 
under both low and high level of expression respectively in [psi- PIN+] strains of two 
series (figure 6.5). Induction was the strongest in the strain OT60, while in GT159, it was 
weak (figure 6.5). [psi- PIN+] derived from OT56 show induction only HPR6.6 expressed 
under its own promoter (figure 6.5 A), while [psi- PIN+] derived from both OT56 and 
GT81-1C show induction when HPR6.6 is expressed under copper inducible promoter 
(figure 6.5 B).  
 
Asymmetric interspecies prion conversion occurs in the Pichia-Saccharomyces 
system 
 
The presence of the [PSI+]S or [PSI+]PS prion state, respectively was monitored by 
growth on –Ade medium (See figure 6.6). When the [SUP35S] [PSI+]S strain was  
 
GT17 Sup35NM  
GT17 Sup35NM-Hpr6.6
OT60 Sup35NM-Hpr6.6





Figure 6.5 Can Sup35NMHPR6.6 chimeric protein expressed from 
A.SUP35 promoter and from B. CUP1 promoter induce [PSI+]? 
[psi- PIN+] and [psi- pin-]  derived from OT56 are designated are OT60 and 
GT17. [psi- PIN+] and [psi- pin-]  derived from GT81-1C are strains GT159 
and GT409 respectively. These strains are transformed with  pRS315 
based vectors expressing either SUP35NMSc or the chimeric 
SUP35NMScHPR6.6 under the SUP35 promoter. The strains were also 
transformed with pYCL1 based vectors expressing SUP35NMSc or the
chimeric SUP35NMScHPR6.6 under the CUP1 promoter. Transformants 
were replica velveteen plated onto selective medium to check for
suppression (-Leu-Ade) and on YPD to check for [PSI+] by color. Plates 
were photographed after 7days and 2 days after refrigeration respectively. 
The transformants expressing CUP1 constructs were checked onto (-Leu-
Ade) and YPD after 3 days of growth on –Leu/Glu + 100uM CuSO4 to 
induce the constructs. Plate was photographed after 5 days and 2 days 
after refrigeration respectively. [PSI+] induction was more efficient by 
chimeric construct in OT60 when expressed from either endogenous or 
Cu-inducible promoters. [PSI+] induction was favored by GT159 by 
chimeric construct only when expressed under CUP1 promoter. [PSI+]  
induction did not take place in [psi- pin-] strains regardless of GT or OT 












Figure 6.6. Prion conversion in the intraspecies and interspecies shuffle 
experiments.
Interspecies prion conversion (A) does not occur from Saccharomyces prion protein 
to the chimeric Pichia-Saccharomyces protein indicating species barrier (see figure 
6.2) (B) but occurs in the opposite direction. Isogenic [RNQ+] strains of S. cerevisiae
used in this experiment bear the sup35∆::HIS3 deletion on the chromosome and 
contain the URA3 centromeric plasmids with either the full length SUP35 gene of S.
cerevisiae (SUP35S) or the chimeric gene SUP35PS (see Chernoff et al., 2000) in 
which the SUP35NM region of S. cerevisiae is substituted with the corresponding 
region of P. methanolica. These strains were transformed with plasmids containing 
SUP35S or SUP35PS but with the LEU2 selective marker. All possible combinations 
were obtained. Growth of the original strains and transformants on the medium 
lacking adenine (-Ade) is compared. (To maintain selection for both plasmids,
transformants were grown on medium that also lacked uracil and leucine). At the 
next stage, the original URA3 plasmids were removed following counterselection
against URA3 marker on the medium with 5-fluoroorotic acid (5-FOA) (see Kaiser et 
al., 1994). Growth of the clones, resulting from such a plasmid shuffle, on -Ade
medium is shown. All plates were incubated for 5 days. Each experiment has been 
repeated several times with at least 8 independent transformants, with the same 
results. All strains contain the [RNQ+] prion.All plasmids used in the experiments 
shown on Fig. 1 contained the SUP35 genes under the endogenous S. cerevisiae
SUP35 promoter. 
Cured  of the         Transformation with         Original Strains Transformed with            Cured of the 







transformed with the [SUP35PS] plasmid, the resulting transformants lost suppression as 
described previously (see figure 6.6 A) (Chernoff, et al., 2000), as non-prion Sup35PS  
protein is sufficient for the efficient termination. Loss of the [SUP35S] plasmid in such a 
strain resulted in the [SUP35PS] [psi-] progeny, confirming the existence of the species 
barrier (Figure 6.6 A). In contrast, the [SUP35PS][PSI+]PS strain, transformed with the 
[SUP35S] plasmid, exhibited the heterogenous growth on –Ade medium, indicating that 
at least a fraction of cells contained the functionally defective (possibly, prion) Sup35S   
 (Figure 6.6 B). After the [SUP35PS] plasmid was lost, the resulting [SUP35S] progeny 
were few Ade+ papillae, indicating the instability of [PSI+]S and very inefficient conversion 
(Figure 6.6 B). The isogenic [SUP35PS] [psi-] strain remained Ade- (that is, [psi-]) after 
transformation with [SUP35S] and subsequent loss of [SUP35PS] (Figure 6.6 B), 
confirming that conversion of Sup35S into a prion state is directed by the pre-existing 
Sup35PS prion isoform only when both Sup35S and Sup35PS are present (ie before 
shuffle).  
 
The interspecies conversion is slower than intraspecies conversion 
Transformation of the [URA3 SUP35] strains with the [LEU2 SUP35] plasmids 
generated both Leu+ Ura+ and Leu+ Ura- transformants. As Sup35 is essential for 
viability, the latter class apparently originated from the cells that have lost the “parental” 
[URA3] –marked plasmid right before transformation and still contained a residual Sup35 
protein when they were transformed. In case of the Sup35PS intraspecies shuffle, all Leu+ 
Ura- transformants were [PSI+] checked by GuHCl curability, suggesting that even a 
short-term coexistence of the residual prion with the identical Sup35 protein coded by 
the newly introduced gene was sufficient to turn the latter protein into a prion. In 
contrast, almost all Leu+Ura- transformants in the interspecies shuffle  ([URA3 
SUP35PS][PSI+] to [LEU2 SUP35S]) remained [psi-] (Figure 6.7 A) in contrast to the Leu+ 
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Ura+ showing only 3-4-fold higher papillatory growth confirmed as [PSI+] by GuHCl 
curability.  
 
Interspecies prion conversion of the Sup35 protein is independent of the presence 
or absence of [RNQ+] prion  
 
            [RNQ+] is the prion isoform of Rnq1, the QN-rich protein of unknown function 
(Sondheimer and Lindquist, 2000). [RNQ+] was previously shown to facilitate de novo 
induction of [PSI+]S by overproduced  Sup35S (Derkatch et al., 2001, Osherovich and 
Weissman, 2001) and to increase aggregation (Osherovich and Weissman, 2001, Meriin 
et al., 2002) and toxicity (Meriin et al., 2002) of the mammalian polyQ proteins in yeast. 
Induction of [PSI+]PS by overproduced Sup35NP (Chernoff et al., 2000) was also 
facilitated in the presence of [PIN+] (Derkatch et al., 1997), later identified with [RNQ+] 
(Derkatch et al., 2001). We have confirmed that [PIN+] strains of our collection indeed 
contain the aggregated (that is, prion) form of Rnq1 (Meriin et al., 2002). However, 
[RNQ+] is not needed for reproduction of pre-existing [PSI+]S (Derkatch et al., 2001, 
Derkatch et al., 1997) or [PSI+]PS (Y. Chernoff and E. Lewitin, data not shown). We have 
observed that both intraspecies shuffles ([SUP35S] [PSI+]S to [SUP35S] and [SUP35PS] 
[PSI+]PS to [SUP35PS]) and interspecies shuffle ([SUP35PS] [PSI+]PS to [SUP35S]) 
produced [PSI+] progeny independently of the presence or absence of [RNQ+] prion 




The SUP35H400S construct did not affect [PSI+] suppression by the endogenous 
Sup35. indicating that Sup35H400S could adopt a prion form. As after shuffle studies could 
not be conducted with this particular construct, it could very well mean that the 
Sup35H400S adopts a non-functinal form and yeast cannot survive in its sole presence.   
From [SUP35PS] [PSI+]PS to
[SUP35PS]   [SUP35S] 
B
[rnq-]
Figure 6.7 Characteristics of the interspecies prion conversion
A. Interspecies conversion requires a long period of co-existence between the inducer
and inducee proteins. The [URA3 SUP35PS ] [PSI+]PS was transformed with the [LEU2
SUP35PS] plasmid in intraspecies shuffle and The [URA3 SUP35PS ] [PSI+]PS was 
transformed with the [LEU2 SUP35S] plasmid in interspecies shuffle . Transformants
were obtained either on –Ura-Leu medium selective for both plasmids (left) or on -Leu
medium containing 5-fluoroorotic acid (5-FOA)  (Kaiser et al., 1994) that
counterselects against URA3 (right). The URA3 plasmid was eliminated from the 
former transformants via incubation on 5-FOA after the colonies were formed. [PSI+] 
is detected by growth on -Ade. Ura- transformants (selected on 5-FOA) remain [psi-].
Intraspecies conversion occurred in both Ura+ and Ura- transformants (data not 
shown and Table 1). 12 independent papillae from each patch of Ura+ (interspecies 
shuffle) were checked for GuHCl curability and most of them (10/12) remained 
curable confirming it as [PSI+]. B. Intraspecies and Interspecies conversion is 
independent of the presence of [RNQ+]. The isogenic [RNQ+] and [rnq-] derivatives of 
the [SUP35PS] [PSI+]PS strain were transformed with either [SUP35PS] or [SUP35S]
plasmids. Plasmid shuffle was performed and presence of [PSI+] detected as growth 









From Ura+ From Ura-
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When yeast contained both SUP35H600S and SUP35S constructs, suppression is lost. 
This can be explained by the fact that the non-prion Sup35HS protein is sufficient for the 
efficient termination. Similar observation was made with Pichia chimeric Sup35p 
(Chernoff et al., 2000). When strain contained only human chimeric Sup35 
(NHs600MCSc), the protein remained non-functional, therefore showed growth on –Ade 
medium. However, the GuHCl test proved this phenomenon to be non-prionic. The 
fusion protein somehow disrupts the Sup35C portion from terminating translation,  
independent of it being turned into a prion. Similarly, huntingtin chimeras also remained 
non-prionic and could efficiently terminate translation. Two possible explanations as to 
why Hpr6.6 chimeric construct facilitated [PSI+] induction were either due to its 
destabilization into peptides that would serve as initial nuclei for prion seeding or that 
Hpr6.6 localises the protein to the membrane increasing the local concentration that in 
turn form nuclei. There exists a yeast homolog of HPR6.6 called YPL170W that lacks the 
transmembrane domain and chimeric studies involving this protein would further resolve 
if it is indeed transmembrane domain facilitating prion induction.  
In case of Pichia chimeric studies, prion state could be transmitted weakly from 
the Sup35P prion-forming domain (PFD) to Sup35S PFD (Figure  6.6 B) but not in the 
opposite direction. This result explains our previous observation (Chernoff, et al., 1995) 
that overproduction of Sup35NP or complete Pichia Sup35 protein (Sup35P) can lead to a 
weak but detectable [PSI+]S induction in the [psi-] strain containing endogenous Sup35S. 
Most likely, the overproduced Sup35P or Sup35NP could be turned into the prion isoform, 
which subsequently converted Sup35S into a prion seen in only fraction of the cells. 
Asymmetry of interspecies prion conversion in yeast resembles the situation previously 
observed in mammals, e. g. in the hamster-mouse system (Kocisko et al., 1995). 
These data are also in agreement with cross-species prion induction observed after 
overproduction of Kluyveromyces lactis Sup35 (Sup35KL) in S. cerevisiae (Nakayashiki 
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et al., 2001). Overproduced Sup35KL was able to induce prion conversion of the 
endogenous Sup35S, but Sup35KL itself could not be induced into a prion by 
overproduced Sup35S. In contrast, the overproduced Sup35 protein from Yarrovia 
lipolytica (Sup35YL) was not able to induce Sup35S into a prion, while induction of the 
Sup35YL prion by overproduced Sup35S was detected (Nakayashiki et al., 2001). 
However, these experiments, as well as Pichia-Saccharomyces cross-induction 
experiments described in our previous paper (Chernoff et al., 2000), always employed 
the overexpressor constructs. Therefore, each experiment began with the [psi-] strain, 
and resulting [PSI+] derivatives apparently originated from a two-step process 
(intraspecies prion induction followed by the interspecies prion conversion) as described 
above.  
Important distinction of the system presented in the current study is that it 
operates at the normal protein levels, so that overproduction-dependent de novo prion 
induction does not make any significant input. This enabled us to specifically 
characterize the actual step of interspecies prion conversion. We have detected the 
following important characteristics distinguishing the yeast interspecies conversion from 
the regular intraspecies conversion. 1) The interspecies conversion is usually less 
efficient than intraspecies conversion. 2) The interspecies conversion requires a longer 
period of coexistence of the prion and non-prion proteins in the yeast cell than in case of 
the intraspecies conversion. 
Our data establish the evidence for that the interspecies prion conversion may 
occur between highly divergent and essentially non-homologous prion-forming domains. 
This points to the potential danger of the secondary wave of prion transmission once the 





EFFECTS OF GLUTAMINE-PROLINE RICH REGIONS OF HUNTINGTIN AND SLA2 





Huntingtin and Sla2 
Human Htt is a large protein comprising 3144 amino acids. The poly-Q domain, 
which begins at the 18th amino acid position, usually contains 11-34 glutamine residues 
in unaffected individuals and expands to > 37 glutamines in HD patients. Two proline-
rich domains –(poly-P which contain 11 and 10 prolines) immediately follow the polyQ 
domain. Proline-rich regions of the protein are implicated to be involved in protein-
protein interactions.They form the most flexible region of the sequence. The Q25 and 
Q103 constructs used previously in chapters 3, 4 and 5 did not contain the proline-rich 
domains. It was observed that when yeast cells overexpress Q25Pro (N-terminal 
fragment of Htt with both poly-Q and poly-P domains) in trans with Q103, poly-Q toxicity 
was eliminated. Similar observation was made when HttPro (N-terminal fragment of Htt 
containing only the poly-P domain) was expressed in trans with Q103 (M. Sherman, 
unpublished results). This result suggested that polypeptides that were proline-rich could 
inhibit aggregation of Q103.  
Sup35, another QN-rich protein also shows cytotoxicity when overexpressed in 
yeast. This protein however does not have any proline rich sequence as seen in the 
huntingtin protein. In order to understand if proline-rich sequence of Htt were able to 
counteract aggregation/toxicity of all Q-rich aggregates in general or whether the 
observation made earlier was only specific with Htt aggregation, we studied its effect on 
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Sup35/Sup35N toxicity. Overexpression of Sup35/Sup35N induces [PSI+] in cells 
containing [PIN+], another QN-rich prion proposed to act as nuclei for prion and Htt 
aggregation. In parallel, we have also studied if proline-rich sequences when expressed 
in trans influence Sup35/Sup35N induction. 
Sla2 like Htt is also rich in glutamine and proline residues. Infact human homolog 
of Sla2-Hip1 binds to huntingtin (Htt) (Kalchman et al., 1997; Wanker et al., 1997). Sla2 
is a member of the widely conserved family of actin-binding proteins. It is essential in 
yeast for the correct organization of cortical actin cytoskeleton (Holtzman et al., 1993) 
and is also required for endocytosis (Raths et al., 1993). Sla2 and related proteins all 
share a similar arrangement of three predicted coiled–coil regions (aa 360-580, aa 700-
730, aa 930-960) as well as a C terminal domain similar to the C-terminal domain of talin 
(see figure 7.1). The proline-rich region is from aa 283-311. The glutamine-rich region is 
located in the first coiled-coil domain from aa 380-434 (see figure 7.1). In this chapter, 
we also study Sla2 effects on [PSI+] related toxicity and induction. 
 
Materials and methods 
Yeast strains 
Yeast strains used in this study are described in Chapter 2. 
 
Plasmid constructs 
Plasmids unique to this study are described below. Other commonly used plasmids are 
described in Chapter 2. Plasmid pYES2-25QP expresses the following protein sequence 
of the portion of human huntingtin MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQ 
QQQQQQQPPPPPPPPPPPQLPQPPPQAQPLLPQPQPPPPPPPPPPGPAVAEEPLHRP
The first 17amino acid region of huntingtin followed by the poly-Q domain containing 25 
Q repeats (underlined section) followed by two proline-rich domains (shown in bold).  
Figure 7.1 Domain arrangement of Sla2 
A. Schematic diagram of Sla2. The three predicted coiled-coil forming 
domains are indicated, as well as glutamine- and proline-rich regions and 
the C-terminal talin-like domain. B. Deletion Analysis Data (Yang et al., 
1999). The sla2∆ is temperature-sensitive (ts) and exhibits defects in 
actin organization and endocytosis.CSK stands for cytoskeleton. The 
Sla2 fragments retaining Q domain but lacking most of the N-terminal 
portion (sla2∆33-359) compensates for ts and endocytosis defects but 
not for actin organization defect. The Sla2 fragment lacking Q domain 
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While plasmid pYES2PRO contains only the region with proline-rich domains following 




Q25Pro effects on Sup35/Sup35N toxicity and Sup35/Sup35N induction 
Sup35 is an essential protein functioning in translation termination. In cells 
containing prions, there is a continuous sequestration of the template protein (Sup35) by 
prion [PSI+] aggregates ([PSI+] is a prion form of Sup35). Such sequestration inhibits 
growth of strong [PSI+] variants where amount of soluble Sup35 is already low. Thus 
Sup35 or even the prion forming domain of Sup35- Sup35N when overexpressed in 
[PSI+] cells is toxic. When Q25Pro was expressed along with Sup35/Sup35N, in one of 
the strong [PSI+] strains GT81-1C, it inhibited Sup35N toxicity, but did not inhibit toxicity 
shown by full length Sup35 (Figure 7.2 A). However, in another strong [PSI+] strain 
OT56, Q25Pro increased Sup35N toxicity slightly and showed no effect on full length 
Sup35 (Figure 7.2 A). Excess Sup35N apparently is less toxic in OT56 than in GT81-1C. 
           Effects of Q25Pro on [PSI+] induction were checked in the [psi- PIN+] derivatives 
of OT56 and GT81-1C – OT60 and GT159 respectively. Figure 7.2 B shows that Q25Pro 
increased [PSI+] induction by Sup35N at a detectable level. 
 
HttPro effects on Sup35/Sup35N toxicity and induction 
When HttPro was expressed along with Sup35/Sup35N,  it did not modulate 
Sup35/Sup35N toxicity in GT81-1C (figure 7.3 A). HttPro increased both Sup35/Sup35N 
in OT56 (figure 7.3 A) as seen with Q25Pro. When checked for [PSI+] induction, HttPro 
did not increase [PSI+] induction to a detectable level as Q25Pro (figure 7.3 B).  
 
Figure 7.2 Effects of HttQ25Pro on Sup35/Sup35N toxicity and induction          
A. Q25Pro decreases Sup35N toxicity in GT81-1C while appears to 
slightly increase Sup35N toxicity in OT56. [PSI+ PIN+] strains OT56 and 
GT81-1C were transformed with plasmids mentioned below.Medium 
used is selective for plasmids and contains galactose to induce the 
constructs (-Ura-His/Gal).Toxicity plates are photographed after 12 days 
of incubation. Both spotting and velveteened plates are shown for OT56. 
B. HttQ25Pro increases [PSI+] induction by Sup35N [psi- PIN+] derivatives 
of OT56 and GT81-1C – OT60 and GT159 respectively were transformed 
with plasmids mentioned below. Transformants grown on –Ura-His/Gal 
for 3-5 days were velveteened onto –Ura-His-Ade plates to check for 
[PSI+] suppression. Plates are photographed after 24 days of incubation. 
8 independent transformants were tested and typical representatives are 
shown.                                                          
Plasmids used: ↑ HttQ25: pYES2-25Q; ↑ SUP35: pLA1-SUP35; ↑
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Sla2 effects on Sup35/Sup35N toxicity, induction and stability 
Excess Sla2 when expressed simultaneously with full length Sup35 facilitates 
[PSI+] induction (figure 7.4 A) in [psi- PIN+] background. Excess Sla2 ameliorates Sup35 
toxicity in weak and strong [PSI+] -OT55 and OT56 respectively. Sla2 did not have such 
an effect in GT81-1C another strong [PSI+] genotypic strain (7.4 B). Excess Sla2 did not 
affect the stability of [PSI+] at detectable levels, when checked on YPD for color change 
after being induced (figure 7.4 C). Yep-based Sla2 facilitated [PSI+] induction by pEMBL-
Sup35, (Figure 7.4 D). Excess Sla2 when expressed from Yep-based vector overcomes 
pEMBL-Sup35 toxicity only in [psi- PIN+] background (Figure 7.4 E). [PSI+] cells are 
difficult to be transformed with pEMBL-Sup35 constructs as Sup35 expression levels 
makes the cells too sick. Thus Sla2 when expressed under gal promoter (Figure 7.4 A 
and B) and when expressed under its own promoter from a multicopy vector (Figure 7.4 
D and E) can overcome Sup35 toxicity and can facilitate [PSI+] induction. 
As overproduction of Sla2 increased [PSI+] induction by excess Sup35, we 
checked whether overproduction of Sla2 fragments shown in figure 7.1 B would exhibit 
the stimulatory effect on [PSI+] induction. The Sla2 fragment missing the proline-rich 
domain (sla2∆33-359) and the full length Sla2 showed similar levels of [PSI+] induction. 
But the Sla2 fragment missing the glutamine-rich domain (sla2∆360-575) showed less 
[PSI+] induction than full length Sla2 (see figure 7.5 A). The Sla2 fragments did not 
modulate the Sla2’s ability to show slight anti-toxic effect towards Sup35 (figure 7.5 B). 
 
Figure 7.3 Effect of HttPro on Sup35/Sup35N toxicity and induction                         
A. HttPro increases Sup35/N toxicity in OT56 to a detectable level. [PSI+ PIN+] 
strains, OT56 and GT81-1C were transformed with plasmids mentioned 
below.Medium used is selective for plasmids and contains galactose to induce 
the constructs (-Ura-His/Gal).Toxicity plates are photographed after 26 days of 
incubation. B. HttPro does not facilitate [PSI+] induction Sup35N at detectable 
levels. [psi- PIN+] derivatives of OT56 and GT81-1C – OT60 and GT159 
respectively were transformed with plasmids mentioned below. Transformants
grown on –Ura-His/Gal for 3-5 days were velveteened onto –Ura-His-Ade
plates to check for [PSI+] suppression. Plates are photographed after 24 days 
of incubation.                                                  
Sup35 ,Sup35N and control plasmids used are same as that mentioned in Fig 
3.2 legend. ↑ HttPRO: pYES2-PRO.
A
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Figure 7.4 Sla2 effects on [PSI+] induction, Sup35 toxicity and stability of [PSI+]             
A. Excess Sla2 facilitates [PSI+] induction in the [psi- PIN+] strain by only full 
length Sup35. The transformants are checked for suppression on -Ura-His-
Ade/Gal. The plate is photographed after 20 days of incubation. [PSI+] induction 
does not take place in [psi- pin-] regardless of the strain background and 
regardless of Sup35/N constructs (data not shown). B. Excess Sla2 overcomes 
Sup35 toxicity to a detectable level in 74-D694 based [PSI+] strains-OT55 and 
OT56 but not in GT81 derived GT81-1C. Growth is monitored on –Ura-His/Gal 
medium and photographed after 10 days of incubation. C. Excess Sla2 does 
not affect the stability of [PSI+]. -Ura-His and –Ura-His/Gal plates were 
velveteened onto YPD and curing was checked by appearance of red sectors. 
A, B and C - Medium used is selective for plasmids and contains galactose to 
induce Sla2 and Sup35/N constructs. D. 2µ Sla2 facilitates [PSI+] induction by 
Sup35 as checked by suppression levels on –Ade medium after being 
velveteened from medium expressing LEU2-d series of Sup35 construct. E. 2µ
Sla2 constructs overcomes Sup35 toxicity in [psi- PIN+] strain. Medium used is –
Ura-His. D and E- Plates are photographed after 10 days of incubation.          
The [psi- PIN+] and [psi- pin-]  derived from OT56 and GT81-1C:  OT60 and 
GT17 (OT56 derivatives) and GT159 and GT409 (GT81-1C derivatives) 
respectively.
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Figure 7.5 Effects of glutamine- and proline- rich regions on A. [PSI+] 
induction and B. [PSI+] toxicity                                                      
A. Glutamine-rich region of Sla2 is required to see [PSI+] induction 
mediated by Sla2 with full length Sup35. Medium used is selective for 
plasmids –Ura-His containing galactose to induce the Sup35 construct 
and lacks adenine to check suppression by [PSI+]. Plate is photographed 
after 13 days. Sla2∆ 360-575 lacks glutamine-rich region (see figure 7.1) 
and suppression is reduced. B. Neither glutamine nor proline rich regions 
of Sla2 seem to have any effect on the anti-toxic effect of Sla2 on Sup35 
toxicity when checked in [psi- PIN+] cells. Just as seen in figure 7.4D full 
length Sla2 slightly reduces Sup35 toxicity, its truncated versions do not 
seem to modulate this effect. Medium used was –Ura-His/Gal selective 
for plasmids and inducing Sup35 construct. Spotting was done to detect 
slight differences existing if any. Plate was photographed after 11 days. 
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Proline-rich region of Huntingtin did not overcome Sup35/Sup35N toxicity in 
contrary to the effects observed with Q103. This implies that anti-Q103-toxicity 
mechanism of proline-rich sequence of Htt is specific to huntingtin and cannot be 
extrapolated. Q25Pro infact did overcome Sup35N toxicity implying that glutamine-rich 
region of huntingtin could interact with glutamine-region of Sup35N domain and possibly 
reduce toxicity. This however was seen only in one specific genotype GT81-1C strain 
(Figure 7.2 A). In all other cases both Q25Pro and HttPro increased Sup35N toxicity. 
The induction and toxicity data fit very well with the OT yeast series (OT56 and OT60), 
where Q25Pro increases Sup35N toxicity in OT56 [PSI+ PIN+] and increases [PSI+] 
induction by Sup35N in OT60 [psi- PIN+]. This data suggests that Q25PRO increases the 
frequency of the misfolded Sup35N protein to form aggregates thus increasing toxicity in 
the already prion containing cells.  
Excess Sla2 facilitated [PSI+] induction only in [psi- PIN+] strains and not in [psi- 
pin-] strains (data not shown) implicating that Sla2 cannot replace Rnq1’s ability to 
enable prion formation inspite of being glutamine rich like Rnq1. The glutamine-rich 
region of Sla2 was previously shown to be necessary for growth and endocytosis (Yang 
et al., 1999) and in this study we also showed it to be important for [PSI+] induction 
based on the study with Sla2 fragments. 
Thus we conclude that the observation made with Htt with respect to proline-rich 
sequence did not hold true for Sup35 possibly because Sup35 is not proline-rich itself 
and therefore does not facilitate any interaction. Yet quite interestingly, glutamine-rich 
sequence seems to reduce Sup35 toxicity as seen with Q25Pro on Sup35N toxicity in 
GT81-1C and Sla2 on Sup35 toxicity. Glutamine-rich region of Sla2 and Htt also 
facilitate [PSI+] induction. Sla1, another member of cytoskeleton associated with actin 
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patches also assisted [PSI+] formation and propagation (Bailleul et al., 1999). It is 
possible that actin patches play an important role in [PSI+] induction rather than in [PSI+] 
propagation as ribbon like structures associated with actin patches are seen in [psi- PIN+] 
cells where [PSI+] is induced. Sla1 and Sla2 possess structural features similar to prion 
forming domains eg: Sla1 contains oligopeptide repeats (Holtzman et al., 1993) and Sla2 
contains a QN-rich region (Michelitsch and Weissman, 2000). Though, neither of them 
were found to form prions themselves, their prion forming domains could act as intial 






















1. Dominant negative Hsp104 mutants antagonized poly-Q toxicity and aggregation 
by eliminating endogenous yeast prions.  
 
2. Some mutant derivatives of Hsp104 with alterations in the middle or C-terminal 
domain, Hsp104-A503V and Hsp104-C*, ameliorated poly-Q toxicity and 
decreased size of poly-Q aggregates without affecting prion propagation.  
 
3. Hsp104-A503V increased size of the Sup35 prion aggregates, providing the first 
known case of synthetic lethality between the chaperone mutation and a prion. 
 
4. Kinetics of [PSI+] curing by the dominant negative Hsp104 derivative (Hsp104-
KT) was shown to be different from [PSI+] curing by the Hsp104-inactivating 
chemical GuHCl.  
 
5. Among the yeast Hsp70 chaperones, only Ssa4 was capable of counteracting 
poly-Q toxicity.  
 
6. Different members of the Hsp40 family, Sis1 and Ydj1, were shown to exhibit 
opposite effects on poly-Q toxicity. Ydj1 increased prion-dependent poly-Q 
aggregation and toxicity, while Sis1 decreased size of poly-Q aggregates and 
antagonized poly-Q toxicity. 
 
7. Interaction between Saccharomyces Sup35 and Hsp70-Ssa proteins was 
detected by two-hybrid assay. 
 
8. Anti poly-Q toxicity mutants called AQT 2, 7 and 9 were shown to be ubc4∆ 
dependent and temperature-resistant at 39°C. 
  
9. Interspecies prion conversion in Pichia-Saccharomyces system is shown to be 
asymmetric.  
 
10. Huntingtin fragment containing poly-Q and Pro-rich region was shown to facilitate 
de novo [PSI+] induction by excess Sup35N.  
 
11. Excess of Sla2, an actin assembly protein with Q-rich region, was shown to 
increase de novo [PSI+] induction by excess Sup35 and decrease toxic effect of 
excess Sup35, confirming role of cytoskeletal networks in de novo prion 
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